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SYNTHESIS OF OLIGONUCLEOTIDE ANALOGUES FOR USE IN DNA
NANOSTRUCTURES
by Adeline Durand
Thanks to its ability to form duplexes through selective base-pair recognition, DNA is a
unique material for orderly self-assembled construction at the nanoscale. To develop a
nanotechnology platform on a grid of addressable molecular building blocks using DNA
node  structures, DNA  complexes  need  to  be  fixed  onto  surfaces.  To  fulfil  this
requirement  on  lipid  membranes, phosphoramidites monomers modified  with  a
cholesterol moiety and a spacer unit were synthesised. The hydrophobic spacer provides
separation between the hydrophobic cholesterol moiety and the phosphate backbone of
the DNA strand. For better anchorage of the network to a lipid surface, a hydrophilic
spacer was also used to link the cholesterol to the nucleoside.
Solution studies demonstrated that the melting temperature (Tm) of the duplex with
adjacent cholesterols on each strand is much higher than that of the unmodified duplex.
The  reliable  and  highly  selective copper(I)-catalysed  azide-alkyne  1,3-dipolar
cycloadition (CuAAC), the best known example of click chemistry, has proven to be of
remarkably  broad  utility in  synthetic  chemistry  and in nucleic  acid  chemistry  in
particular. CuAAC was exploited for the synthesis of a very stable double stranded
catenane duplex. The catenane was formed from a single stranded cyclic template and
its linear complement, using a third short oligonucleotide (ODN) as a helper for the
circularisation  of  the  second  ODN. The copper(I)-catalysed cyclisation  of
oligonucleotides occurred by reaction between their terminal azide and their opposite
terminal  alkyne, to  produce  a  1,2,3-triazole  linkage  between  the  two  reactants.  The
catenane  was characterised by denaturing  polyacrylamide  gel  electrophoresis,  UV
melting studies and enzyme digestion.ii
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CHAPTER 1
Introduction2
1. Introduction
1.1 DNA structure
1
1.1.1 Primary structure
The  nucleic  acids  DNA  and  RNA  are  macromolecules  composed  of  nucleotide
monomer subunits, linked together by a sugar-phosphate backbone. Each nucleotide
consists  of  three  building  blocks:  a  furanose  sugar,  a  phosphate  moiety  and  a
heterocyclic base. The heterocyclic bases in nucleic acids are derivatives of purine or
pyrimidine. In DNA there are two bicyclic purine bases, adenine (A) and guanine (G);
and two monocyclic pyrimidine bases, cytosine (C) and thymine (T). Nucleobases are
covalently attached between a nitrogen atom and the C
1’ of a 2’-deoxy-ribofuranose
sugar  (dR)  to  form the  nucleosides,  deoxyadenosine  (dA),  deoxyguanosine  (dG),
deoxycytidine (dC) and thymidine (T) respectively. The pyrimidine bases are covalently
bonded via the N
1-atom, and the purine bases, via the N
9-atom (Figure 1.1).
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Figure 1.1: Structures of the purine and pyrimidine heterocyclic bases present in DNA and RNA; and
deoxiribonucleoside and ribonucleoside.3
For RNA, the sugar moiety is ribofuranose, namely it has a hydroxyl group in the 2’-
position, and thymine is replaced by uracil, which lacks a methyl group at the 5-position
(Figure 1.1).
Geometry of nucleotides within the macromolecule or polymer, and of the nucleosides,
is  governed  by  sugar  and  sugar-base  conformations. The  sugars can  adopt  two
characteristic non-planar conformations where the furanose ring twists out of plane to
minimise non-bonding interactions between its substituents: the C
2’ endo (S type) and
the C
3’endo (N-type) (Figure 1.2).
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Figure 1.2: Structures of the C
2’-endo (S) and C
3’-endo (N) sugar puckers.
In  standard  orientation  the  base  lies  above  the  plane  of  the  sugar  to  give  a  β  N-
glycosidic  bond.  There  are  two  principal  orientations  of  the  base  and  sugar  in  a
nucleoside,  which  are  structurally  important.  These  are  known  as  the anti and syn
conformations (Figure 1.3).
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Figure 1.3: Syn- and anti- conformations of thymidine and deoxyadenosine nucleosides
A nucleotide is a nucleoside with a phosphate covalently bound to the 3’ or 5’-end of
the sugar, giving the oligonucleotide its directionality. At neutral pH each phosphate
group carries a single negative charge; hence nucleic acids are highly charged polymers.4
Convention denotes that the DNA sequence is recorded from the 5’-terminus to the 3’-
terminus using the single letter abbreviations of the different nucleotides.
1.1.2 Secondary structure
The basic features of the double helix were deduced and published by James Watson
and  Francis  Crick  in  1953,
2 following  extensive  X-ray  diffraction  studies  by  their
associates,  Franklin  and  Gosling,
3 and Wilkins et  al.
4 The  two  DNA  strands  were
observed to be wound around each other in a helical path with the negatively charged
sugar-phosphate backbone on the outside of the structure, which forms the hydrophilic
part of the structure. The planar bases were found to lie perpendicular to the axis of the
helix  on  the  inside,  stacking  above  one  other via - interactions  and  forming  the
hydrophobic core of the structure. The four bases form Watson-Crick base pairs;
5 G
pairs with C via three intermolecular hydrogen bonds, and A pairs with T via two
hydrogen-bonds (Figure 1.4).
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Figure 1.4: Structures of the GC and AT Watson-Crick base pairs. The GC base pair has three hydrogen
bonds and the AT base pair has two.
The two strands are antiparallel as their 5’-3’ phosphodiester backbones run in opposite
directions (Figure 1.5).5
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Figure 1.5: DNA single strand structure and B-DNA double helix showing the major and minor groove.
There are two principal conformations for the DNA double helix, A and B, both of
which have been characterised by X-ray crystallography.
B-DNA, the most biologically relevant form, occurs in conditions of high humidity/low
salt. It is  an  anti-parallel  right-handed  duplex with  a  10  base  pair (34 Å) per  turn
periodicity, in which the base pairs sit directly on the helical axis and the sugars adopt
the C
2’-endo pucker. The attachment of bases to the sugar-phosphate backbone through
glycosidic bonds is asymmetrical, resulting in the formation of two different grooves,
the major groove and the minor groove. The major groove is 12 Å wide and 9 Å deep;
and the minor groove is 6 Å wide and 8 Å deep. Both are lined with potential hydrogen
bond acceptors and donors but these are more exposed in the major groove.
The A-form duplex (A-DNA) is also an antiparallel right-handed helix with an 11 base
pair per turn periodicity with sugar adopting the C
3’-endo pucker, and occurring under
conditions of low humidity/high salt. This form of duplex is most commonly adopted by
DNA. RNA  hybrids  and  RNA  duplexes  and  the  A-form  is  also  adopted  by  DNA
duplexes in G-rich sequences. The major groove is narrow and deep and the minor
groove wide and shallow and the phosphate backbone is stiffer than that of B-DNA.
6 Å
12 Å6
1.2 Nanotechnology
1.2.1 Introduction on nanotechnology
The first mention of nanotechnology (not yet using that name) occurred in a talk given
by Richard Feynman in 1959, entitled “There's Plenty of Room at the Bottom”.
The term “Nanotechnology” was created by Tokyo Science University professor Norio
Taniguchi in 1974 to describe the precision manufacture of materials with nanometre
tolerances. In the 1980s the term was reinvented and its definition expanded by K Eric
Drexler,  particularly  in  his  1986  book Engines  of  Creation:  The  Coming  Era  of
Nanotechnology.
6 Since then the word “nanotechnology” has become very popular and
is used to describe many types of research where the characteristic dimensions are less
than about 1,000 nanometres.
At the nanometer scale, matter behaves differently to the meter scale. It often becomes
more  reactive and, for  example, a  material’s  electrical  conductivity,  strength  and
melting point may all change. Since the invention of Scanning Tunnelling Microscopy
(STM) in the 1980s, researchers have developed increasingly powerful techniques for
observing and manipulating surfaces at the nanoscale. This has led to the development
of new materials and even to the conceptual design of molecular pumps and motors.
7-10
A number of commercial applications have already reached the market. These include
biocompatible  medical  implants,  high-performance  computer  hard  drives,  scratch-
resistant  paints  and  self-sterilising  surfaces.
11,12 Many of  these  applications  are  the
results of unexpected discoveries made in the course of fundamental research.
1.2.2 DNA and nanotechnology
An  increasing  number  of  researchers  within  nanoscience  are  using  nucleic  acids  as
building-blocks at the bottom-up approach towards novel materials with predictable 2D
or  3D  structures.
13 DNA  is indeed a  promising  candidate  for  achieving  the  desired
structural  formation  and  arrangement  in  nanosciences.  Despite  its  simplicity the
outstanding specificity  of  the  A-T  and  G-C  base-pairing  system  allows  convenient
programming. It is a building block with a very high information content. It has well-
known diameter scale structural  geometry, a 3.4 nm helical  repeat and about 2 nm
diameter (as described in section 1.1.2) and it has combined stiffness and flexibility; the7
persistence length, that is, the length up to which polymers can be considered essentially
rigid and straight, is about 50 nm, which corresponds to 150 base pairs in the double
helix. Below  this  size,  double-stranded DNA (dsDNA)  behaves  as  a  rather  rigid
polymer,  on  the  other  hand,  single-stranded  DNA (ssDNA)  is  very  flexible.
Furthermore, it is easy to synthesise using automated phosphoramidite chemistry,
14 and
to amplify via the polymerase chain reaction (PCR). Lastly, it is particularly noteworthy
that  nature  provides  us  with  a  variety  of  highly  specific  enzymes  which  allow  the
processing of DNA material with atomic precision and accuracy at the Angstrom level
(e.g. restriction endonucleases).
1.2.2.1 Consideration of DNA-sequence design
When planning to assemble materials by simple DNA-programmed processes the first
thing to consider is how  to  design  the  sequences  to  obtain  the  desired  assembly.
15
Several  major  steps  are  required  for  the  design  and  construction  of  DNA-based
nanoarchitecture. Firstly, any requirements to be satisfied by the envisioned construct
and its potential application should be identified. For example, it may eventually be
wished to use the scaffold for the directed attachment of non-nucleic acid components,
such as nanoparticles or proteins. In this case it needs to be determined whether the
DNA scaffold should be rigid or flexible. The next question might concern whether the
construct is to be used as a static scaffold or as a dynamic mechanical device that
undergoes  reversible  or  irreversible  transitions  between  distinct  and  predictable
conformations. It must also be determined whether symmetric or nonsymmetric patterns
are to be produced by the assembly of the array, what kind of periodicity is desired, in
how  many  dimensions  the  scaffold  should  grow,  and  whether  this  growth  is  to  be
terminated or potentially infinite.
16
It is also necessary to tackle the conjugation of the material and DNA (or analogs). The
power  of  automated  oligonucleotide  synthesis  makes  small  oligonucleotides  easily
accessible  and many  DNA-modifiers  are  commercially  available  and  can  be
incorporated during automated DNA-synthesis. These include phosphoramidites with
modified nucleoside bases, fluorescent dyes, bio-labels such as biotin and a variety of
functional chemical groups (FCG).
17 Modifications can be incorporated at the 5 or 3’-8
ends of the DNA sequence using a modifier with a phosphoramidite group for coupling
with  the  5 or  3’-OH  of  the  DNA  sequence  and  a  protected  FCG;  but  internal
modifications within the sequence can also be included using the relevant protected
FCG.  It  is  relatively  easy  to  conjugate  DNA  with  organic  molecules  that  carry
functional groups which react with the FCGs.
17 Biomolecules and chemically modified
biomolecules  can  be  conjugated  with DNA  in  a  similar  manner (e.g.  biotin  for
subsequent association with streptavidin).
18,19 The inorganic material most frequently
used in conjugation with DNA is nanoparticulate gold.
20 DNA sequences with a thiol
modifier can react directly with the naked gold nanoparticle or, by ligand exchange,
react with monolayer-covered particles to form thiolate-Au bonds.
21
In addition to these considerations, it is required that DNA-sequences are of sufficient
length. Typically 10- to 25-mer DNA sequences are used. A 10-mer dsDNA helix has a
melting temperature between 25 and 35 °C. Guanine (G) and cytosine (C) interact via
three hydrogen bonds leading to higher stabilization (ca. 6 kcal mol
–1) than the two-
hydrogen bond interaction between thymine (T) and adenine (A) (ca. 4.5 kcal mol
–1)
(see section 1.1.2).
Finally, the various different DNA oligomers designed have to be assembled. The way
to  self-assemble  complex  patterns  can  generally  be  divided  into  four  categories.
Traditionally,  DNA-based  nanostructures  self-assemble  from  a  set  of  unique
oligonucleotides with carefully chosen base sequences. The oligonucleotides are mixed
in buffer solution and annealed by heating the solution to a high temperature (around
95
oC) and slowly letting it  cool to  room temperature. During the  cooling process,
complementary sequences hybridize with each other and lead the nanostructure into a
unique structure. The second method is hierarchical self-assembly. Selected groups of
tiles are mixed in separate tubes and then combined sequentially. The algorithmic self-
assembly  programs  the  nanostructure  with  specific  binding  domains  that  can  be
specifically and cooperatively bound to form a complex pattern following an algorithm
rule.  A  few  years  ago,  a  radically  different  approach  towards  DNA  assembly  was
developed by Rothemund
22 (and previously introduced by Yan et al.
23), which is based
on folding a single, long scaffold strand into a desired shape with the help of multiple
staple strands (Figure 1.6). In contrast to the traditional assembly approach, there is
no need to observe strict stoichiometric ratios, and assembly occurs quite quickly and
with an extraordinary yield. This is because after initial attachment of the staple strands9
to the scaffold, folding occurs locally within the scaffold. When a large excess of staple
strands are used, mismatches in the assembly are healed by strand displacement.
24
Many  self-assembly  systems  with  complex  patterns  actually  use  a  combination  of
methods.
Figure 1.6: Design of DNA origami: a, A shape (red) approximated by parallel double helices joined by
periodic crossovers (blue). b, A scaffold (black) runs through every helix and forms more crossovers
(red). c, As first designed, more staples bind two helices and are 16-mers. Adapted with permissions from
ref. 22.
1.2.2.2 Design and assembly
1.2.2.2.1 DNA toolbox: junctions and crossovers
The study of artificial DNA structures for applications in nanotechnology began in the
early 80s when Seeman conducted pioneering work on the construction of artificial
nucleic acid architectures combining sticky-end cohesion and branched DNA junction
motifs.
25 The  branched  molecule  used  is  an  analog  of  a  biological  intermediate  in
genetic  recombination,  the  Holliday  junction. However,  the  naturally  occurring
Holliday  junction  is  usually  formed  between  two  duplex  molecules  with  the  same
sequence. This sequence symmetry destabilises the position of the branch point so that
it is free to migrate. Seeman showed that by specifically designing sequences which
were able to exchange strands at a single specified point and by breaking the sequence
symmetry, this allowed the branch junction to migrate. This idea is illustrated in Figure
1.7, which shows that a four-arm branched DNA junction with complementary sticky
ends could self-assemble into 2D square lattices.10
These  lattices  are  potentially  useful  as  scaffolds  with  nanometer-spaced repetitive
structural features.
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Figure 1.7: Sticky-ended assembly of branched molecules. A branched molecule is shown on the left
with four sticky ends; a complementary to a’ and b complementary to b’. Four of them are shown to self-
assemble in a 2D lattice, with further sticky ends on the ends on the outside, so that an infinite lattice
could be formed by the addition of further components (adapted from ref
26)
DNA duplexes or Holliday junction structures were found to be too flexible to achieve
2D or even 3D structures. To solve this problem, Seeman and co-workers constructed
inherently rigid building  blocks  for  DNA  construction,  the  crossover  tiles.  Double
crossover (DX) consist of two double-stranded helices, which interchange single strands
at two crossover points.
27 DX tiles are usually designed such that they comprise sticky
ends at their four arms which can be used for self-assembly. They became the initial
building blocks for the construction of periodic assemblies and the formation of the first
two-dimensional  crystals  of  DNA  tiles.
28 These  large  lattices  provide  multiple
attachment sites, so the basic structure of a DX motif could possibly be addressed in
many different ways. The use of paired crossovers greatly increases the stiffness of the
tiles over that of linear dsDNA. Following the success of DX lattices, triple crossover
(TX)
29 and paranemic crossover (PX)
30 were demonstrated and used in the construction
of nanostructures. (Figure 1.8)11
a) b)
Figure 1.8: Key motifs of DNA Nanotechnology. a) DX is a double crossover molecule, resulting from a
double exchange of DNA backbones; b) TX is a triple crossover that results from two successive double
reciprocal exchanges.
1.2.2.2.2 DNA tiles
Crossover  tiles  have  also  been  used  as  building  blocks  for  the  generation  of  larger
motifs, which were then used as building blocks themselves. For example, a cyclic
double-stranded  supramolecular  structure  which  included  three  flexible  bulges  was
constructed using DX motifs only at first,
31 and then DX and PX tiles.
32 TX molecules
were  used  to  build  linear  arrays,
33 2D  lattices,
29 and  DNA  tubes.
34 Lattices  with
rhombus-like units have been made in which the helix crossing angles are about 60. A
set of rhombids was subsequently assembled into 1D “railroad tracks” as well as into
2D lattices (Figure 1.9).
3512
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a)
Figure 1.9: The rhombus motif. Combination of four junctions into a rhombus-like motif. Four molecules
are combined. There are six turns of DNA in each helix, and four turns between crossover points, leading
to one-turn overhangs on the ends (a), which can be used as a basic component for the self-assembly of a
1D linear railroad track-like arrangement (b), or a 2D latticework of DNA (c) (adapted from ref
35).
Mao et  al. constructed  an  array  of triangular  tiles made  of flexible  four-arm  DNA
junctions,
36 and two versions of triangular tiles which form hexagonal patterns were
also prototyped.
37,38
While  all  crossover  tiles  can  be  considered  as  flat  and  rigid  building  blocks,  the
structural variety of individual types offers a large range of options for modulating the
spacing and connectivity of the building blocks and of the final superstructure desired.13
Moreover, crossover motifs can be further modified and expanded to include additional
functionalities.
Yan et al. constructed a DNA nanostructure, so called 4  4 tiles, consisting of four
four-arm junctions oriented with a square aspect ratio.
18 The tiles were assembled to
form  linear  ribons  and  2D  nanogrids.  Arrays  of  the  4  4  tiles  were  used  for  the
fabrication of ohmic conductors through metalisation of a ribbon-type assembly with
silver.
18,39 Moreover, protein periodic arrays were achieved by templated self-assembly
of streptavidin onto the DNA nanogrids containing biotinylated oligonucleotides.
18,19
Typically, the assembly of complex structures requires a large number of DNA strands
with  distinct  base  sequences.  The  sequences  must  be  chosen  carefully  to  avoid
unwanted interactions between the strands and this makes sequence design challenging.
Recently,  Mao  and  co-workers  introduced  the  concept  of  “sequence  symmetry”.
Utilising the four-fold symmetry of the 4  4 tiles developed by Yan et al., which is
composed of nine distinct strands of DNA, they developed a related structure, which
can be formed by only three types of DNA strands with symmetric sequences (Figure
1.10).
40
It is argued that sequence symmetry reduces the number of unique DNA strands needed,
thus  minimizing  both  cost  and  experimental  errors. It  also  helps  to  minimise  the
required unique sequence space, and thus greatly simplifies the sequence design for the
possible  formation  of  very  large  structures.  Though  useful,  structures  with  complex
patterns are hard to achieve using the fully symmetric design.14
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Figure  1.10: Sequence  symmetry  reduces  the  complexity  of  assemblies.  a)  An  asymmetric  crossbar
structure composed of four Holliday junctions, which are formed by nine strands of DNA with distinct
sequences. The arrows indicate the 3’ ends of the DNA strands. b) A symmetric crossbar structure that is
formed by nine DNA structures with symmetric sequences. The number of strands with distinct base
sequences is reduce to three (adapted from ref
40).
1.2.2.2.3 DNA objects
Seeman and co-workers constructed the first object with a non-trivial connectivity of 3
or greater: a DNA molecule whose helix axes were connected like the edges of a cube;
41
followed by a truncated octahedron using 4-arm junctions.
42 Turberfield and co-workers
reported  the  single-step  synthesis  of a  tetrahedron, constructed  out  of  four  55-mer
ssDNA oligomers.
43 This object is a more-rigid wire frame than the cube because its
triangular  sides fulfil the  tensegrity  concept:  a  combination  of  tense  and  integrity,
instead of rigidly joining rigid building blocks.
44 Tensegrity is again used by Mao an co-
workers  who prepared supramolecules  using DNA triangles  made of rods  (DNA
duplexes) and connected by junction motifs, which are stable thanks to the rigid rods
pushing the 3D structure outward and the flexible junctions pulling it inward.
36 The
conformational  stability  of  the  tetrahedron  was  recently  validated  through  AFM
imaging with an ultrasharp tip.
45 Tensegrity clearly proves to be a promising tool for the
design of 3D DNA nanoarchitecture.
46
Another example of a putative DNA tetrahedron was reported by von Kiedrowski et
al.
47 They  synthesised  trisoligonucleotides  in  which  three  strands  of  DNA  are
covalently connected to an organic linker molecule with a three fold symmetry axis.15
Recently,  using  20  distinct  trisoligonucleotides  as  vertices,  they  succeeded  in
assembling mechanically stable DNA-based molecular dodecahedra.
48
Shih et al. designed a 1.7-kilobase single-stranded DNA which after addition of five 40-
mer  ODNs,  readily  folded  into  an  octahedron  structure  by  a  simple  denaturation-
renaturation procedure.
49
A set of Borromean rings was built from the combination of a right-handed B-DNA 3-
arm  junction  connected  to  a  left-handed  Z-DNA  3-arm  junction.  They  are  all
disconnected by cleavage of just a single ring.
50
In a recent breakthrough, He et al. built molecular tetrahedra, dodecahedra, and bucky
balls, from a minimal of intrinsically stiff crossover structures, adopting the rules of
sequence symmetry.
51
1.2.2.3 Applications
The 2D arrays and 3D structures assembled from DNA represent interesting objects in
their own right, but their real usefulness will come from their application as scaffolds
and templates upon which chemical reactions are performed, their use as mechanical
elements or the utilisation of the information content of DNA constructs for computing.
1.2.2.3.1 Mechanical devices
DNA is not only useful for the construction of static scaffolds but it can also be used for
the  fabrication  of  dynamic  assemblies for  nanomechanical  action.  Environmental
changes can induce a conformation change in a DNA nanostructure. For example, one
of  the  first  switches,  created  by  Seeman  and  co-workers,  was  relatively  small  and
consists  of  two  DX  molecules  connected  by  a  shaft (Figure  1.11).  Double-stranded
DNA with the sequence (CG)n can be flipped from the usual right-handed helix B-DNA
to a left-handed confirmation Z-DNA. Conditions which promote the transition are high
ionic strength or an effector that emulates high ionic strength, such as Co(NH3)6Cl3. The
yellow  nucleotides  on  the  shaft  represent  20  nucleotide  pairs  that  are  capable  of
undergoing  the  B-Z  transition.  In  the  absence  of  Z-promoting  conditions,  these
nucleotides will be in the B state, as shown at the top of the panel, but in the presence of
Z-promoting conditions they convert to Z-DNA. The transition was demonstrated by16
measuring FRET differences between the two states.
52 Alteration of pH value has also
been  used  to  induce  the  conformational  change  of a DNA  triplex,  used  as
nanomechanical actuator.
53,54
Figure 1.11: A DNA nanomechanical device based on the B-Z transition.
Another  method,  called “Strand Replacement” can  also  be  made  reversible  by  the
simple addition of a well-designed DNA ODN. The strand replacement mechanism is
demonstrated with the DNA tweezers from Yurke at al (Figure 1.12).
55 This principle
has been used to effect conformational changes in a wide variety of systems and a
number of variations on the tweezers have been reported.
56,57
Simmel and co-workers also employed this method for the construction of a protein-
bearing molecular machine based on a DNA aptamer. They opened and closed a G-
quadruplex-shaped  thrombin-binding  aptamer,  allowing  the  release  or  binding  of  a
thrombin molecule in the presence of a specific DNA sequence.
58 There also have been
a variety of elegant designs of walking devices produced.
8,59,60
B-Z transition
+ Co(NH3)6Cl3
Z-B transition
- Co(NH3)6Cl317
Figure  1.12: Construction  and  operation  of  the  molecular  tweezers. a, Molecualr  tweezer structure
formed by hybridisation of ODN A, B and C. b, Closing and opening the molecular tweezers. Closing
strand F hybridises with the dangling ends of strands B and C (blue and green) to pull the tweezers
closed. Hybridisation with the overhang section of F (red) allows F strand to remove F from the tweezers,
forming a double-stranded waste product FF and allowing the tweezers to open. Adapted with permission
from ref. 48.
1.2.2.3.2 DNA assembly of biomolecules
Assembly of other biomolecules on DNA templates and arrays may prove useful for
fabrication  of  biomimetics  and  other  devices  with  applications  such  as  biochips,
immunoassays, biosensors, and a variety of nanopatterned materials.
The  conjugation  of  DNA  and  streptavidin via a  covalent  linker  was  reported  by
Niemeyer et al., and these conjugates were applied to DNA-programmed assembly on a
macroscopic DNA array on a surface and in a nanoscale array made by aligning DNA-
tagged proteins to specific positions along a oligonucleotide template.
61,62
Biotin  labelled  oligonucleotides  are  commercially  available, routinely  used  in
biotechnology, and their application for nanostructuring is growing in popularity.
63,64 As
described previously (see section 1.2.2.2.2), Yan et al. used the 4  4 tiles to template
the self-assembly of streptavidin proteins into periodic 2D arrays through a biotin group
attached in the centre of the tile.
18 The streptavidin protein array can be programmed
with controlled spatial distance and density of the proteins, as seen on AFM pictures.
1918
A number of applications of materials assembled by structural DNA nanotechnology are
already  starting  to  emerge  in  biotechnology. Tuberfield  and  co-workers showed  the
binding of the protein RuvA to the Holliday junction of a 2D lattice. This resulted in a
2D crystal array of this protein, which allowed for its structural elucidation by using
electron microscopy.
65 By assembling different DNA tile arrays, each with a specific
recognition molecule and "bar-coded" with a specific fluorescent dye, Yan developed a
platform that allows the simultaneous detection of multiple biological analytes. This
method may be faster than DNA or protein microarrays for small-scale profiling of
bioanalytes.
66
1.2.2.3.3 DNA scaffolds for nanoelectronics
The  conjugation  of  DNA  with  metal,  semiconductor  and  magnetic  nanoparticles  is
becoming increasingly important since DNA self-assembly provides a framework for
the  spacing  and  hierarchical  organisation  of  nanomaterials.  The  periodicities  and
interparticle spacings defined by DNA nanostructures are readily adjustable, with sub-
nanometer spatial resolutions. This level of precision provides exquisite control in the
construction of rationally defined 2D and 3D nanoscale assemblies.
Pioneering reports on the assembly of gold nanoparticles by hybridisation of DNA-
nanoparticle conjugates were published in 1996 by two groups. Mirkin et al. developed
a  method  for  assembling  colloidal  gold  nanoparticles  rationally  and  reversibly into
macroscopic  aggregates.
67 When  they attached non-complementary  ODNs  on  the
surface of two batches of gold nanoparticles, using thiol groups, and added a DNA
target complementary to both DNA-nanoparticles sequences, hybridisation forced the
particles to aggregate. The resulting colour change in the presence of the target is a very
efficient and easy method for DNA-detection. At the same time, Alivisatos and co-
workers applied gold nanoparticles labelled with only single ODN molecules for the
synthesis of homodimeric or homotrimeric nanoparticle assemblies.
68
Another strategy of using DNA as a scaffold for gold nanoparticles relies on the biotin-
streptavidin  binding.  Yan et  al. used  TX  molecules  functionalised  with  biotinylated
DNA  strands,  which  were incubated  with  streptavidin-coated  gold  nanoparticles  to
assemble them in periodic arrays.
6919
Sleiman et  al. developed  DNA  building  blocks,  containing  two  arms  of  different
sequences, and a rigid organic corner unit, which selectively assembled into a discrete
DNA  hexagon.  This  approach  was  used  to  organise  six  gold  nanoparticles  into  a
hexagon.
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1.2.2.3.4 DNA-based computation and algorithmic assembly
In 1994 Adleman demonstrated that DNA can be used for computationally solving a
small example of a Hamiltonian path problem in computer science.
11 The idea behind
DNA-based  computation  is  that  for  some  classes  of  computational  problems  the
parallelism  of  molecular  assembly  overcomes  the  slow  speed  of  the  required
macroscopic  manipulations. An  example  of  DNA  computing  based  on  regular
assemblies of DNA motifs as building blocks is the work done by Winfree et al. on the
“Wang tiles”. He described the similarity of DNA branched junctions with sticky ends
to Wang tiles. Two such tiles only assemble if the joint edges have the same colour
specific sticky ends (Figure 1.13). The assembly of Wang tiles can be used to simulate a
cellular automaton. This is a theoretical model of a computer which can be used to
execute, in principle, any calculations done by a conventional computer. As an example,
they designed a set of DX tiles capable of solving a small example of the Hamilton-path
problem.
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Figure 1.13: Computational assembly of the DNA tile motifs. a) Relationship between Wang tiles and
branched junction, indicating that the sticky ends on a branched junction can emulate a Wang tile. b)
Wang tiles with colour-coded edges can be assembled according to the edge codes, thereby executing
computations.
Algorithmic DNA self assembly has been used to realise simple logic functions such as
XOR. The XOR calculation yields a 1 if the two inputs are different and a 0 if they are
the same. The concept of algorithmic assembly has been extended in recent years and
most  importantly  by  Rothemund et  al.,  who  assembled  DX  tiles into  Sierpinski
triangles.
12 These  are  symmetric triangle  structures  which  represent  the  iteration  of
XOR calculations. A polymeric nucleating scaffold strand was used at the starting point
of the assembly, to suppress spurious nucleation and carry the input information for the
computation.
Based on the concept of nucleated  DNA self-assembly  and previous  DNA junction
structures, a recent breakthrough in structural DNA nanotechnology toward creating
complex shapes and patterns came from Rothemund’s scaffolds, DNA origami.
22 This
method is based on folding a simple, long single-stranded DNA into a desired shape
with  the  help  of  multiple  “staple”  strands.  In  contrast  to  the  traditional  assembly
approach, there is no need to observe strict stoichiometric ratios, and assembly occurs21
quite quickly and in good yields. A variety of 2D shapes are created with the same long
strand and different sets of the “staple” strands: squares, rectangles, five-pointed stars, a
smiley face, and different triangles, all roughly 100 nm in dimensions.
1.3 AMNA project
1.3.1 General
The objective of the Addressable Molecular Node Assembly  (AMNA) project is to
develop a nanotechnology platform based on a sub-micron-size 2-D grid of addressable
molecular building blocks (“nodes”). DNA base-pair recognition will then be used to
construct the network, with each node having typically three oligonucleotide strands.
Oligonucleotide synthesis starts with a single oligomer strand, then incorporation of a
simple branching monomer followed by an orthogonal deprotection strategy, allows the
synthesis of two independent oligonucleotide strands from this point, forming a node as
shown in Figure 1.14. The two different oligonucleotide sequences synthesised from the
branch point, can be constructed 3’ to 5’ or 5’ to 3’ (using reverse amidites) as desired.
This  provides  a  great  deal  of  flexibility  in  the  ways  that  the  nodes  can  be  linked
together.22
1 2 3 4
Figure 1.14: a) Oligonucleotide synthesis: The first strand is synthesised as in 1, then the branching
monomer is incorporated as in 2 and selective deprotection allows the synthesis of the second arm (blue)
as in 3 then the third arm (pink) as in 4. b) Three way symmetrical node used.
A group of six nodes will connect to form a hexagon (Figure 1.15) providing a planar
network  of  hexagons.  The  aim  will  be  to  incorporate  interesting  functional  groups
which could be used to attach various moieties on the grid map, including chromophoric
“radiation sources”, extending perpendicular to the grid surface.
Figure  1.15: Formation  of  the  hexagons  by  using  branching  points  and Watson-Crick base-pair
recognition
Incorporation of fluorescent labels and lipophilic groups (to anchor the network to a
lipid surface) is to be achieved using modified phosphoramidite building blocks.
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o
4
4
a) b)23
Figure  1.16: To  the  left - molecular  model,  and  to  the  right - schematic  picture  of  start  hexagon
consisting  of  six  nodes,  each  bearing  three  deoxyribonucleotide  (DNA)  arms  with  mutually
complementary sequences of ten bases. Lipid chains, covalently tethered to the DNA strands, serve the
role of anchoring the hexagon to a lipid matrix. The grid will be built up, radially from the start hexagon,
by a net of hexagons and nodes, each being uniquely addressable by its base-sequence code. ©AMNA
project.
1.3.2 Lipophilic oligonucleotides
Chemical  modifications  are  introduced  using  the  appropriate  phosphoramidite
monomers  and  incorporating  them  during  oligonucleotide  assembly.  Attachment  of
lipid moieties is carried out using cholesterol with a hydrophilic group as a spacer. In
this way the hydrophilic group will form a bridge between the lipophilic group and the
phosphate backbone of the DNA chain and will enable the oligonucleotide to interact
with lipid membranes and at the same time remain in a hydrophilic environment at a
fixed distance from the lipid surface.
Lipid-conjugated oligonucleotides (L-ODN) will be studied with respect to assembly in
an effectively planar lipid bilayer. Highly monodisperse liposomes made of different
natural and synthetic lipids will be prepared through extrusion techniques and L-ODN
incorporation will be investigated as a function of the lipid composition, insertion of
double bonds, charge, solution ionic strength and in the presence of lyotropic agents.
Hexagonal  phases  are  commonly  encountered  as  lipid  mesophases  and  should  be
affected by the presence of three-armed oligonucleotides tethered to lipids and by the
length of the spacer. In this case the hexagonal network is not only confined to a 2D
space, but may also propagate into 3D. At this stage a proper tailoring of the spacing24
agent should be crucial in imparting appropriate protrusion length to the three-branched
oligonucleotidic groups.
Parameters  of  the  binding  affinity  (lipid  chain  length,  membrane  charge  and  ionic
strength) between the membrane and nodes will have to be fine-tuned. A very strong
membrane  affinity  of  hexagons  and  an  optimal,  medium  binding  affinity  of  the
monomer nodes are desirable. In this case the nodes will ideally be present at a high
concentration on the membrane surface, but still be able to dissociate and associate
quickly, until they find and hybridise to their membrane-bound target sequences of the
growing network.
1.4 Click chemistry
1.4.1 Introduction
Following nature’s lead, a new concept in organic chemistry has been defined which has
the potential to accelerate the syntesis of substances with useful purposes. The way this
is being done is by using nature’s small molecule building blocks that have C-C bonds
to  create heteroatom  links, which  are  much  easier to  make  efficiently than  carbon-
carbon  bonds.  This  approach has  been  termed  by Sharpless and  co-workers  “click
chemistry”.
To be called “click”, the reactions must be modular, have a high thermodynamic driving
force (give very high yields) and the starting material and reagent should be readily
available. They should proceed under simple conditions using solvents that are benign
(such as water), generating only inoffensive by-products and necessitate simple work-up
and purification procedures. This makes click chemistry both clean and green.
These click reactions achieve their required characteristics because they start with “high
energy” compounds, proceed to virtually complete conversion of these reagents and
tend to be highly selective. Such reactions are often termed “spring-loaded”. The ideal
click chemistry reactions are based on stereospecific processes with virtually all of the
control  elements  and  the  enabling  “energy  packets”  present  in  the  reactive
components.
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Olefins  are  among  the  most  attractive  starting  materials  available  to  the  synthetic
chemist  as  their  chemistry  provides  for  the  creation  of  diverse  scaffolds,  and the25
attachment  and  display  of  various  functionalities  through  the  oxidative  addition  of
heteroatoms  to  specifically  placed  olefinic  sites (Figure  1.17).  For  example, their
importance is enhanced by their role as progenitors of still higher-energy intermediates
such  as  epoxides,  aziridines, episulfonium  ions  and  aziridinium  ions,  which  are  all
suitable for a click chemistry approach.
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Figure 1.17: A selection of reactions which meet the Click Chemistry criteria. Unsaturated compounds
provide the carbon framework. New groups are attached via carbon-heteroatom bonds (shown in red).
Sharpless and co-workers have identified a set of the most useful click reactions where
the best are pure fusion processes. This characteristic is based on the understanding of
the  limitation  of  raw  material,  combined  with  environmental  concerns,  which
necessitate rethinking the strategies towards complex organic synthesis and recognising
the advantages of atom-economical reactions.
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 Nucleophilic opening of Spring-Loaded Rings:
These  are  the  SN2  ring-opening  of  epoxides,  aziridines,  cyclic  sulfates,  cyclic
sulfamidates, aziridinium ions and episulfoniums ions, which are strained heterocyclic
electrophiles from olefins or their oxidation products (Figure 1.18).26
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Figure 1.18: Opening of spring-loaded cyclic electrophiles
 Cycloaddition Reactions:
The two typical examples are hetero-Diels-Alder and 1,3-dipolar cycloadditions. The
latter is the most useful and reliable of the click reactions because the azide group is by27
far the most convenient of the 1,3-dipolar components to introduce and to “carry” until
needed.
 Non aldol carbonyl chemistry:
Acetals, ketals and some of their aza-analogues, usually used as diol protecting groups,
can  be  viewed  as  an  attractive  class  of  heterocycles  for  medicinal  chemistry
applications. They represent one of the rare click chemistry module based on reversible
carbonyl chemistry.
 Addition to multiple carbon-carbon bonds:
These  reactions  are typically  oxidation,  such  as  epoxidation,  dihydroxylation,
aziridination,  and  nitrosyl  and  sulfenyl  halide  additions,  but  also  certain  Michael
additions.
1.4.2 Huisgen reaction
The Cu
I-catalysed 1,3-dipolar cycloaddition has become, within the past few years, a
premier component of the click chemistry paradigm.
The prime example of a click reaction is the copper catalysed variant of the ubiquitous
Huisgen 1,3 dipolar cycloaddition of alkynes and azides.
75,76 The azides and alkynes are
easily installed into a molecule and despite being some of the more energetic species
known,  they  are  also  very  stable  under  a  variety of  conditions.  Indeed,  they  are
essentially inert to most biological and organic conditions and the majority of common
conditions  in  organic  synthesis.
77,78 This  stability,  being  purely  kinetic  in origin,  is
responsible for the slow nature of the cylcoaddition reaction, which requires elevated
temperatures and long reaction times
79-83 Unless the acetylene component is attached to
a highly electron-deficient group, the cycloaddition reaction affords mixtures of the 1,4-
and 1,5-disubstituted-regioisomers (Figure 1.19).28
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Figure 1.19: The thermally induced Huisgen cycloaddition of azides to alkynes usually results in
mixtures of the 1,4 and 1,5-triazole stereoisomers. In contrast, Cu (I) catalysed reaction results in
exclusive formation of the 1,4-triazole.
The reaction has benefited from a dramatic rate enhancement (up to 10
7) by copper
catalysis (Figure 1.19), reported independently by the Sharpless
78 and Meldal groups.
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This new reaction process is experimentally simple, proceeds with almost complete
conversion and selectivity for the 1,4-disubstituted-1,2,3-triazole, and appears to have
enormous scope for many reactions.
The  reaction  performs  best  in  aqueous  systems,  is  tolerant  to  a  broad  range  of
temperatures, is remarkably insensitive to pH, and is not significantly affected by the
steric and electronic properties of the groups attached to the azide and alkyne reactive
centres.
85,86
Different sources of copper (I) can be utilised in the reaction. Sources of Cu
I are copper
salts (CuI, CuBr), coordination complexes (such as [Cu(CH3CN)4]PF6, CuOTf·C6H6
78,
[Cu(PPh3)3]Br
87) and with a mixture of Cu
0 and Cu
II 85. As Cu
I is thermodynamically
unstable, the catalyst is better prepared in situ by reduction of Cu
II salts by ascorbic acid
and/or  sodium  ascorbate.  However,  at  very  low  concentration  of  the  reagents,  the
reaction  is  not  fast  enough,  and  copper- or  ascorbate-mediated  degradation  of  the
biological  scaffolds  has  been  observed.  The  use  of  the  ligand  tris-
(benzyltriazolylmethyl)amine  (TBTA)  significantly  accelerates  the  reaction  and
increases the redox potential of Cu
I/Cu
II (Figure 1.20).
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Figure 1.20: Tris-(benzyltriazolylmethyl)amine, TBTA.
1.4.3 Mechanism
The  process  of  this  catalytic  reaction  has  been  postulated  to  occur  by  a stepwise
mechanism as opposed to the thermal dipolar cycloaddition, which occurs through a
concerted mechanism.  The  lowest  calculated  barrier  of  any  concerted  1,3-dipolar
cycloaddition  of  a  copper-acetylene π  complex is  23.7  kcal/mol,  too  high  to  be
responsible  for  significant  rate  effect  of  Cu
I catalysis.  The  proposed  catalytic  cycle
lowers the activation barrier relative to that of the non-catalysed by as much as 11
kcal/mol (Figure 1.21).
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Figure 1.21: Proposed catalytic cycle for 1,3-dipolar cycloaddition30
The sequence begins with the complexation of the alkyne (step A) to the Cu
I metal
centre to form a copper acetylide 2 via the π complex. Alkyne π complexation was
calculated to be endothermic by 0.6 kcal/mol in acetonitrile and exothermic by 11.7
kcal/mol in water. This result is in good agreement with experimental observation of a
rate acceleration of a ligand dissociation in water. Moreover, the copper coordination of
acetylene is calculated to lower the pKa of the alkyne terminal proton by up to 9.8 pH
units, making deprotonation in aqueous system possible without the use of strong base.
Formation of the Cu
I–acetylide species allows for subsequent azide displacement of one
ligand and results in the intermediate 3 (step B). The key bond is created in the next step
(step C) by nucleophilic attack of the nitrogen distal to the acetylide, generating the
unusual six membered metallacycle 4. This step is endothermic by 12.6 kcal/mol with a
calculated barrier of 18.7 kcal/mol, which is considerably lower than the barrier for the
non-catalytic reaction (26.0 kcal/mol), and explains the tremendous rate acceleration of
the copper catalysed process. The regiospecificity can be explained by the fact that both
azide and alkyne are linked to the copper prior to the formation of the C-C bonds.
The resulting metallacycle 4 undergoes facile ring contraction (step D).  Indeed, the
energy barrier which leads to the triazolyl-copper derivative 5 is especially low (3.2
kcal/mol).  Protonation  (step  E)  of  the  triazole-copper  derivative  affords  the  1,4-
disubstituted 1,2,3-triazole, thus regenerating the catalyst and ending the cycle.
85,86,89
1.4.4 Selected applications
Within  a  short  time-frame,  click  chemistry,  and  essentially  the  Copper(I)-catalysed
azide-alkyne 1,3-dipolar cycloadition (CuAAC), has proven to be of remarkable utility
and broad scope not only in organic synthesis, but also in bioscience (drug discovery,
bioconjugation) and material science.
90-92
1.4.4.1 Use in organic chemistry
CuAAC has been used for the construction of a library of asymmetric organocatalysts
for  the  highly  diastereo- and  enantioselective  Michael  addition
93,94. Pericàs et  al.31
anchored a hydroxyproline derivative to a Merrifield resin using click chemistry and
used the resulting catalyst to direct the aldol reaction in water.
95
1.4.4.2 Drug discovery
Click chemistry is playing an important role in biomedical research, facilitating the
development  of  lead  discovery  libraries,  assisting  optimisation  and  also  tagging
biological systems. The lack of by-products and high conversion often allows screening
of reaction products without further purification
90
Using established, extensive internal medicinal chemistry capabilities that utilise click
chemistry,  laboratories  at  Lexicon  Pharmaceuticals, have  generated  a variety  of
sophisticated  libraries of  small  molecule  chemical  compounds  with  drug-like
characteristics. Each library compound was produced in only one or two synthetic steps,
from key building blocks reagents, using solution-phase chemistry.
Examples  include  nucleophilic  opening  of  strained  epoxides  and aziridines  for  the
formation of 1,2-difunctionalised compounds, generation of five-membered aromatic
heterocycles with imidoesters
96, synthesis of 1,2,3-triazole-derived libraries with azides
via  1,3-dipolar  cycloaddition  with  β-ketoesters
97, and  preparation  of  non-aromatic
heterocycle libraries with 3-aminoazetidines. A targeted library led to the discovery of
Peroxisome Proliferator-Activated Receptor γ (PPAR-γ) agonists.
98
The  reliability  of  click  chemistry  has  had  a  significant  impact  on  high  throughput
methodology.  For  instance,  Wong  et  al  identified  a  nanomolar  inhibitor  of  α-1,3-
Fucosyltransferase. The library of 85 donor substrates were synthesised via CuAAC and
screened in situ within the same well in which they were synthesised.
99
Lokey et al. have demonstrated the utility of click chemistry in the on-resin cyclisation
of a series of leucine-rich tetra-, penta-, hexa-, and heptapeptides, which makes possible
the generation of vast libraries of cyclic peptides. The cyclisation is complete within 6
hours, utilising mild conditions that are orthogonal to the protection groups common to
solid phase peptide synthesis (Scheme 1.1).
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Scheme 1.1: Reagents and conditions (i) CuBr (1eq), Na ascorbate (3eq), DIPEA (10 eq), 2,6-lutidine
(10eq), DMF, 6 h, 25 °C.
Two highly versatile cycloadditions (aza-Diels-Alder and CuAAC) have recently been
used for the rapid assembly of proline mimetic libraries.
101
The  1,2,3-triazole  moiety  is  a  potential  pharmacophore  that  can  mimic  the  atom
placement and electronic properties of a peptide bond without the same susceptibility to
hydrolysis.
72,102 Therefore it can be readily incorporated into a design strategy, rather
than being used merely as a linking functionality. Several examples exist within the
literature where the biological activity of 1,2,3-triazoles have been described, including
HIV-1  protease  inhibitor,
103,104 antibacterial,
105,106 anti-inflammatory,
107 tuberculosis
inhibition
108,109 to name a few.
1.4.4.3 Bioconjugation
The highly chemoselectivity of click  chemistry  has recently  emerged as a powerful
conjugation strategy for the preparation of diverse bioconjugates including conjugation
with peptides, proteins, oligosaccharides, glycoconjugates and DNA.
The original demonstration of versatility of CuAAC towards bioconjugation was hinted
by Meldal and co-workers in their breakthrough article as the joint discoverers of the
CuAAC.
84 They used the triazole as a peptide bond mimic and showed that the reaction
conditions  of  CuAAC were  fully  compatible  with  solid-phase  peptide  synthesis.
Triazole  ligations  allow  a  broad  possibility  of  oligopeptide  designs  such  as  cyclic
peptides using triazole-based spacers or triazoles as peptide isosteres.
110,111 Maarseveen
et al. proved that 1,4-disubstituted 1,2,3-triazoles can serve as transoid  amide bond33
mimics  and  demonstrated  the  retention  of biological  activity  of  the  cyclic
peptidomimetic.
111
Following  the  discovery  and  development  of  CuAAC  in  water,  the  potential  for
attachment of synthetic labels to a biomolecular environment has been realised. Finn et
al. applied CuAAC to conjugation of fluorescin dye molecules to the cowpea mosaic
virus.
112 The virus itself is a structurally rigid assembly of 60 identical copies of a two-
protein  asymmetric unit  around  a  single-stranded  RNA  genome.  The  virus  particle
presents  functionality  on  its  exterior  surface,  including  reactive  lysine  or  cysteine
residues, which were decorated with azide and alkynes, which were therefore used for
conjugation via CuAAC.
The procedure was developed in a further study by Finn et al., where they used a new
water-soluble  sulfonated  bathophenanthroline  ligand (Figure  1.22).  The  ligand
displayed  higher  reaction  rates  than  TBTA  with  lower  concentration  of  labelling
substrate.  However,  as  the  ligand  increases  the  sensitivity  of  the  copper  catalyst  to
oxidation, the reaction has to be carried out in an inert atmosphere.
113
N N
NaO3S SO3Na
Figure 1.22: Water sulfonated bathophenanthroline ligand
In carbohydrate chemistry, several examples exist where one or more saccharides have
been linked to themselves, to a central core (drug, peptide, etc), or functional groups by
CuAAC.  Indeed,  the  synthesis  of  triazole-linked  glycosaccharides  has solved the
problem of  sensitivity  of  glycosidic  linkages  towards  chemical  and  enzymatic
hydrolysis which make them poor lead-compounds.
114 115 Such ligation is versatile
enough  to  allow  for  example  the  formation  of  hybrid  structures  such  as  defined
glycopeptides.
116,117 For  instance, Danishefsky and  co-workers  used  multiple  click
triazole formation to combine three tumor-associated carbohydrate antigens on a single
polypeptide scaffold (Figure 1.23).
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Figure 1.23: Synthetic  glycopeptide  fragments  conjugated  to  a  modified  carrier  protein via click
chemistry.
The  power  of  bioconjugation  with  click  chemistry  extends  to  the  labelling  of
biomolecules in vivo.  The bioorthogonal azide  and alkyne functionalities have been
exploited by Cravatt et al. for use in activity-based profiling of proteins (ABPP). ABPP
is a rather new postgenomic method in which affinity labels are used to profile proteins
on the basis of their function in biological systems. Commonly used reporter groups in
ABPP (fluorophores, biotin, etc) are quite bulky and may inhibit cellular uptake. A
rhodamine alkyne was reacted with sterically inconspicuous azido-modified enzymes
using CuAAC. Mice were used to prove that the click chemistry-ABPP method could
identify changes in enzyme activity in vivo. However, the click reaction was still only
performed after sacrifice of the animal and cell lysis, due to the toxic nature of the
copper catalysis (Figure 1.24).
119,12035
N3-(CH2)6-OSO2Ph
Nu
in vivo
Nu (CH2)6 N3
Tag in vitro CuAAC
Nu (CH2)6 N N
N
Tag
Figure 1.24: Click activity-based protein profiling
Although the reactivity of the participating groups are almost perfectly orthogonal to
those of the diverse functional groups in biological systems, this reaction still does not
provide a final solution. In fact, the ideal bioconjugation reaction can be carried out
without the requirement of Cu
I catalysis (which exhibits considerable cell toxicity) and
ancillary  ligands. Bertozzi et  al. investigated  novel  substituted  “spring-loaded”
cyclooctynes as an  alternative means of activating alkynes for catalyst  free [3 + 2]
cycloaddition with azides. They performed in vivo labelling and the validity of this
copper-free approach in living cells was demonstrated.
121,122. Cycloaddition reactions
involving cycloalkynes are not regioselectives but present some “click” features such as
chemoselectivity and ready applicability in physiological conditions.
1.4.4.4 Click chemistry and DNA
Click chemistry has been used in the field of DNA sequencing to improve the efficiency
of the Sanger method in mild conditions without the need of additives or the formation
of by-products.
123 The M13-40 universal forward sequencing primer was tagged at its
5’-end with alkynyl 6-carboxyfluorescein (FAM) without further purification by  gel
electrophoresis  or  HPLC  required  for  conventional  fluorescent  oligonucleotides
synthesis.  The  FAM-triazole-M13-40  primer  was  successfully  used  in  the  Sanger
method.
124 However, in this early work, a standard metal-free Huisgen cycloaddition
was  performed. Carell et  al. used  CuAAC  to  post-synthetically  decorate  alkyne
modified DNA with a high density of azido-labels. They demonstrated the utility of the36
TBTA ligand which stabilises the Cu
I oxidation state since copper ions in the presence
of O2 induce DNA cleavage.
125,126
CuAAC  has  also  proven  to  be  useful  for  the  immobilisation  of  acetylene-bearing
ssDNA to gold-coated azide-functionalised self-assembled monolayers in the presence
of TBTA. The ligand here also prevented the production of potentially DNA damaging
oxygen radicals via the redox chemistry of copper (I).
127
CuAAC has been used in the nucleic acid field to attach various labels to modified
DNA  such  as  polypeptides
128,  fluorescent  labels
129,  or  after  methyltransferase-
mediated site-specific alkylation
130. It has also been used with microwave assistance, for
the preparation of DNA-glycoconjugates using  alkynes attached to phosphoramidate
linkages present in synthetic oligonucleotides.
131 Microwave irradiation has also been
used to accelerate CuAAC reactions between pyren-1-yl azides and ODNs incorporating
several insertions of azides to form twisted intercalating nucleic acids.
132
Kocalka et  al. used  CuAAC  to  covalently  cross-link  complementary  DNA  strands
internally utilising several alkyne and azide-modified uracil monomers to form very
stable duplexes.
133
The synthesis of large covalently closed DNA catenanes was achieved by Kumar et al.
who developed an efficient method of oligonucleotide ligation using CuAAC (Figure
1.25). First, two different strands, one containing a 3’-azide and the other a 5’-alkyne,
were connected by a templated triazole cyclisation. This approach was applied for the
intramolecular circularisation  of  a  single  stranded  ODN  to  form  macrocylcic  DNA
without the use of template. When the complementary DNA strand, also possessing 3’-
azide and 5’-alkyne termini, was allowed to anneal to the cyclic DNA and treated with
Cu(I), a double-stranded DNA catenane resulted, connected with two stable triazole
units.
134 This strategy has also been used to produce extremely stable and very short
duplexes, containing hexaethylene glycol bridges, by forming triazole linkages between
the sugar-phosphate backbone at the termini.
13537
N3
ligand
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Figure  1.25: Synthesis  of  a  double-stranded  DNA  catenane  from  a  single-stranded  cyclic  template
(shown in red), followed by annealing of the complementary strand (shown in blue) and ligation (triazoles
are reprensented by pink pentagons).
1.5 Gel electrophoresis
136
Electrophoresis  is  generally  used  for  separation  and  sometimes  purification  of
macromolecules that differ in size, charge or conformation. This widely-used technique
can result in very high resolution. The charged macromolecules are placed in an electric
field and travel through a matrix of inert material, which acts as a molecular sieve,
allowing separation of macromolecules.
1.5.1 PAGE
Nucleic acids are electrophoresed within a gel matrix composed of either agarose or
polyacrylamide. Polyacrylamide is a cross-linked polymer of acrylamide. The length of
the  polymer  chains  is  dictated  by  the  concentration  of  acrylamide  used,  typically
between  5  and  20%.  Acrylamide  polymerises  in  head-to-tail  fashion  to  form  long
polymers, which form a complex network held together by bis-acrylamide crosslinks.
The cross-linked polymers create pores in the gel; the size of pores is determined by the
acrylamide concentration, therefore the separation can be tuned depending on the size
range of the molecules being separated.38
1.5.2 Ferguson plot
The  electrophoretic  mobility (μ) observed  for  a  macromolecule  in  solution  is
determined by Equation 1.1:
μ = v/E =q/f
Equation 1.1: Electrophoretic mobility in solution. v = velocity, E = electric field strength, q = total
charge of the macromolecule, f = frictional coefficient.
For large DNA molecules, both q and f are directly proportional to DNA molecular
weight. Hence, μ is expected to be independent of molecular weight. In gels, μ of a
macromolecule is determined primarily by the volume fraction of pores within the gel
that the macromolecule can enter. Small DNA molecules migrate through the matrix
faster than larger DNA molecules because they encounter less frictional drag in the gel.
The relationship between mobility in free electrophoresis and that through a gel was
developed by Ferguson
137 (Equation 1.2)
logμi = logμ0i–KiC
Equation 1.2: Electrophoretic mobility of a macromolecule (i) in gel matrix. μ0= free solution mobility,
C = gel concentration, KR = retardation coefficient (constant specific of i).
Semilogarithmic plots of mobility vs gel concentration are called Ferguson plots and
illustrate the behaviour of various macromolecules (Figure 126). The relative mobility
(μri) of a macromolecule can be determined relative to a high mobility dye (μd)
(Equation 1.3).
μri = μi/ μd =di/dd
Equation 1.3: Electrophoretic relative mobility of a macromolecule (i) in gel matrix. μ= mobility, d =
distance that the macromolecule (i) or the dye (d) travels.39
Figure 1.26: Ferguson plot of a mixture of macromolecules of different molecular weights. This situation
applies to DNA fragments.
1.6 Methods for studying the properties of nucleic acids
1.6.1 UV melting
138
Ultraviolet spectroscopy (UV) is a commonly used technique to determine the quantity
of absorbing species (chromophores). The chromophores in nucleic acids are the purine
and pyrimidine heterocyclic bases and the measure of UV absorption determines the
concentration of nucleic acids in solution according to the  Beer-Lambert law  given
below.
Absorbance (An) = log10(I0/I) = cl
Equation 1.4: The Beer-Lambert law. An = absorbance at n nm, I0 = intensity of the incident light, I =
intensity  of  the  transmitted  light,  =  molar  absorption  coefficient  (extinction  coefficient),  c  =
concentration of the chromophore in mol/Land l = path length in cm.
The UV absorption profiles of nucleosides are due to base compositions which give rise
to absorption in the 240-280 nm range at neutral pH. ODNs have strong absorption40
maxima (max) at 260 nm. The base nitrogen atoms can protonate and therefore such
spectra  are  highly  pH  dependent. The  absorption  at  260  nm  (A260 or  OD,  optical
density) is commonly used as a measure of total nucleic acid concentration in a buffered
solution.
The temperature dependence of UV absorption can also be used for determining the
stability of nucleic acids structures. The stacked bases in multi-stranded nucleic acid
structures  absorb  less  UV light  than  do  unstacked  bases. This  effect  is  called
hypochromism. The input of thermal energy disrupts the base pairing and causes the
strands to separate. The Tm of a duplex is defined as the temperature at which 50% of
the ODN strands are hybridised, whilst the other 50% have been separated into single
strands. The Tm value is affected by the length of the ODN, its sequence composition
and base or sugar modifications.
The  Tm of  a  duplex  is  determined  by  calculating  the  maximum  point  of  the  first
derivative of the melting curve. A typical melting curve is shown in Figure 1.27.
Figure 1.27. Illustration of the melting temperature (Tm) of a DNA duplex.41
CHAPTER 2
Synthesis and properties of hydrophobic
monomers and oligonucleotides for Addressable
Molecular Node Assembly42
2. Synthesis and properties of hydrophobic monomers and
oligonucleotides for Addressable Molecular Node Assembly
2.1 Introduction
The objective of the AMNA project, of which this PhD research project is a part thereof,
is to develop a nanotechnology platform on a grid of addressable molecular building
blocks  using  DNA  node  structures.  Lipophilic  groups  are  incorporated  into  the
oligonucleotides (ODNs) for subsequent anchorage of the network to a lipid surface.
This chapter describes the syntheses of phosphoramidite monomers functionalised with
cholesterol and a spacer unit. The spacer provides separation between the hydrophobic
cholesterol moiety and the phosphate backbone of the DNA strand. The monomers are
subsequently  incorporated  into  oligonucleotides  for  studying the  assembly  of  Lipid-
conjugated oligonucleotides (L-ODNs) in the planar lipid bi-layer.
The main objective was to realise the synthesis of lipophilic phosphoramidite monomers
in order to incorporate lipohilic groups into oligonucleotides.
2.2 Cholesterol-linked benzyl alcohol monomer, 8
The  first  monomer  to  be  synthesised  was  a  benzyl  alcohol derivative, attached  to a
cholesterol group, separated by a spacer unit 3 (Scheme 2.1).43
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Scheme 2.1: Reagents and conditions (i) Ethyl trifluoroacetate (1.5 eq), Et3N (3 eq), MeOH, rt; (ii) prop-
2-yn-1-amine (1 eq), EDC (1.3 eq), CH2Cl2, rt; (iii) 3 (1.1 eq), CuI (0.2 eq), Pd(PPh3)4 (0.1 eq), Et3N (5
eq), DMF, rt, dark; (iv) ethanolic methylamine (80 eq), rt; (v) cholesteryl chloroformate (1.2 eq), CH2Cl2,
rt; (vi) 2-O-cyanoethyl-N,N-diisopropyl chlorophosphoramidite (1.1 eq), DIPEA (2.5 eq), THF, rt.
2.2.1 Synthesis
The  amine  of  commercially  available  12-aminododecanoic  acid 1, was  protected  by
reaction  with  ethyl  trifluoroacetate  in  MeOH with  Et3N  at  room temperature.  The
product 2 was  coupled  with  prop-2-yn-1-amine  using  EDC  in  CH2Cl2 at  room
temperature. Purification by column chromatography gave 3, in a 79% overall yield for
the two steps.44
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Scheme 2.2: Reagents and conditions (i) Ethyl trifluoroacetate (1.5 eq), Et3N (3 eq), MeOH, 22.5 h, rt;
(ii) prop-2-yn-1-amine (1 eq), EDC (1.3 eq), CH2Cl2, 24 h, rt, 79% overall.
Spacer synthesis was repeated on a substantial scale (57 mmol) in order to have a
sufficient quantity of compound 3 to use in future derivatisation with various lipophilic
groups.
Spacer 3 was attached to 4-iodobenzylalcohol 4 via a Sonogashira coupling in DMF at
room temperature. Purification by column chromatography gave 5 in 75% yield.
The terminal TFA-protected amine of 5 was deprotected using ethanolic methylamine
at room temperature to generate 12-amino-N-{3’-[4’’’-(hydroxymethyl)phenyl]prop-2’-
ynyl}dodecanamide 6. This was coupled with cholesteryl chloroformate in CH2Cl2 at
room temperature to afford compound 7 in a 19% overall yield for the two steps, after
purification  by  column  chromatography.  An  increased  overall  yield  of  33%  was
achieved by altering the reaction conditions.
139 Compound 6 was dried overnight under
high vacuum to remove traces of ethanolic methylamine and the quantity of cholesteryl
chloroformate was increased to an excess, with 1.2 equivalents.
Compound 7 was  then  phosphitylated  with 2-O-cyanoethyl-N,N-diisopropyl
chlorophosphoramidite  and  DIPEA  in  THF  at  room  temperature.  This  reaction
successfully afforded the phosphoramidite monomer 8 in a 43% yield after purification
by column chromatography (Scheme 2.3).45
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Scheme 2.3: Reagents and conditions (i) 3 (1.1 eq), CuI (0.2 eq), Pd(PPh3)4 (0.1 eq), Et3N (5 eq), DMF,
2 h, rt, dark, 75%; (ii) ethanolic methylamine (80 eq), 24 h, rt; (iii) cholesteryl chloroformate (1.2 eq),
CH2Cl2,  2  h  at  0 °C then  1.5  h  at  rt,  33%  overall;  (iv)  2-O-cyanoethyl-N,N-diisopropyl
chlorophosphoramidite (1.1 eq), DIPEA (2.5 eq), THF, 1.5 h, rt, 43%.
2.2.2 Biophysical studies
Monomer 8 (Bz
Chol) was  incorporated  into  the  oligonucleotide  ODN-1
(Bz
Chol TTTTTTTTTTTT) using standard solid phase synthesis conditions as described
in Chapter  4 (see  section  4.3.1),  to  assess  coupling  efficiency,  and  to  optimise
purification protocols. The hydrophobicity of the cholesterol aided HPLC purification
by increasing retention time on the column (see Appendix). Analysis by MALDI-TOF
MS showed successful incorporation of Bz
Chol into the oligonucleotide ([M+H]
+ calcd,
4421.5; found, 4420.0).
The stability of Bz
Chol to aqueous ammonia was studied using ODN-1 and ODN-2
(Bz
CholTTT). ODN-2 was heated at 55 °C in aqueous ammonia for 3 hours; one sample
of ODN-1 was also heated at 55 °C in ammonia for 3 hours and another sample for 15
hours. Analysis of all samples by MALDI-TOF MS indicated in all cases, both the
intact oligonucleotide  (ODN-1,  ODN-2)  and  the  corresponding  oligonucleotides
without the cholesterol modification.
The sample of ODN-1 which was heated for 15 hours, was purified by HPLC and the
main fraction was analysed by MALDI-TOF MS. The resultant peak corresponded to
the loss of Bz
Chol.46
Expected mass [M+H]+ Observed mass [M+H]
+
1683.8 1680.7 and 933.8
heated 3 h 4421.5 4416.4 and 3666.4
heated 15 h 4421.5 4421.7 and 3669.3
heated 15 h and purified 4421.5 3669.0
ODNs / Conditions
ODN-2 heated 3 h
ODN-1
Table 2.1: MALDI-TOF MS analysis on a ThermoBioAnalysis Dynamo MALDI-TOF
mass spectrometer in positive ion mode using internal Tn standards.
140 (see Section 4.1).
It  is  possible  that  the  peak  at  mol  wt  3669.0  could  have  been  due  to  incomplete
coupling caused by presence of residual phosphitylating agent, therefore Bz
Chol was
purified a second time and then incorporated into ODN-2. One sample was treated in
aqueous ammonia for 30 min and a second was heated in aqueous ammonia for 65
hours. MALDI-TOF analysis showed two peaks, which were identical to those obtained
in the first experiment. Since there is no difference in the ratio of oligonucleotide to
decomposition product under 30 min or 65 hours at 55 °C in aqueous ammonia, this is
not a problem caused by instability in ammonia. Decomposition could be occurring due
to a problem  with purification of the monomer.  It is also possible that the desired
oligonucleotide  was  retained  on  the  HPLC  column,  or  that  coupling  of  Bz
Chol was
incomplete.
ODNs / Conditions Expected mass [M+H]
+ Observed mass [M+H]
+
ODN-2 treated 30 min 1683.8 1684.8 and 946.6
ODN-2 treated 65 h 1683.8 1685.5 and 931.5
Table 2.2 : MALDI-TOF MS analysis on a ThermoBioAnalysis Dynamo MALDI-TOF
mass spectrometer in positive ion mode using internal Tn standards.
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2.3. Synthesis of the Thymidine monomer linked to Cholesterol by a
hydrophobic spacer, 13
The  cholesterol moiety was  attached  this  time  to  a 2’-deoxythymidine nucleoside,
separated by the same hydrophobic spacer unit 3 (Scheme 2.4).
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Scheme  2.4:. Reagents and  conditions (i) Ethanolic  methylamine  (90  eq),  rt; (ii) cholesteryl
chloroformate (1.2 eq), CH2Cl2, 2 h at 0 °C then at rt; (iii) 10 (1.1 eq), CuI (0.2 eq), Pd(PPh3)4 (0.1 eq),
Et3N (5 eq), DMF, rt, dark; (iv) 2-O-cyanoethyl-N,N-diisopropyl chlorophoramidite (1.1 eq), DIPEA (2.5
eq), THF, rt.
2.3.1 First route
The first step toward synthesis of this cholesterol-linked thymidine monomer was to
deprotect the amine then attach the cholesterol prior to the Sonogashira reaction. This
prevents reaction between cholesteryl chloroformate and the secondary 3’-alcohol of
the  nucleoside.  Secondly,  the  acidic  nature of  the  cholesteryl  chloroformate  could
cleave the acid-labile DMT of the 5’-O-(4,4’-dimethoxytrityl)-5-iodo-deoxyuridine 11.
The amine of 3 was deprotected with ethanolic methylamine to give 12-amino-N-(prop-
2-ynyl)dodecanamide 9. This was subsequently coupled with cholesteryl chloroformate
by  the  same  method  as  in Scheme  2.3.  Following purification  by  column48
chromatography, 12-(cholesteryloxycarbonylamino)-N-(prop-2-ynyl) dodecanamide 10,
was afforded in a 40% overall yield over the two steps (Scheme 2.5).
The  conditions  for  the  Sonogashira  reaction  between  alkyne 10 and  5’-O-(4,4’-
dimethoxytrityl)-5-iodo-2’-deoxyuridine 11
141 (synthesised by Chaturong Suparpprom)
were investigated, because standard conditions
142,143 afforded 12 in only 17% yield.
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Scheme  2.5: Reagents  and  conditions (i) Ethanolic  methylamine  (90  eq),  31  h,  rt; (ii) cholesteryl
chloroformate (1.2 eq), CH2Cl2, 2 h at 0 °C then 2 h at rt, 40% over two steps; (iii) 10 (1.1 eq), CuI (0.2
eq),  Pd(PPh3)4 (0.1  eq),  Et3N  (5  eq),  DMF,  2  h,  rt,  dark.;  (iv) 2-O-cyanoethyl-N,N-diisopropyl
chlorophoramidite (1.1 eq), DIPEA (2.5 eq), THF, 2 h, rt.
The first approach in solving this problem was to examine whether the number of
equivalents  of  Et3N  or  the  temperature made  any difference  to  the  yield  obtained.
Reactions were carried out using either 5 or 20 equivalents of Et3N and the temperature
at either rt or 60 °C. However, the results of these tests were inconclusive. The second
approach employed microwave techniques, but this did not improve the yield either.
The reaction was repeated using unprotected thymidine and 50 equivalents of Et3N, but
the compound obtained was not pure and the yield was low. This poor yield could be
rationalised by the bulkiness of the cholesterol, which may have prevented the coupling
to take place.49
2.3.2 Second route
As the first route did not work, an alternative route to monomer 13 was considered. The
Sonogashira cross-coupling was achieved by using the protected thymidine 11 and a
shorter alkyne 3, as shown in Scheme 2.6. Purification by column chromatography gave
14 in a 66% yield. This compound was then subjected to conventional phosphitylation
conditions:  addition  of  2-O-cyanoethyl-N,N-diisopropyl  chlorophosphoramidite  and
DIPEA in THF under an argon atmosphere to give 15 in a 47% yield (Scheme 2.6).
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Scheme 2.6: Reagents and conditions (i) CuI (0.4 eq), Pd(PPh3)4 (0.2 eq), Et3N (10 eq), DMF, rt, dark,
23 h, 66%; (ii) 2-O-cyanoethyl-N,N-diisopropyl chlorophosphoramidite (1.1 eq), DIPEA (2.5 eq), THF,
1.5 h, rt, 47%.
The  amine  could  be  easily  deprotected  to  enable  the  attachment  of  a  dye,  such  as
rhodamine, to compound 14. After phosphitylation, the monomer could be incorporated
into  oligonucleotides  using  standard  solid  phase  oligonucleotide  synthesis  and  then
deprotected under standard deprotection conditions.
Synthesis of the cholesterol-modified monomer using the shorter alkyne 3, requires that
the  Sonogashira  reaction  between  the  deprotected  alkyne 9 and  the  5-iodo-2’-50
deoxyuridine derivative, is carried out before the cholesterol is coupled to the alkyne. It
is necessary therefore, to protect the nucleoside at the 3’- and 5’-positions (acetyl) to
avoid a possible reaction between these hydroxyl groups and cholesteryl chloroformate.
Then the 5’-position would have to be tritylated following deprotection of the acetyl
groups. The last step is the phosphitylation of the 3’-position to give monomer 13, as
shown in Scheme 2.7.
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Scheme 2.7: Reagents and conditions: (i) Ac2O (3 eq), pyridine, rt; (ii) ethanolic methylamine (70 eq), rt,
24 h; (iii) 17 (1.1 eq), CuI (0.2 eq), Pd(PPh3)4 (0.1 eq), Et3N (5 eq), DMF, rt, dark; (iv) cholesteryl
chloroformate (1.2 eq), CH2Cl2; (v) ethanolic methylamine; (vi) 4,4’-dimethoxytrityl chloride (1.2 eq),
pyridine,  rt;  (vii)  2-O-cyanoethyl-N,N-diisopropylchloro phosphoramidite (1.1  eq),  DIPEA  (2.5  eq),
THF, rt.51
5-Iodo-2’-deoxyuridine 16 was  protected  in  the  5’- and  3’-positions  using  acetic
anhydride  in  pyridine  to  generate 17 quantitatively  after  column  chromatography
(Scheme  2.8). The  amino  group  of  the  spacer 3 was  deprotected  using  ethanolic
methylamine at 55 °C to give 12-amino-N-(prop-2-ynyl)dodecanamide 9. After further
investigations  into  the  conditions  of  the  Sonogashira  coupling,  compound 9 was
attached to the protected nucleoside 17 in DMF at room temperature followed by a
simple filtration through celite as workup. Purification by column chromatography gave
18 in a 73% overall yield (Scheme 2.8).
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Scheme 2.8: Reagents  and  conditions: (i) Ac2O  (3  eq),  pyridine,  rt,  16.5  h,  quant.;  (ii)  ethanolic
methylamine (70 eq), 55 °C, 20 h; (iii) 17 (2.2 eq), CuI (0.4 eq), Pd(PPh3)4 (0.2 eq), Et3N (40 eq), DMF,
rt, dark, 30.5 h, 73% overall.
Compound 18 was coupled with cholesteryl chloroformate in a mixture of CH2Cl2 and
DMF  at  room  temperature  with  DIPEA  as  a  base.  Purification  by  column
chromatography  gave 19 in  only  32%  yield.  The  first  conditions  used  for  the
deacetylation of 19 were ethanolic methylamine in CH2Cl2, but analysis of the product
did not show formation of the free nucleoside. Reactions were carried out using either
15 or 62 equivalents of ethanolic methylamine and the temperature at either rt or 55 °C.
However, the results of these tests were inconclusive. Another attempt at deprotecting
19 using potassium carbonate in a mixture of methanol and water successfully resulted
in 20.52
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Scheme  2.9: Reagents  and  conditions: (i)  Cholesteryl  chloroformate  (1.2  eq),  DIPEA  (1.2  eq),
CH2Cl2/DMF, 2 h at 0 °C and 2 h at rt, 32%; (ii) 0.4 M K2CO3 in MeOH:H2O (4:1, v/v) (6 eq), 1 h 45
min, rt.
Without  further  purification, 20 was  tritylated  with  4,4’-dimethoxytrityl  chloride  in
pyridine and CH2Cl2. Purification by column chromatography gave 12 in a 45% overall
yield.  Compound 12 was  then  phosphitylated  with 2-O-cyanoethyl-N,N-diisopropyl
chlorophosphoramidite  and  DIPEA  in  THF at  room  temperature.  This  reaction
successfully  afforded  the  phosphoramidite  monomer 13 in  a  82%  yield  after
purification by column chromatography.
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Scheme 2.10: Reagents and conditions: (i) 4,4’-dimethoxytrityl chloride (3 eq), pyridine, CH2Cl2, rt, 5 h,
45%  overall;  (vii)  2-O-cyanoethyl-N,N-diisopropyl  chlorophosphoramidite (1.1  eq),  DIPEA  (2.5  eq),
THF, rt, 0.5 h, 82%.53
2.3.3 Biophysical studies
2.3.3.1 10-mers
Monomer 13 (T
Chol) was incorporated into oligonucleotides ODN-3 and ODN-4 using
standard automated DNA synthesis conditions as described in section 4.3.1. UV melting
experiments were performed on a Varian Cary 400 Scan UV-Vis spectrophotometer,
monitoring at 260 nm, in buffer at pH 7.0 (10 mM sodium phosphate with 0.2 M NaCl
and 1 mM Na2EDTA). A 1:1 ratio of each oligonucleotide at 1 M concentration was
used.  Full  details  are  given  in  section  4.3.4.  A  schematic  representation  of  the  UV
melting duplex is shown below, in Figure 2.1.
ODN-3 5’-CGCAT
cholAT
cholCGC-3’
ODN-4 3’-GCGT
cholAT
cholAGCG-5’
Figure 2.1: Duplex UV melting experiment. T
chol = monomer 13.
Using a standard melt programme (20-80-20 °C at 1 °C/min, see section 4.3.4), UV
melting of these two oligonucleotides and each with their non-modified complementary
strand showed no duplex formation. The concentration of salt was then increased to 0.5
M and 1 M NaCl but no duplex was formed with ODN-3 and ODN-4 together, or with
their non-modified complementary strands. A buffer solution of 0.2 M NaCl with 1%
sodium dodecyl sulphate was used, in order to aid solubilisation of the cholesterol
moiety. Again no duplex was formed.
These  oligonucleotides  were  studied  by  fluorescence  melting  using  a  Roche
LightCycler
® and  the  fluorescent  intercalator  SYBR  Green  I,  which  was  used  to
measure the fluorescence change upon heating the oligomer mixtures. The studies were
performed  using  a  10  mM  sodium  phosphate  buffer  with  0.2  M  NaCl  and  1  mM
Na2EDTA at pH 7.0 with intercalator:total volume 1:10 v/v. The fluorescence melting
results did not show any duplex formed.54
2.3.3.2 18-mers
T
Chol was then incorporated into the oligonucleotides ODN-5 and ODN-6, 18-mers with
only  one  modification.  Duplex  formation  between  ODN-5 and  two  probe
oligonucleotides was analysed by UV melting experiments. A schematic representation
of the UV melting duplex is shown below, in Figure 2.2.
ODN-5 5’-ACCAAGGTGCTA T
cholCGTCG-3’
Probe1 3’-CACGATAGCAGC-5’
ODN-5 5’-ACCAAGGTGCTA T
cholCGTCG-3’
Probe2 3’-TGGTTCCACGAT-5’
ODN-5 5’-ACCAAGGTGCTAT
cholCGTCG-3’
ODN-6 3’-TGGTTCCACGAT
cholAGCAGC-5’
Figure 2.2: Duplex UV melting experiment. T
chol = monomer 13.
The UV melting experiment was performed at pH 7.0 (10 mM sodium phosphate buffer
with 0.2 M NaCl and 1 mM Na2EDTA). A standard duplex melt programme was used
(20-80-20 °C at 1 °C/min, see section 4.3.4).
 ODNs ODN-5/Probe 1 ODN-5/Probe 2 ODN-5/ODN-6
Tm  (°C) 48.7 54.0 nd
Table 2.3: Duplex UV melting experiment at pH 7.0 (10 mM sodium phosphate buffer with 0.2 M NaCl
and 1 mM Na2EDTA) using a standard melt programme (20-80-20ºC at 1ºC/min). nd = not determined-
Tm above 70 °C.
These results show that the Tm of the duplex between the two modified oligonucleotides
is too high to be measured by UV melting.
These  oligonucleotides  were  studied  by  fluorescence  melting  using  the  fluorescent
intercalator SYBR Green I. Experiments were conducted at pH 7.0 (10 mM sodium55
phosphate  buffer  with  0.2  M,  0.4  M  or  0.6  M  NaCl,  and  1  mM  Na2EDTA)  with
intercalator:total volume 1:10 v/v .
ODNs ODN-5/Probe1 ODN-5/Probe2 ODN-5/ODN-6
Tm (ºC) 44.5 46.2 67.6
ODNs ODN-5/Probe1 ODN-5/Probe2 ODN-5/ODN-6
Tm (ºC) 42.6 46.9 75.7
ODNs ODN-5/Probe1 ODN-5/Probe2 ODN-5/ODN-6
Tm (ºC) 39.7 46.5 78.4
buffer with NaCl 0.2 M
buffer with NaCl 0.4 M
buffer with NaCl 0.6 M
Table 2.4: Fluorescence melting experiment at pH 7.0 (10 mM sodium phosphate buffer with 0.2 M, 0.4
M or 0.6 M NaCl, and 1 mM Na2EDTA). Each Tm is an average of two separate runs.
The fluorescence melting data shows the dependence of the Tm of the duplex ODN-
5/Probe1 on salt concentration. This is likely due to increased hydrophobic interaction
between  the  cholesterol  moiety  and  the  DNA  bases  at  high  salt  concentration  and
possible  formation  of  a  hairpin  structure.  However,  the  duplex  formation  of  ODN-
5/ODN-6 is enhanced by increasing the concentration of NaCl. In this case, the two
cholesterol  groups  interact more favourably  with  each other with  increasing  salt
concentration.
Duplex formation between ODN-5 and ODN-6 was studied by fluorescence melting
(see  Figure  2.2).  A  comparison  of  the  data  obtained  with  the T
Chol modified
oligonucleotides (ODN-5, ODN-6) and the control T oligonucleotides (ODN-5’ and
ODN-6’)  is  showed  in Figure  2.4.  Experiments  were  performed  using  the  same
conditions as described above. A schematic representation of the UV melting duplex is
shown below, in Figure 2.356
ODN-5 5’-ACCAAGGTGCTAT
cholCGTCG-3’
ODN-6 3’-TGGTTCCACGAT
cholAGCAGC-5’
ODN-5’ 5’-ACCAAGGTGCTATCGTCG-3’
ODN-6’ 3’-TGGTTCCACGATAGCAGC-5’
Figure 2.3: Duplex UV melting experiment. T
chol = monomer 13.
Figure 2.4: (a) Fluorescence melting curves at pH 7.0 (10 mM sodium phosphate buffer with 0.2 M NaCl
and 1 mM Na2EDTA). The concentration of each ODN was 0.5 M. (b) d(F)/d(T) Melting data were
processed using the OriginPro 7.5 software.
The Tm of the duplex ODN-5/ODN-6, is higher than that of the natural duplex ODN-
5’/ODN-6’ (+2.4 ºC) and much higher than that of ODN-5’/ODN-6 and ODN-5/ODN-
6’ (+8.1 ºC and +8.8 ºC respectively) (Table 2.5).
ODNs ODN-5'/ODN-6' ODN-5'/ODN-6 ODN-5/ODN-6' ODN-5/ODN-6
Tm  (ºC) 67.6 61.9 61.2 70.0
buffer with NaCl 0.2 M
Table 2.5: Fluorescence melting experiment at pH 7.0 (10 mM sodium phosphate buffer with 0.2 M
NaCl and 1 mM Na2EDTA). Each Tm is an average of two separate runs.
a)
b)57
The fluorescence melting data in Table 2.5 clearly illustrates a lower Tm of the duplex
with a cholesterol moiety on one DNA strand, but higher melting temperature when
cholesterol is present on both strands.
2.4. Synthesis of 6-(cholesteryloxycarbonyl)-hexanol
phosphoramidite, 23
Since  the  first  phosphoramidite 8 was  not  stable  under  standard  oligonucleotide
deprotection conditions, a monomer was proposed with a simple alkyne chain as linker
between the cholesterol and the phosphoramidite moiety.
2.4.1 Synthesis
Commercially  available  6-amino-hexanol 21 was  reacted  with  cholesteryl
chloroformate in CH2Cl2 at room temperature. Purification by column chromatography
gave 22 in 86% yield. The next and final step was the phosphitylation of 22 with 2-O-
cyanoethyl-N,N-diisopropyl chlorophosphoramidite and DIPEA in THF under an argon
atmosphere which gave 23 in a 43% yield.
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Scheme 2.11: Reagents and conditions: (i) 6-amino-hexanol (2.2 eq), CH2Cl2, 2 h at 0ºC then 16.5 h at
rt, 86%; (ii) 2-O-cyanoethyl-N,N-diisopropyl chlorophosphoramidite (1.1 eq), DIPEA (2.5 eq), THF, rt,
0.5 h, 43%.
2.4.2 Biophysical studies
Monomer 23 (H
Chol)  was  incorporated  into  oligonucleotide  ODN-7,  using  standard
solid phase oligonucleotide synthesis to assess the coupling efficiency, and to optimise
the purification protocols. Due to the very high hydrophobic nature of the cholesterol,58
the  purification  of  the  oligonucleotide  on  a  reverse  phase  column  has  only  been
successful  analytically.  Analysis  by  MALDI-TOF  MS  showed  the  successful
incorporation of the H
Chol into ODN-7 ([M+H]
+ calcd 4235.45, found 4234.38).
2.5. Synthesis of the thymidine monomer, linked to cholesterol by a
hydrophilic spacer
The use of a hydrophobic spacer for monomer 13 would allow its penetration into the
lipid bilayer. A linker such as poly(ethylene glycol), which is hydrophilic, would allow
the monomer to anchor to the lipid bilayer via the cholesterol moiety only, rather than
the cholesterol-linker unit.
A new nucleoside-based cholesteryl 2’-deoxythymidine phosphoramidite monomer 34
was  synthesised,  with  a  hydrophilic  hexa(ethylene  glycol) linker  for  use  in
oligonucleotide synthesis.
The route to the target is described below in Scheme 2.12.
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Scheme 2.12: Reagents and conditions (i) TsCl (0.25 eq), Et3N (1 eq), DMAP (0.12 eq), CH2Cl2, rt; (ii)
potassium phthalimide (1.5 eq), DMF, reflux; (iii) TEMPO (0.2 eq), BAIB (3eq), H2O:CH3CN (1:1 v./v),
rt; (iv) 4,4’-dimethoxytrityl chloride (1.2 eq), pyridine, rt; (v) prop-2-yn-1-amine (1.1 eq), CuI (0.2 eq),
Pd(PPh3)4 (0.1 eq), Et3N (5 eq), DMF, rt , dark; (vi) 27 (1eq), EDC (1.3 eq), CH2Cl2, rt; (vii) hydrazine
monohydrate (98% w/v) (8 eq), EtOH, rt; (viii) cholesteryl chloroformate (1.2 eq), DIPEA (1.2 eq),59
CH2Cl2, 2 h at 0ºC then rt; (ix) 2-O-cyanoethyl-N,N-diisopropyl chlorophosphoramidite (1.1 eq), DIPEA
(2.5 eq), THF, rt.
2.5.1 Synthesis
2.5.1.1 Tosylation of hexaethylene glycol
Sutherland
144 described the synthesis of hexaethylene glycol mono-p-toluenesulfonate
25 using a workup procedure which avoids purification by column chromatography and
allows recovery of the starting material. Using this method, one terminal alcohol of 24
was  selectively  tosylated  using  toluenesulfonyl  chloride with  Et3N  and DMAP  in
CH2Cl2. The  reaction  mixture  was  washed with  distilled  water,  saturated  sodium
bicarbonate and citric acid solutions. However, the extraction did not produce a pure
product. The reaction was repeated following the same procedure, but an attempt to
recrystallise  from  ethyl  acetate  and petroleum ether  40-60ºC  was  not  successful.
Finally, column chromatography afforded 25 in 54% yield.
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Scheme 2.13: Reagents and conditions (i) TsCl (0.25 eq), Et3N (1 eq), DMAP (0.12 eq), CH2Cl2, 2 h at
0ºC then 5 h at rt, 54%.
This step has been repeated to improve the yield of the tosylation from 52% to 60%.
2.5.1.2 Displacement  of  the  tosyl  group  with
phthalimide
Following Muller’s procedure,
145 25 was reacted with potassium phthalimide in DMF at
reflux, but no precipitate was observed after 4h, contrary to the description in the paper.
Diethyl ether was added and the reaction was stirred for a further 30 mins in an ice bath.
The precipitate was then filtered, washed with ether, and then dissolved in CH2Cl2. The
insoluble impurities were filtered off and the filtrate was concentrated. The residue was
then dissolved in CH2Cl2 but no precipitate was formed with addition of ether, and a60
pure product could not be obtained. Another attempt of making HEG-phthalimide 26
was carried out by modifying the workup procedure. After removal of DMF, the residue
was  redissolved  in  ethyl  acetate  and  washed  with  water  and  saturated  sodium
bicarbonate. Again, a pure product was not obtained.
The reaction was repeated a third time and the workup procedure altered again. After
removing DMF, the residue was dissolved in CH2Cl2 and washed with water and then
saturated potassium chloride solution. The aqueous layer was re-extracted three times
with CH2Cl2. The resultant residue was purified by column chromatography and gave
26 in 78% yield.
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Scheme 2.14: Reagents and conditions (i) Potassium phthalimide (1.5 eq), DMF, 8 h, reflux, 78%.
2.5.1.3 Oxidation of the primary alcohol
The  oxidation  of  the  primary  alcohol  was  carried  out  according  to  the  procedure
described by Bessodes
146 on a 1 g scale. Compound 26 was dissolved in a 1:1 v/v
mixture of water and acetonitrile with TEMPO as a catalyst and BAIB as co-oxidant.
Purification by column chromatography gave 27 in only 28%  yield, contrary to the
quantitative yield obtained in the procedure. No other product and starting material was
seen on TLC except BAIB which has been added in excess.
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Scheme 2.15: Reagents and conditions (i) TEMPO (0.2 eq), BAIB (3eq), H2O:CH3CN (1:1 v/v), 3.5 h, rt,
72%.61
An alternative oxidation using Jones’ reagent was then carried out. The reaction was
successful  on  a  small  scale,  as  observed  by  MS.  At  the  same  time,  the  catalytic
oxidation with BAIB was carried out again and the conditions for the silica gel column
chromatographic purification were changed. The solvent was changed from a gradient
of MeOH in CH2Cl2 to isocratic elution using CH2Cl2 with 3% MeOH to give 27 in
72% yield.
2.5.1.4 Amide coupling reaction
It was decided that firstly the carboxylic acid 27 would be coupled with prop-2-yn-1-
amine.
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Scheme 2.16
Several  conditions  using  different  coupling  reagents  were  tried  as  detailed  below
(Scheme 2.16):
 CDI with DIPEA in THF: 21% yield
 HBTU and HOBT with DIPEA in MeCN: 37% yield
 EDC in CH2Cl2: 22% yield
 EDC and HOBT with DIPEA in CH2Cl2: not purified
All these conditions showed several spots on TLC and gave low yields.
Following  this,  the  order  of  the  steps  in  the  synthetic  protocol  was  changed.  The
Sonogashira reaction was carried out with unprotected prop-2-yn-1-amine but column
chromatographic purification over silica gel was difficult, due to the product’s high
polarity. Thus,  the  reaction  was  carried  out  with  2’,2’,2’-trifluoro-N-(prop-2-
ynyl)acetamide 34 previously  synthesised  in  the  laboratory  by  Simon  Gerrard)  and62
5'-O-(4,4-dimethoxytrityl)-5-iodo-2’-deoxyuridine 11 (repurifed  from  a  previous
synthesis in the laboratory by Simon Gerrard).
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Scheme 2.17: Reagents and conditions (i) 2’,2’,2’-trifluoro-N-(prop-2-ynyl)acetamide 34(1.1 eq), CuI
(0.2 eq), Pd(PPh3)4 (0.1 eq), Et3N (5 eq), DMF, 1.5 h, rt , dark, 96%; (ii) 33 wt % ethanolic methylamine
(50 eq), rt, 2 h.
The nucleoside has an acid-labile dimethoxytrityl group on the 5’-position, therefore
column chromatography was carried out in the presence of a small amount of Et3N.
However, the TLC showed that cyclisation to the furanopyrimidine occurred during or
after purification. This is a known side reaction that occurs if the product is left in the
presence of CuI and/or Et3N for an extended period.
147,148 In order to avoid this issue,
the column chromatography was carried out with pyridine affording 35 in an excellent
96% yield. The amine was then deprotected with ethanolic methylamine to give 28,
which was used without purification (Scheme 2.17).
In order to investigate the reactivity of the amine in the coupling reaction, a similar
nucleoside  with  two  more  carbons  between  the  free  amine  and  the  alkyne,  was
compared with 28, using two different conditions:
 EDC and HOBT with DIPEA in CH2Cl2
 EDC and DMAP with DIPEA in CH2Cl2.
The reactions worked in all four cases, but with several byproducts, as shown by TLC.63
O
OH
DMTO
N
NH
O
O
H2N
28
(i)
27
O
OH
DMTO
N
NH
O
O
N
H
29
O
O
5
N
O
O
Scheme 2.18: Reagents and conditions (i) 27 (1.1 eq), PyBrOP (1.1 eq), DIPEA (3 eq), CH2Cl2, 1.5 h, rt,
49%.
Two other coupling reagents, PyBOP and PyBrOP
149 were then compared with HBTU
in CH2Cl2 in the above reaction on 5-[3-amino-(propynyl)]-2’-deoxyuridine 28. Both
showed clean formation of the correct product by TLC, but PyBrOP was much quicker
to react. The reaction was carried out on 1 g scale and gave 29 in 49% yield (Scheme
2.18).
2.5.1.5 Hydrazinolysis
Cleavage of the phthalimide protecting group to give the primary amine was carried out
in 96% yield using hydrazine monohydrate in a mixture of CH2Cl2 and ethanol. The
product of the reaction is not readily soluble, which gives broad NMR spectra.
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Scheme 2.19: Reagents and conditions (i) Hydrazine monohydrate (98% w/v) (8 eq), CH2Cl2/ethanol,
3 h, rt, 96%.64
MS analysis implied the successful hydrazinolysis of 30 ([M + MeOH + H]
+ = 894),
however subsequent coupling reaction with cholesterol did not give the right product.
Further characterisation showed that the product of the hydrazinolysis reaction was not
what  was  expected,  but  a  possible  adduct  with  hydrazine  (+32  in  mass).
Trifluoroacetylation of this compound also indicated a product with an adduct of +32,
therefore test hydrazinolysis reactions were carried out:
Changing the solvent from a mixture of CH2Cl2 and methanol to DMF gave a 45%
yield, but MS again showed the formation of the adduct (+32).
The reaction was carried out using only 1 equivalent of hydrazine and was followed by
TLC and MS. At the start, compound 30 was formed, but the starting material remained.
Addition  of  another  equivalent  of  hydrazine  and  extra  reaction  time  caused  adduct
formation.
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Scheme 2.20: Reagents and conditions (i) Hydrazine monohydrate (98% w/v) (8 eq), ethanol, 1h 20 min,
rt, 71%.
Successful cleavage  of  the  phthalimide  protecting  group  on 33 was  achieved using
hydrazine monohydrate in ethanol. These conditions converted the phthalimide into the
primary amine, in 71% yield, despite previously being unsuccessful on the modified
nucleoside 29. This suggests possible addition of hydrazine to the DNA base on C
4, due
to the electron withdrawing effect of the alkyne on C
5. Adduct formation (+32) does not
occur without the modification on C5.
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Following this, the order of the steps in the synthesis (Scheme 2.12) was changed again
for the procedure shown in Scheme 2.21.65
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Scheme 2.21: Reagents and conditions (i) TsCl (0.25 eq), Et3N (1 eq), DMAP (0.12 eq), CH2Cl2, 2 h at
0ºC then 5 h at rt, 60%; (ii) potassium phthalimide (1.5 eq), DMF, 8 h, reflux, 80%; (iii) TEMPO (0.2 eq),
BAIB (3 eq), H2O:CH3CN (1:1 v/v), 3.5 h, rt, 72%; (iv) prop-2-yn-1-amine (1.1 eq), PyBrOP (1.1 eq),
DIPEA (3 eq), CH2Cl2, rt; (v) hydrazine monohydrate (98% w/v) (8 eq), EtOH, 1.25 h, rt, 71%; (vi)
cholesteryl chloroformate (1.2 eq), DIPEA (1.2 eq), CH2Cl2, 2 h at 0ºC then rt; (vii) 4,4’-dimethoxytrityl
chloride (1.2 eq), pyridine, 3.5 h, rt, 75%; (viii) 37 (1.1 eq), CuI (0.2 eq), Pd(PPh3)4 (0.1 eq), Et3N (5 eq),
DMF, rt , dark; (ix) 2-O-cyanoethyl-N,N-diisopropylamino chlorophosphoramidite (1.1 eq), DIPEA (2.5
eq), THF, rt.
Compound 36 was coupled with cholesteryl chloroformate in CH2Cl2 at rt, with DIPEA
as base, to give 37 in 88% yield. Sonogashira coupling reaction of 37 and protected
nucleoside 11 afforded 31 in 63% yield. At this stage, the whole synthetic scheme was
repeated on an 11 g scale. The coupling reaction between the carboxylic acid 27 and
prop-2-yn-1-amine was carried out using PyBrOP as coupling reagent, affording 33 in
53% yield (Scheme 2.22).66
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Scheme 2.22: Reagents and conditions (i) cholesteryl chloroformate (1.7 eq), DIPEA (1.2 eq), CH2Cl2, 2
h at 0ºC then 19 h at rt, 88%; (ii) 37 (1.5 eq), CuI (0.4 eq), Pd(PPh3)4 (0.1 eq), Et3N (7 eq), DMF, rt, dark,
3.5 h, 63%; (iii) prop-2-yn-1-amine (1.5 eq), PyBrOP (1.1 eq), DIPEA (3 eq), CH2Cl2, 1h 15 min, rt,
53%.
2.5.1.6 Phosphitylation
Compound 31 was  then  subjected  to  conventional  phosphitylation  conditions  by
addition of 2-O-cyanoethyl-N,N,diisopropylamino chlorophosphoramidite and DIPEA
in  CH2Cl2 under  an  argon  atmosphere.  However,
31P NMR  analysis  in d6-DMSO
showed a  chemical  shift  at  15.1  ppm  in  addition to the desired phosphoramidite
diastereoisomeric  mixture  at  148.8  and  148.3  ppm.  This  inferred the  presence  of a
different phosphorous  species  and  therefore  the  conditions  for  this  reaction  were
investigated.
The first approach to resolve this problem was to change the conditions of column
chromatography.  The  new  method  employed CH2Cl2 with  an acetone gradient  of
25-45%, instead of CH2Cl2 with a MeOH gradient of 1-2%. However, after purification,
31P-NMR  didn’t  show  the  presence  of  any  phosphoramidite. Another  attempt  was
carried out using the same reaction conditions and
31P NMR of the crude product again
showed a  chemical  shift  at  15.1  ppm, in  addition  to  the  phosphoramidite67
diastereoisomeric mixture. TLC showed the degradation of the phoshoramidite into two
more polar products.
Thus, to  investigate  this  fully,  the  phosphitylation  was conducted on  5’-O-(4,4-
dimethoxytrityl)-thymidine 11. The addition of an excess of phosphitylating reagent
again showed the degradation of the phosphoramidite into two more polar products, one
with a similar Rf as the starting material.
It  was  considered  that 2-O-cyanoethyl-N,N,diisopropylamino  chlorophosphoramidite
was  too  reactive  for  the  phosphitylation  of 31.  Therefore 2-O-cyanoethyl-N,N,N,N’-
tetraisopropylphosphoramidite was used as phosphitylating reagent, in the presence of
the  activator  diisopropylamine  hydrotetrazolide  (DIHT).  Column  chromatography  in
hexane with  an  EtOAc gradient  of 80-100% allowed  the  separation  of  the  two
compounds  which  were  visualised  on  TLC.  NMR  and  MS  analysis  confirmed  the
isolation of the pure phosphoramidite in a 66% yield, but the nature of the other product
was  not  identified.  It  is  likely  to  be  a  mixture  of  starting material,  phosphonato-
thymidine and a phosphoramidite at position N
3, all of which have the same Rf.
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Figure 2.5: Possibles phosphonates and phosphoramidites as by-products
Finally, 31 was  successfully  converted  to  its  2-O-cyanoethyl-N,N-diisopropyl
phosphoramidite 32 in 66% yield, using these same conditions (Scheme 2.23).68
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Scheme 2.23: Reagents and conditions (i) 2-O-cyanoethyl-N,N,N,N’-tetraisopropylphosphoramidite (1.1
eq), DIHT (0.5 eq), CH2Cl2, 2h 20 min, rt, 66%.
2.6 Conclusions
Four cholesterol monomers (Bz
Chol, T
Chol, H
Chol and monomer 32) were synthesised for
subsequent incorporation into oligonucleotides, in order to assess the assembly of lipid-
conjugated  oligonucleotides (L-ODNs)  in  the  planar  lipid  bi-layer. The  first  two
monomers were synthesised using the hydrophobic spacer 3 to link the cholesterol to a
benzyl or 2’-deoxyuridine monomer. In both cases, Sonogashira cross-coupling was
used  to  attach  the  spacer  to  the  monomers. T
Chol was  incorporated  into  ODNs  and
biophysical studies showed a stabilisation of the duplex when cholesterol was present
on  both  strands. The  simple  monomer  H
Chol,  synthesised  using  only  cholesteryl
chloroformate and 6-amino-hexanol, was incorporated into ODN-7 with success.
For better anchorage of the network to a lipid surface, a hydrophilic spacer was used to
link the cholesterol to the 2’-deoxyuridine nucleoside. Problems were encountered with
the amide coupling and the hydrazinolysis (see sections 2.5.1.4 and 2.5.1.5) during the
synthesis of monomer 32 and several amendments in the order of the synthesis were
required. Study and modification of the method of phosphitylation was also necessary,
namely a modification of the phosphitylating reagent69
2.7 Future work
Problems  with  the  synthesis  of phosphoramide  monomer 32 resulted  in  a  number
alterations being made to the original procedure. Now that a reliable synthesis of the
target monomer has been found, the next step is to incorporate the monomer into a
series of appropriately designed oligonucleotides. Biophysical studies would be carried
out in order to analyse the monomer’s influence on duplexes and compare it with the
hydrophobic linked nucleoside-based cholesterol-dT phosphoramidite. It would then be
necessary to study incorporation into the lipid bi-layer and to assess the stability given
by this ligation to the hexagonal array.
The AMNA project was halted along with the collaboration with the other European
laboratories. In the future, a positive development for this work would be to finalise the
attachment of single hexagons and then the array of the hexagons to the lipid surface.70
CHAPTER 3
Synthesis of DNA nanostructures: use of click
chemistry for the closure of catenanes71
3. Synthesis of DNA nanostructures: use of click chemistry for the
closure of catenanes
3. 1. Introduction
Click  chemistry has  been  applied  to  DNA  systems  in  a  variety  of  applications as
described  in  Section 1.4.4.3. These  include  coupling  ODNs  to  self-assembled
monolayers,
127 labelling  ODNs,
125,131,132,151,152 inter-strand  cross  linking
133 and  intra-
strand  cyclisation  reaction  and  catenation  of  DNA  duplexes
134 and  to  produce  very
stable cyclic DNA miniduplexes.
135
Cyclic duplexes have potential applications in biology. They could be for instance used
for  drug  delivery as  they  are  resistant  to  DNase  enzymic degradation.  Because
intracellular enzymatic degradation occurs principally from the 3’ end, cyclic duplexes,
which by definition have no ends, are therefore resistant to exonucleases.
152,153. Kumar
et  al. have  exploited  Copper(I)-catalysed  azide-alkyne  1,3-dipolar  cycloadition
(CuAAC)  for  the  chemical  ligation  of  two  oligonucleotide  strands,  with  or  without
template, and also for the circularisation of oligonucleotides, for use in the synthesis of
pseudohexagonal catenanes.
134 The catenanes could be used as DNA building blocks for
the construction of nanoarrays as their covalent linkers offer more stability than that of
simple linear oligonucleotide nanostructures.
CuAAC  is  very  fast  and  clean,  tolerant  of  other  functional  groups  and  functions
efficiently in aqueous media. The cyclisation of an oligonucleotide occurs by reaction
between its terminal azide and its opposite terminal alkyne. It is catalysed by Cu[I] to
produce a 1,2,3-triazole linkage between the two reactants.
86
The aim of the work described in this chapter was to use the CuAAC, the best example
of click chemistry,
78 to make a double stranded catenane duplex from a single stranded
cyclic template and its linear complement.
The triazole is linked to the single stranded  cyclic ODN by multiple hexa(ethylene
glycol) units (HEG) or multiple thymidines (T) in order to let the complement strand
thread through the centre of the circularised ODN and form the required duplex before72
cyclising itself (Figure 3.1).
Figure 3.1: Formation of double-stranded catenane from single-stranded cyclic template and its linear
complement strand. In this representation the DNA is shown in dark green and pink, whilst multiple T
bases and multiple HEG units are in orange and yellow/green respectively.
3.2 Synthesis of oligonucleotides for click chemistry
3.2.1 Synthesis of alkyne oligonucleotides
5-Hexyn-1-ol was subjected to conventional phosphitylation conditions by addition of
2-O-cyanoethyl-N,N,diisopropylamino  chlorophosphoramidite  and  DIPEA  in  CH2Cl2
under an argon atmosphere. The pure phosphoramidite 42 was isolated in 20% yield.
This monomer 42 was then incorporated into  ODNs at the 5’-terminus by standard
oligodeoxynucleotide synthesis method
14,154 as described in section 4.3.1, to give ODN-
8 and ODN-9 which were purified by HPLC and characterised by MALDI-TOF MS for73
ODN-8 ([M+H]
+ calcd, 12876; found, 12884) and ES
- MS for ODN-9 ([M-H]
- calcd,
8860; found, 8867) (see section 4.3.3).All ODN sequences are given in Chapter 4 (see
section 4.3.2).
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Scheme 3.2: Reagents and conditions (i) 2-O-cyanoethyl-N,N-diisopropylamino chlorophosphoramidite
(1.1  eq),  DIPEA  (2.5  eq),  CH2Cl2,  40  min,  rt, 20%;  (ii)  oligonucleotide  synthesis:  OH-ODN-
resin/tetrazole; Ac2O/N-methylinidazole, I2/H2O/THF/Pyridine; NH3/H2O.
3.2.2 Synthesis of azide oligonucletotides
Successful azidation of ethyl-6-bromohexanoate 40 was achieved using sodium azide
and potassium bicarbonate at 50 °C, in 86% yield. Compound 41 was then hydrolysed
using a solution of sodium hydroxide in a mixture of water and dioxane in 91% yield.
The following esterification of 42 was carried out with N-hydroxysuccinimide and EDC
as an activating agent and afforded 43 in a 52% yield (Scheme 3.3).74
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Scheme 3.3: Reagents and conditions (i) NaN3 (2 eq), K2CO3 (1.5 eq), DMF, 5 h 45 min, 50 °C, 86%; (ii)
NaOH 2 M, H2O:dioxane 1:2 v/v, 1  h, rt, 91%; (iii) N-hydroxysuccinimide (1.3 eq), EDC (1.4 eq),
6.5 h, rt, 52%; (iv) Na2CO3/NaHCO3 0.5 M (pH 8.75), DMSO.
Azide L-ODN-10 and 11 were prepared by labelling 3’-amino-modified L-ODN-8 and
9 with 43 in bicarbonate buffer at pH 8.75. The resultant 3’-azide-labelled ODNs were
then purified by reversed-phase HPLC (see Appendix) and characterised by MALDI-
TOF MS for L-ODN-10 ([M+H]
+ calcd, 13015; found, 130227) and ES
- MS for ODN-
11 ([M-H]
-calcd, 8999; found, 9006) (see section 4.3.3).
3.3. Click chemistry
3.3.1 First catenane
3.3.1.1 Cyclisation
The Cu[I] complex was generated in situ from Cu[II] sulfate and sodium ascorbate. All
ligation reactions were carried out in 0.2 M aqueous NaCl in the presence of the water
soluble tris-(hydroxypropyltriazolylmethyl)amine ligand.
88 Self-circularisation reactions
of  L-ODN-10  and  its  complementary  L-ODN-11  gave  C-ODN-10  and  C-ODN-11
respectively, characterised by MALDI-TOF MS (see section 4.3.3).75
ODNs sequences:
L-ODN-10 5’-K-TTTTTTTTTTGCACCAGAATTCATCACGGAGTTTTTTTTTT-Z-3’
L-ODN-11 3’-Z-HHHCGTGGTCTTAAGTAGTGCCTCHHH-K-5’
A  quantitative  conversion  of  L-ODN-10  to  the  cyclic  C-ODN-10  was  observed  by
capillary electrophoresis (CE). (Figure 3.2)
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Figure 3.2: Capillary electrophoresis analysis: (a)  L-ODN-10; (b) cyclisation reaction  mixture of  L-
ODN-10; (c) mixture of L-ODN-10 and reaction mixture of C-ODN-10.
Similar CE analyses were obtained after cyclisation of L-ODN-11 in C-ODN-11.
3.3.1.2 Catenation of  cyclic  oligonucleotides  with  their
linear complements
Formation of the double stranded catenane from C-ODN-10 and the L-ODN-11 was
carried out in parallel with C-ODN-11 and the L-ODN-10. The purified cyclic ODNs
were mixed with their respective linear complementary strands and the click reaction
was carried out at 0.2 M aqueous NaCl. The reaction was monitored by denaturing
polyacrylamide gel electrophoresis (PAGE). (Figure 3.3)
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Figure 3.3: Gels visualised by UV shadowing (254 nm) (a) Denaturing 8% PAGE analysis: 1-L-ODN-
10,2-C-ODN-10, 3-crude mixture of the catenation of L-ODN-10 and C-ODN-11, 4-crude mixture of the
circularisation  of  L-ODN-10  into  C-ODN-10, 5-crude  mixture  of  the  catenation  of  L-ODN-11  and
C-ODN-10, 6-C-ODN-11, 7-L-ODN-11.  (b) Denaturing  20%  PAGE  analysis: 1-L-ODN-10, 2-
C-ODN-10, 3-crude mixture of the catenation of  L-ODN-10 and C-ODN-11, 4-crude mixture of the
catenation of L-ODN-11 and C-ODN-10, 5-C-ODN-11, 6-LODN-11.
On the 8% PAGE analysis, L-ODN-10 and C-ODN-10 run at the same velocity but C-
ODN-11  runs faster than  L-ODN-11. On the 20% PAGE  analysis, C-ODN-11  runs
slower than L-ODN-11 and also C-ODN-10 runs slower than L-ODN-10.
On the 8% PAGE analysis, there is a new retarded band, lane 3, but this band cannot
confidently  be  attributed  to  a  catenane  as  this  band  is  not  present  on  20%  PAGE
analysis. Analysis by capillary electrophoresis (CE) also showed no additional peaks.
The catenation reaction was repeated on a bigger scale with similar results.
UV  melting  of  C-ODN-11  and  L-ODN-10  followed  by  C-ODN-10  and  L-ODN-11
using a standard melt programme (20-80-20 C at 0.5 C/min), showed only a small
decrease in thermal stability (ΔTm = -2 or -3 C) compared with the duplex of the two
linear oligonucleotides L-ODN-10 and L-ODN-11 (Table 3.1). This suggests that the
failure of the catenane formation was not due to thermal instability of the circularised
ODN.
The attempted formation of the catenane duplex at 1 M NaCl was also unsuccessful.
catenane
a) b)77
ODNs L-ODN-10/L-ODN-11 L-ODN-10/C-ODN-11 C-ODN-10/L-ODN-11 C-ODN-10/C-ODN-11
Tm (ºC)
0.5 ºC intervals
ODNs L-ODN-10/L-ODN-11 L-ODN-10/C-ODN-11 C-ODN-10/L-ODN-11 C-ODN-10/C-ODN-11
Tm (ºC)
0.25 ºC intervals
nd
buffer with NaCl (1 M)
71.1 68.3 68.1
buffer with NaCl (0.2 M)
63.4 61.9 61.3 69.0
Table  3.1: Duplex  (0.25 M)  UV  melting  experiment  at  pH  7.0  (10  mM  sodium  phosphate  buffer
containing 0.2 M or 1 M NaCl and 1 mM Na2EDTA). Each Tm is an average of three separate runs. nd =
not determined.
Figure 3.4: (a) Duplex UV melting experiment at pH 7.0 (10 mM sodium phosphate buffer containing
0.2 M  NaCl  and  1  mM  Na2EDTA).  The  concentration  of  each  ODN  was  0.25 M. (b)  derivative
d(A)/d(T). Melting data were processed using the OriginPro 7.5 software.
The ODNs have 21 matching base pairs, constituting two turns of a double helix. This
may have caused the ODN to be too rigid to ligate to its complementary ODN (Figure
3.5).
a) b)78
Figure 3.5: Non  formation  of double-stranded catenane  from  single-stranded cyclic  template and its
linear complement strand as the alkyne and azide of the second ODN are too far from each other. In this
representation the DNA is shown in dark green and pink, whilst multiple T bases and multiple HEG units
are in orange and yellow/green respectively.
For this reason, two new ODNs were synthesised with only 12 matching base pairs (just
over one helix turn). A fluorescein label was incorporated into the linear ODN, in order
to  improve  the  visualisation  of  the  products  by  gel  electrophoresis,  using
transillumination in addition to UV-shadowing. A third short ODN, complementary to
the  extremities  of  this  second  ODN  to  cyclise, was  also  used  to  help  the  second
circularisation (Figure 3.6).
ODNs sequences:
L-ODN-14 5’-K-TTTTTTTTTTTTTTTCCAGAATTCATCTTTTTTTTTTTTTTT-Z-3’
L*-ODN-15                  3’-Z-GCGTHHHGGTCTTAAGTAGHHHT*GCG-K-5’79
Figure 3.6: Formation of double-stranded catenane from single-stranded cyclic template and its linear
complement strand with a short ODN strand as a helper. In this representation the DNA is shown in dark
green and pink and blue (for the helper), multiple T bases are in orange, multiple HEG units are in
yellow/green and the fluorescein is a yellow/green star.
3.3.2 Ligation of shorter catenane sequence
L-ODN-14 and L*-ODN-15 were prepared using standard automated DNA synthesis as
described  in  section  4.3.1 and  labelled  with  3’-azide  and  5’-alkyne  as  described  in
section 3.2.2. Self-circularisation of L-ODN-14 and L*-ODN-15 gave C-ODN-14 and
C*-ODN-15 respectively.
ODNs sequences:
L-ODN-14 5’-K-TTTTTTTTTTTTTTTCCAGAATTCATCTTTTTTTTTTTTTTT-Z-3’
L*-ODN-15                  3’-Z-GCGTHHHGGTCTTAAGTAGHHHT*GCG-K-5’
The catenane was prepared by mixing the C-ODN-14, the L*-ODN-15, and the helper
ODN-16.The click reaction was carried out at 200 mM aqueous NaCl. A new retarded
band appeared on the denaturing 20% PAGE gel on lane 3 (Figure 3.7), which was
attributed to the formation of the covalently linked double stranded catenane. Lane 3
showed also no more L*-ODN-15 and C-ODN-14 but a band corresponding to C*-
ODN-15, which means that some of L*-ODN-15 cyclised during the catenation step.80
However, the crude mixture of the circularisation of L*-ODN-15, lane 4, showed also a
faint retarded band at the same retention factor which could be attributed to a dimer of
L*-ODN-15 on 20% PAGE (Figure 3.7 b).
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Figure 3.7: Denaturing 20% PAGE analysis: 1-L-ODN-14, 2-C-ODN-14 not purified by HPLC, 3-crude
mixture  of  the  catenation  of C-ODN-14 and L*-ODN-15, 4-C*-ODN-15  not purified  by  HPLC, 5-
L*-ODN-15. (a): gel visualised by UV shadowing (254 nm) (b) gel trans-illuminated at 302 nm.
The reaction conditions of the self-circularisation were investigated in an attempt to
improve the yield. Firstly, a 20-mer template of poly A (A20.) was added to the reaction
mixture during the ligation of L-ODN-14. It was hoped that it would form a duplex with
the multiple T bases at both extremities of L-ODN-14 and therefore help its closure, in
the same way as the helper in Figure 3.5. However, this did not improve the yield as
shown in Figure 3.8.
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Figure 3.8: Denaturing 20% PAGE analysis visualised by UV shadowing (254 nm): 1-linear L-ODN-14,
2-circularisation  of L-ODN-14 into C-ODN-14, 3-circularisation  of L-ODN-14 into cyclic C-ODN-
14with A20. (1 eq), 4- A20.
Following this, it was established experimentally that when the concentration of the
ODN was  low  (0.8 μM)  a  concentration  of  8  μM  (10  equivalents)  of  copper  was
sufficient to ensure cyclisation. However at high ODN concentration (8 μM), a very
high  concentration  of  copper  (400  μM,  50  equivalents)  was  necessary  to  obtain  a
quantitative conversion of linear oligonucleotides into cyclic oligonucleotides (Figure
3.9). A possible explanation of this concentration effect is that L-ODN-14 could form a
6 base pairs dimmer at the EcoR1 site, at high ODN concentration, that would prevent
cyclisation.
ODNs sequences:
L-ODN-14 5’-K-TTTTTTTTTTTTTTTCCAGAATTCATCTTTTTTTTTTTTTTT-Z-3’
L-ODN-14 3’-Z-TTTTTTTTTTTTTTTCTACTTAAGACCTTTTTTTTTTTTTTT-K-5’
Catenation was also carried out in the presence of an increased amount of copper (50
equivalents), but again no improvement of the yield was seen by PAGE analysis.82
1        2      3       4       5
Figure 3.9: Denaturing 20% PAGE analysis visualised by UV shadowing (254 nm): 1-circularisation of
L-ODN-14 (8 μmol) into C-ODN-14with copper (400 μmol), 2-circularisation of L-ODN-14 (8 μmol)
into C-ODN-14 with copper (80 μmol), 3-circularisation of L-ODN-14 (8 μmol) into C-ODN-14 with
copper (80 μmol), 4-circularisation of L-ODN-14 (0.8 μmol) into C-ODN-14 with copper (8 μmol), 5- L-
ODN-14.
Finally, Ferguson plot analysis
70,136 on linear and cyclic oligonucleotides (log mobility
vs gel concentration) showed an increasing gel retardation coefficient with cyclisation
of the ODN, while the catenane had a much higher retardation coefficient in comparison
to the single stranded ODNs. This therefore made it possible to distinguish between the
catenane and the dimerised ODN-17, confirming the success of the catenation reaction
(Figure 3.10).83
Figure  3.10: Ferguson  plot  analysis  of  L-ODN-14,  C-ODN-14,  L*-ODN-15,  C-*ODN-15  and  the
catenane  from  L*-ODN-15  and  C-ODN-14 in  polyacrylamide  gels.  The  logarithm  of  the  absolute
mobility  is  plotted  against  polyacrylamide  gel  concentration.  Melting  data  were  processed  using  the
OriginPro 7.5 software.
In order to disprove unambiguously that the retarded band was not due to a dimer of the
linear ODN, the strategy was modified so that the first ODN that is cyclised contained a
fluorescein. Therefore new sequences were designed for the catenation: L*-ODN-19
was used instead of L-ODN-14 and L-ODN-20 instead of L*-ODN-15
ODNs sequences:
L*-ODN-19 5’-K-TTT*TTTTTTTTTTTTCCAGAATTCATCTTTTTTTTTTTTTTT-Z-3’
L-ODN-20                       3’-Z-GCGTHHHGGTCTTAAGTAGHHHTGCG-K-5’
3.3.3 Alternative sequence of the catenane
3.3.3.1 Catenation
L*-ODN-19 and L-ODN-20 were prepared using standard automated DNA synthesis as
described  in  section  4.3.1 and  labelled  with  3’-azide  and  5’-alkyne  as  described  in84
section  3.2.  Self-circularisation  reaction  of  L*-ODN-19  and  L-ODN-20  were  then
carried out to give C*-ODN-19 and C-ODN-20 respectively.
The catenane was prepared by mixing the cyclic C*-ODN-19, the linear L-ODN-20, and
the  helper  ODN-16.  The  click  reaction  was  carried  out  at 0.2 M  aqueous  NaCl.
Figure 3.11 shows a clear retarded band which was attributed to the formation of the
covalently closed double stranded catenane. According to the intensities on the gel, the
yield of the reaction appeared to be around 50%.
1     2 3 4      5 1     2           3 4      5
Figure 3.11: Denaturing 20% PAGE analysis: 1-L-ODN-20, 2-C-ODN-20 non purified, 3-crude mixture
of the catenation of cyclic C*-ODN-19 and L-ODN-20, 4-C*-ODN-19 not purified, 5-L*-ODN-19. (a):
gel visualised by UV shadowing (254 nm) (b) gel trans-illuminated at 302 nm.
Purification of the catenane by reversed-phase HPLC and anion-exchange HPLC was
attempted but failed because the catenane has a similar retention times than C*-ODN-19
and C-ODN-20. However, the catenane was successfully purified by gel-electrophoresis
extraction with an overall yield of 25% (catenation and purification). The catenation
reaction and purification were repeated on a bigger scale and gave similar results.
a) b)
catenane85
3.3.3.2 Enzyme digestion
L*-ODN-19 and L-ODN-20 were designed so that their duplex would contain an EcoR1
restriction site (Figure 3.12 a). As EcoR1 only recognises and cuts double strands, the
formation of the catenane can then be proved.
Figure 3.12: Digestion of the catenane by EcoR1. a) EcoR1 restriction site on the ODNs. K = alkyne, Z =
azide. b) In this representation the DNA is shown in dark green and pink, multiple T bases are in orange,
multiple HEG units are in yellow/green and the fluorescein is a yellow/green star.
Figure  3.13  shows  a  gel  analysis  of  the  digestion  of  the  oligonucleotides  with  and
without  the  enzyme  (controls).  The  catenane  was  cut  by  EcoR1  and  shows the
formation of the digested cyclic C*-ODN-19 and the digested cyclic C-ODN-20, in lane
7, proving the existence of the catenane. There is a band for the catenane in lane 9 and
10 on the gel b) stained with SYBR Green I, which is due to the horizontal migration of
the catenane.
L*-ODN-19K-…GTAATTC…-Z K-…G     AATTC-…Z
L-ODN-20Z- …CTTAAG…-K Z-…CTTAA     G-…K
a)
b)86
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Figure 3.13: Denaturing 20% PAGE analysis of EcoR1 ODN digestion: Even lanes are controls: DNA-
only without EcoR1.1-L*-ODN-19 and L-ODN-20 + EcoR1; 2-L*-ODN-19 and L-ODN-20, 3-C*-ODN-
19 and L-ODN-20 + EcoR1; 4-C*-ODN-19 and L-ODN-20, 5-L*-ODN-19 and C-ODN-20 + EcoR1; 6-
L*-ODN-19 and C-ODN-20, 7-catenane (from C*-ODN-19 and L-ODN-20) + EcoR1; 8-catenane (from
C*-ODN-19 and L-ODN-20), 9-C*-ODN-19 and C-ODN-20 + EcoR1; 10- C*-ODN-19 and C-ODN-20.
(a) gel trans-illuminated at 302 nm (b) gel trans-illuminated at 302 nm after 30 min staining with SYBR
Green I
digested L*-ODN-19
digested C-ODN-20
impurity of C-ODN-20
C*-ODN-19
digested C*-ODN-19
C-ODN-20
L*-ODN-19
L-ODN-20
digested L*-ODN-19
digested C*-ODN-19
C*-ODN-19
L*ODN-19
catenane
a)
digested L-ODN-20
digested L-ODN-20
digested C*-ODN-19
b)
catenane
digested C-ODN-2087
The results of the EcoR1 digestions suggest a few points:
 C-ODN-20 is not digested as well as C*-ODN-19. This may be due to the
presence of HEG in the oligonucleotide, which increases the oligonucleotide
stability towards the enzyme.
 The impurity of C-ODN-20 is totally digested by EcoR1, implying it is in a
double stranded conformation.
3.3.3.3 Native gel
The catenane was analysed on a native 14% PAGE gel, giving same retention factors to
those obtained by denaturing PAGE gel analysis. (Figure 3.14) This result invalidates
the existence of a secondary structure for the catenane. On Figure 3.14 a), the catenane
appeared pure, but some impurities appeared on Figure 3.14 b) because fluorescence is
a very sensitive technique.
1    2 3     4        5    6 1    2 3   4         5 6
Figure 3.14: Native 14% PAGE analysis: 1-L-ODN-20, 2-C-ODN-20 purified by  gel, 3&4-catenane
purified by gel, 5-C*-ODN-19 purified by gel, 6-L*-ODN-19. (a): gel visualised by UV shadowing (254
nm) (b) gel trans-illuminated at 302 nm.
a) b)88
3.3.3.4 Thermodynamic studies of the catenane
Using a standard melt programme (20-80-20 C at 0.5 C/min with a hold time between
melting and annealing), UV melting of the catenane showed no duplex-random coil
transition in the range of UV melting temperatures, in contrast with the duplexes of L-
ODN-20/L*-ODN-19, L-ODN-20/C*-ODN-19 and C-ODN-20/L*-ODN-19.
Figure 3.15: (a) Duplex UV melting experiment at pH 7.0 (10 mM sodium phosphate buffer containing
200  mM  NaCl  and  1  mM  Na2EDTA).  The  concentration  of  each  ODN was 2 M. (b)  derivative
d(A)/d(T). Melting data were processed using the OriginPro 7.5 software.
A control melting experiment with single strands also showed no duplex formation.
Therefore,  formamide  was  added  to  the  buffer  to  reduce  the  Tm of  the  catenane,
enabling observation of its melting transition.
a) b)89
Figure 3.16: (a) Duplex UV melting experiment at pH 7.0 (10 mM sodium phosphate buffer containing
200 mM NaCl and 1 mM Na2EDTA with 20% formamide). The concentration of each ODN was 2 M.
(b) derivative d(A)/d(T). Melting data were processed using the OriginPro 7.5 software.
The  addition  of  formamide  caused  the  derivative  of  the  catenane  to  show  another
transition  with  a  lower  Tm,  but  corresponding  to  a  very  stable  duplex. This  is
unexplained  at  this  stage  as  no  other  evidence  shows  the  presence  of  a  secondary
structure of the catenane or any relevant impurities. Indeed, both denaturing and native
gels  showed  the  presence  of  only  one  significant  spot  for  the  purified  catenane.  A
hypothetic explanation would be that this transition is due to the formation of a catenane
from 2 L-ODN-20 that would form a duplex at the Eco R1 site and both cyclised;
although  no  significant  band  appeared  on  PAGE  analysis  that  would  confirm  this
hypothesis.
ODNs sequences:
L-ODN-20 5’-K-GCGTHHHGATGAATTCTGGHHHTGCG-Z-3’
L-ODN-20 3’-Z-GCGTHHHGGTCTTAAGTAGHHHTGCG-5’
buffer no formamide 20% formamide 40% formamide
Tm  (ºC) nd 71.6 61.4
Catenane
Table  3.2: Duplex  UV  melting  experiment  at  pH 7.0 (10  mM  sodium  phosphate  buffer  containing
200mM NaCl and 1mM Na2EDTA without or with 20% or 40% formamide). Each Tm is an average of
five separate runs.
a) b)90
The evolution of the melting curves and derivatives by the addition of formamide is
shown in Figure 3.17.
Figure 3.17: Duplex UV melting experiment at pH 7.0 and 2 M of duplex in 10 mM sodium phosphate
buffer containing 200mM NaCl and 1mM Na2EDTA without or with 20% or 40% of formamide. Melting
data were processed using the OriginPro 7.5 software.
3.4 Conclusions
Azides  were  incorporated  to  alkyne-modified  oligonucleotides  by  post-synthetic
modification  in  order  to  circularise  them,  using  CuAAC.  Catenation  of  two
complementary  DNA  strands  was  eventually  completed  after  modification  of  the
oligonucleotides sequences. The ODNs were designed with only twelve matching base
pairs to make just over one helix turn and a fluorescein was incorporated in one of them
to  facilitate  visualisation.  A  third  short  ODN  was  also  used  as  a  helper  for  the
circularisation of the second ODN.
These results clearly show that the design of the ODNs’ sequences is crucial for the
realisation of the catenation and that a maximum of one helix turn is required for the
success of the second closure, but it might be possible to create a catenane of less than
one helix turn. The hypothetic formation of catenane made by the two L-ODN-20 could
be prevented by omitting the EcoR1 site that is avoiding self-complementarity.
a) b)91
3.5 Future work
The resulting double stranded catenane duplex is very stable since the 1,2,3-triazole unit
has a high chemical stability (in general, being inert to severe hydrolytic, oxidising, and
reducing conditions even at high temperature).
86 It is therefore a suitable candidate as a
DNA building block for the construction of various nanostructures.
Owing  to  the  interesting  biological  activity  of  1,2,3-triazoles  and  the  nature  of  the
ODNs, the catenanes have vast potential biological uses. It would be interesting to use
the catenane for drug delivery by designing the sequences in order to elicit cleavage of
one of the ODNs after cell penetration. A cysteine or a thiol group could be easily
incorporated into the ODNs during chemical synthesis for subsequent synthesis of a
disulfide bond. The reversible nature of the disulfide bond and its stability in plasma
make it an attractive tool for drug delivery. Indeed, the bond is stable in the oxidising
extracellular space, but can undergo facile cytoplasmic scission due to reducing agents
in the intracellular space.
155 This route could be investigated for later application of the
catenane as a delivery tool.92
CHAPTER 4
Experimental93
4. Experimental
4.1 General experimental
All reagents used were purchased from Aldrich, Fluka, Avocado, Alfa Aeasar, Fisher
Scientific,  Acros or  Lancaster  and  used  without  further  purification,  except  for  the
reaction  solvents,  CH2Cl2 and  DIPEA, pyridine  and Et3N which  were  purified  by
distillation (over calcium hydride), MeOH (over iodine and magnesium) and THF (over
sodium  wire  and  benzophenone). All  reactions  were  carried  out  under  an  argon
atmosphere. Glassware  was  oven-dried  overnight  before  use,  for  reactions  requiring
exclusion  of  moisture.  Column  chromatography  was  carried  out  under  air  or  argon
pressure  using  Fisher  Scientific  DAVSIL  60Ǻ  (35-70  micron)  silica.  Thin  layer
chromatography was performed using Merck Kieselgel 60 F254 silica plates (0.22 mm
thickness, aluminium backed). Compounds were visualised by irradiation at 254/365
nm or by staining with potassium permanganate (A), PMA (B), p-anisaldehyde (C),
ninhydrin (D, G) 2,4-DNPH (E), Mary’s reagent (F), followed by heating.
A: KMnO4 :K2CO3 (3:20 g) / aqueous NaOH (5% w/v):water (5:300 mL)
B: phosphomolybdic acid 10% in ethanol
C: p-anisaldehyde / glacial AcOH / conc. H2SO4 / ethanol 95% (9.2:3.8:12.5:338
v/v)
D: ninhydrin (0.3% w/v) / butanol: glacial AcOH (97:3 v/v)
E: 2,4-dinitrophenyl hydrazine/ethanol/H2SO4
F: 4,4’-bis-dimethylamino benzhydrol/acetone
G: ninhydrin (5 g) / acetone (100 mL)
1H NMR spectra were measured at 300 MHz on a Bruker AC300 spectrometer or 400
MHz on a Bruker DPX400 spectrometer.
13C NMR spectra were measured at 100 MHz
on  a  Bruker  DPX400  spectrometer.  Chemical  shifts  are  given  in  ppm  relative  to
tetramethylsilane, and J values are given in Hz and are correct to within 0.5 Hz. All
1H
NMR spectra are internally referenced to the appropriate residual undeuterated solvent
signal
156 and the
13C NMR spectra to the appropriate residual deuterated solvent signal.
Multiplicities of
13C signals were determined using DEPT spectral editing technique and94
are described as s (quaternary carbon), d (CH), t (CH2) and q (CH3). Assignment was
also aided by COSY (
1H-
1H) and HMQC experiments.
31P NMR spectra were recorded
on a Bruker AC300 spectrometer at 121 MHz and were externally referenced to 85%
phosphoric acid in D2O.
Low-resolution  mass  spectra  were  recorded  using  electrospray  inisation  (ES)  on  a
Fisons VG platform instrument or a Waters ZMD quadrupole mass spectrometer in
HPLC grade acetonitrile or methanol. High-resolution mass spectra were recorded using
electrospray  ionisation  on  a  Bruker  APEX  III  FT-ICR  mass  spectrometer  in  HPLC
grade acetonitrile or methanol.
Mass spectra of oligonucleotides were recorded using electrospray ionisation (ES) on a
Fisons  VG  platform  instrument  in  HPLC  grade  water,  with  tripropylamine  to  aid
ionisation;  or  using  MALDI-TOF  MS  analysis  on  a  ThermoBioAnalysis  Dynamo
MALDI-TOF mass spectrometer in positive ion mode using internal Tn standards.
140
IR spectra were recorded on a Satellite FT-IR using a Golden Gate adapter and WIN
FIRST-lite software or using a Smart Orbit adapter and OMNIC software. Absorptions
are described as strong (s), medium (m) and weak (w).
Melting points were measured on a Gallenkamp electrothermal melting point apparatus
and are uncorrected.
Elemental (CHN) Thermal Combustion Analysis was carried out by MEDAC Ltd.,
Egham, Surrey, UK.95
4.2 Synthesis
Compounds synthesised:
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12-(2’’,2’’,2’’-Trifluoroacetamido)-N-(prop-2’-ynyl)dodecanamide, 3
N
H
H
N
O
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12-Aminododecanoic acid (5.00 g, 23.2 mmol) was dissolved in MeOH (55 mL) and
Et3N (10 mL) was added. Ethyl trifluoroacetate (4.14 mL, 34.8 mmol) was added and
the solution was stirred under an argon atmosphere, at rt. The reaction was complete
after  22.5  hours.  The  solvents  were  removed in  vacuo to  give 12-(2”,2”,2”-
trifluoroacetamido)’dodecanoic  acid  (2) as a  pale  yellow  solid.  This was  then
redissolved in distilled CH2Cl2 (100 mL), EDC.HCl (7.14 g, 37.3 mmol) and prop-2-yn-
1-amine (1.96 mL, 28.7 mmol) were added and the solution was stirred at rt for 24
hours. The reaction was diluted with CH2Cl2, washed with saturated aqueous NaHCO3,
then saturated aqueous KCl, dried (Na2SO4), filtered and the solvents removed in vacuo
to  give  a  pale  yellow  solid.  The  crude  mixture  was  purified  by  silica  gel  column
chromatography (EtOAc:hexane 6:4) to give 3 as a colourless solid (6.35 g, 79% over
two steps).
Rf (EtOAc:hexane 6:4, A) 0.33; (CH2Cl2:MeOH 4:1,A) 0.74.
mp 91-92 C.
νmax(neat)/cm
-1 3315 (m, NH), 3290 (m, NH), 2918 (m, CH2), 2851 (w, CH2), 1697 (s,
CO), 1644 (s, CO), 1570 (w), 1531 (m), 1470 (m, CH2), 1448 (w, CH2), 1416 (w), 1373
(w), 1207 (s, CF3), 1179 (s, CF3), 719 (s).
1H NMR (400MHz, CDCl3): H 6.43 (1H, br s, NH), 5.65 (1H, s, NH), 4.04 (2H, dd,
J = 5.0, 2.5 Hz, H
1’), 3.35 (2H, q, J = 6.9 Hz, H
12), 2.22 (1H, t, J = 2.5 Hz, H
3’), 2.18
(2H, t, J = 7.5 Hz, H
2), 1.59 (4H, m, H
3,11), 1.28 (14H, m, H
4-10).
13C NMR (100MHz, CDCl3): C 172.8 (s, C
1O), 157.3 (s, C
1’’O), 117.5 (s, C
2’’), 79.8
(d, C
3’), 71.6 (s, C
2’), 40.1 (t, C
12), 36.6 (t, C
2), 29.0-29.4 (8t, C
1’,11,4-9), 26.7 (t, C
10),
25.6 (t, C
3).
LRMS [ES
+]: m/z 371 ([M+Na]
+, 100%), 349 ([M+H]
+, 80%).
HRMS [ES
+]: m/z for C17H28F3N2O2[M+H]
+: calcd 349.2098, found 349.2093.101
Anal calculated: C, 58.61; H, 7.81; N, 8.04, found: C, 58.78; H, 7.84; N, 7.95.
12-(2’’,2’’,2’’-Trifluoroacetamido)-N-{3’-[4’’’-(hydroxymethyl)phenyl]prop-2’-
ynyl}dodecanamide, 5
N
H
H
N
O
12
11
10
9
8
7
6
5
4
3
2
1
OH
1'
2'
2'''
3'''
4'''
F3C
O
2'' 1''
4-Iodobenzyl alcohol (500 mg, 2.14 mmol) was dissolved in anhydrous DMF (5 mL) to
which 3 (819 mg, 2.35 mmol), Et3N (1.49 mL, 10.7 mmol) and CuI (81 mg, 0.43 mmol)
were added. The solution was stirred in the dark, at rt, under an argon atmosphere for 10
min  before  adding  tetrakis(triphenylphosphine)palladium  (247  mg,  0.21  mmol).  The
reaction went to completion after 1 hour 50 min. The solvents were removed in vacuo
and  the  residue  was  redissolved  in  CH2Cl2.  After  washing  with  saturated  aqueous
NaHCO3, then saturated aqueous KCl, the solution was dried (Na2SO4), filtered and the
solvents removed in vacuo to give a yellow solid. The crude mixture was purified by
silica gel column chromatography (EtOAc:hexane 7:3) to give 5 as a yellow solid (0.73
g, 75%).
Rf(EtOAc:hexane 7:3, B) 0.35.
mp 100 C.
νmax(neat)/cm
-1 3305 (m, NH), 2915 (m, CH2), 2849 (w, CH2), 1701 (s, CO), 1639 (s,
CO), 1565 (w), 1525 (s, Aryl C=C), 1446 (m, CH2), 1413 (w),1372 (w), 1210 (s, CF3),
1167 (s, CF3), 1092 (m), 1008 (s, CH
Ar), 853 (m), 814 (m), 720 (s).102
1H NMR (400MHz, d6-DMSO): H 9.35 (1H, br s, NH), 8.28 (1H, s, NH), 7.36 (2H, d,
J = 8.0 Hz, H
2’’’), 7.30 (2H, d, J = 8.0 Hz, H
3’’’ ), 5.23 (1H, t, J = 5.2 Hz, OH), 4.50
(2H, d, J = 5.0 Hz, CH2OH), 4.09 (2H, d, J = 5.0 Hz, H
1’), 3.16 (2H, q, J = 6.5 Hz,
H
12), 2.10 (2H, t, J = 7.3 Hz, H
2), 1.48 (4H, m, H
3,11), 1.24 (14H, s, H
4-10).
13C NMR (100MHz, d6-DMSO): C 181.1 (s, C
1O), 171.9 (s, C
1’’O), 143.0 (s, C
4’’’),
131.0 (d, 2C
2’’’), 126.5 (d, 2C
3’’’), 128.8 (s, C
2’’), 120.5 (s, C
1’’’), 86.7 (s, C
3’), 81.5 (s,
C
2’), 62.4 (t, CH2OH), 38.9 (t, C
12), 35.1 (t, C
2), 28.1-28.9 (8t, C
1’,11,4-9), 26.1 (t, C
10),
25.1 (t, C
3).
LRMS [ES
+]: m/z 477 ([M+Na]
+, 100%).
HRMS [ES
+]: m/z for C24H33F3N2O3Na [M+Na]
+: calcd 477.2335, found 477.2334.
12-(Cholesteryloxycarbonylamino)-N-{3’-[4’’’-(hydroxymethyl)phenyl]prop-2’-
ynyl}dodecanamide, 7
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Compound 5 (2.12 g, 4.68 mmol) was dissolved in ethanolic methylamine (33% w/v,
45.2 mL, 368 mmol). The reaction mixture was stirred at rt for 24 hours. The solvent
was removed in vacuo and the residue was dried overnight under high vacuum to give
12-amino-N-{3’-[4’’’-(hydroxymethyl)phenyl]prop-2’-ynyl}dodecanamide  (6) as a
brown solid (1.88 g). This compound was dissolved in distilled CH2Cl2 (40 mL) to
which a solution of cholesteryl chloroformate (2.52 g, 5.62 mmol) in distilled CH2Cl2
(20 mL) was added. The solution was stirred at 0 ºC, under an argon atmosphere for 2103
hours and then at rt for a further 1.5 hours. The reaction was diluted with CH2Cl2,
washed with water and saturated aqueous KCl, dried (Na2SO4), filtered and the solvents
removed in vacuo to give a yellow solid. The crude mixture was purified by silica gel
column chromatography (gradient of EtOAc:hexane 2:3 to 3:2) to give 7 as a colourless
solid (1.19 g, 33% overall).
Rf (EtOAc:hexane 3:2, A) 0.30.
mp 110-111ºC.
νmax (neat)/cm
-1 3284 (m, NH), 2919 (s, CH2), 2848 (m, CH2), 1686 (m, CO), 1636 (s,
CO), 1528 (s, C=C Ar), 1464 (m, CH2), 1253 (s, C-O),1012 (s, C-OH), 652 (m, C=C).
1H NMR (400 MHz, CDCl3): δH7.39 (2H, d, J = 8.0 Hz, H
2’’’), 7.30 (2H, d, J = 8.0 Hz,
H
3’’’), 5.80 (1H, br s, NH), 5.36 (1H, m, H
6 Chol), 4.68 (2H, s, CH2OH), 4.61 (1H, br s,
NH), 4.49 (1H, m, H
3 Chol), 4.26 (2H, d, J = 5.0 Hz, H
1’), 3.12 (2H, q, J = 6.0 Hz, H
12),
2.21 (2H, t, J = 7.5 Hz, H
2), 1.48 (4H, m, H
3,11), 1.25 (14H, s, H
4-10), 0.67-2.37 (44H, br
m).
13C NMR (100 MHz, CDCl3): δC 173.4 (s, C
1O), 157.5 (s, C
1’’O), 142.1 (s, C
4’’’), 140.5
(s, C
5 Chol), 132.5 (2d, C
2’’’), 127.4 (2d, C
3’’’), 123.1 (d, C
6 Chol), 122.3 (s, C
1’’’), 85.6 (s,
C
2’), 83.9 (s, C
3’), 65.4 (t, CH2OH), 57.4 (d), 56.8 (d), 50.7 (d), 43.0 (s), 40.4 (s and t),
40.2 (2t), 39.3 (2t), 37.2 (2t), 36.9 (2t), 36.5 (d), 32.6 (2t and d) 29.9 (2t), 28.9 (3t),
28.7(d), 26.2 (2t), 24.9 (2t), 24.5 (2t), 23.5 (d), 23.2 (2q), 21.7 (t), 20.0 (q), 19.4 (q),
12.5(q).
LRMS [ES
+]: m/z 793 ([M+Na]
+, 60%).
HRMS [ES
+]: m/z for C50H78N2O4Na [M+Na]
+: calcd 793.5854, for found 793.5865.
Anal calculated: C, 77.87; H, 10.19; N, 3.63, found: C, 77.43; H, 10.19; N, 3.52.104
12-(Cholesteryloxycarbonylamino)-N-{3’-[4’’’-(O-(2-cyanoethyl-N,N-diisopropyl
phosphoramidyl)oxymethyl)phenyl]prop-2’-ynyl}dodecanamide, 8
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Under  an  argon  atmosphere,  2-O-cyanoethyl-N,N-diisopropyl  chlorophosphoramidite
(47 μL, 0.21 mmol) was added dropwise to an argon-degassed solution of 7 (147 mg,
0.19 mmol) in THF (2 mL) with DIPEA (83 μL, 0.48 mmol). After stirring at rt for 1.5
hours,  the  solution  was  transferred via cannula  under an argon atmosphere to  a
separating  funnel  containing  degassed  ethyl  acetate.  The  mixture  was  washed  with
degassed saturated aqueous KCl, dried (Na2SO4) and the solvent was removed in vacuo.
Purification by silica gel column chromatography under argon pressure (EtOAc: hexane
1:1, 1% pyridine) gave 8 as a colourless air- and acid-sensitive foam (83 mg, 43%).
Rf (EtOAc:hexane 1:1) 0.35.
1H NMR (300 MHz, d6-DMSO): δH 8.27 (1H, br s, NH), 7.38 (2H, d, J = 8.4 Hz, H
2’’’),
7.33  (2H,  d, J =  8.4  Hz, H
3’’’),  6.98  (1H, br  s,  NH),  5.33  (1H,  d,
J =  5.1  Hz, H
6 Chol),  4.68  (2H,  m,  CH2-OP),  4.22  (1H,  m, H
3  Chol),  4.09  (2H,  d,
J = 5.1 Hz, H
1’), 3.76 (2H, m, OCH2CH2CN), 3.60 (2H, m, iPr-CH), 2.92 (2H, q,
J = 6.6 Hz, H
12), 2.77 (2H, t, J = 5.9 Hz, CH2CN), 2.09 (2H, t, J = 7.5 Hz, H
2), 0.69-
2.13 (73 H, br m).
31P NMR (121 MHz, d6-DMSO): δp 148.9.
LRMS [ES
+]: m/z 994 ([M+Na]
+, 50%).
HRMS [ES
+]: m/z for C59H95N4O5PNa [M+Na]
+: calcd 993.6932, found 993.6916.105
12-Cholesteryloxycarbonylamino-N-(prop-2’-ynyl)dodecanamide, 10
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Compound 3 (1.00 g, 2.87 mmol) was dissolved in ethanolic methylamine (33% w/v)
(31.88 mL, 256 mmol). The mixture reaction was stirred at rt for 31 hours. The solvent
was removed in vacuo and the residue was dried overnight under high vacuum to give 9
as a beige solid (980 mg). This compound was dissolved in distilled CH2Cl2 (20 mL) to
which a solution of cholesteryl chloroformate (2.09 g, 4.66 mmol) in distilled CH2Cl2
(20 mL) was added. The solution was stirred at 0 ºC, under an argon atmosphere for 2
hours and then at rt for 2 hours again. The reaction was diluted with CH2Cl2, washed
with water and saturated aqueous KCl, dried (Na2SO4), filtered and the solvents were
removed in vacuo. The crude mixture was purified by silica gel column chromatography
(EtOAc:hexane 2:3) to give 10 as a colourless solid (759 mg, 40% overall).
Rf (EtOAc:hexane 2:3, A) 0.29.
mp 108ºC.
νmax(neat)/cm
-1 3298 (m, NH), 2919 (s, CH2), 2846 (m, CH2), 1696 (m, CO), 1655 (s,
C=O), 1463 (m, CH2), 1270 (m, C-O), 1235 (m, C-O), 649 (m, C=C), 618 (m, C-H
alkyne).
1H NMR (400 MHz, CDCl3): δH5.62 (1H, br s, NH), 5.42 (1H, m), 5.37 (1H, t, J = 2.5,
H
6 Chol), 4.68 (1H, m), 4.57 (1H, br s, NH), 4.49 (1H, m, H
3 Chol), 4.05 (2H, dd, J = 5.3,
2.7 Hz, H
1’), 3.14 (2H, m, H
12), 2.22 (1H, t, J = 2.7 Hz, H
3’), 2.19 (2H, t, J = 7.5 Hz,
H
2), 1.48 (4H, m, H
3,11), 1.26(14H, s, H
4-10), 0.68-2.47 (41H, br m).
13C NMR (100 MHz, CDCl3): δC 171.7 (s, C
1O), 153.7 (s, C
1’’O), 138.9 (s, C
5 Chol),
122.9 (d, C
6 Chol), 82.1 (d, C
3’), 70.6 (s, C
2’), 55.7 (d), 55.2 (d), 49.1(d), 41,4 (s), 38.8
(s and t), 38.6 ( 2t), 37.6 (t), 35,8 (t), 35.5 (2t), 35.2 (2t), 34.8 (d), 31.0 (t), 30.9 (t and106
d), 28.4 (2t), 28.3 (2t), 28.2 (t), 27.3 (t), 27.2 (t), 27.0 (d), 26.4 (t), 23.3 (2t), 22.9 (t),
21.8 (d), 21.6 (2q), 20.1 (t), 18.4 (q), 17.8 (q), 10.9 (q).
LRMS [ES
+]: m/z 688 ([M+Na]
+, 60%), 666 ([M+H]
+, 30%).
HRMS [ES
+]: m/z for C43H72N2O3Na [M+Na]
+: calcd 687.5435, found 687.5441.
5'-O-(4,4-Dimethoxytrityl)-5-[12-(2’’,2’’,2’’-trifluoroacetamido)-N-(prop-2’-
ynyl)dodecanamido]-2’-deoxyuridine, 14
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Nucleoside 11 (500 mg, 885 μmol) was dissolved in anhydrous DMF (3.5 mL) to which
3 (678 mg, 2.00 mmol), Et3N (1.23 mL, 8.84 mmol) and CuI (68 mg, 354 μmol) were
added. The solution was stirred in the dark, at rt, under an argon atmosphere for 10 min
before adding tetrakis(triphenylphosphine)palladium (204 mg, 176 μmol). The reaction
had gone to completion after 23 hours. The solvents were removed in vacuo, the residue
was  dissolved  in  CH2Cl2,  washed  with  saturated  aqueous  KCl and  water,  dried
(Na2SO4), filtered and the solvents were removed in vacuo. The crude mixture was
purified by silica gel column chromatography (EtOAc:hexane 4:1, 0.5 % pyridine) to
give 14 as yellow solid (510 mg, 66%).107
Rf (EtOAc:hexane 4:1, 0.5% Et3N, A) 0.24; (EtOAc:hexane 9:1, 0.5% Et3N, C) 0.43.
νmax(neat)/cm
-1 3297 (m, NH), 3058 (m, C-H), 2923 (m, CH2), 2851 (m, CH3), 1704 (s,
CO), 1665 (s, CO), 1507 (s, C=C), 1436 (s, CH2), 1174 (s, C-O), 1152 (s, C-O), 1091 (s,
C-O), 721 (s, CH Ar).
1H NMR (400 MHz, CDCl3): δH 9.09 (1H, br s, NH
3 dU), 8.12 (1H, s, H
6 dU), 7.09-7.61
(9H, m, H
DMT), 6.77 (4H, dd, J = 8.8, 1.3 Hz, H
3 DMT), 6.62 (1H, s, NH
1), 6.25 (1H, dd,
J = 6.8, 6.8 Hz, H
1’ dU), 5.38 (1H, t, J = 5 Hz, NH
1’’), 4.47 (1H, dt, J = 6.0, 3.0 Hz,
H
3’ dU), 4.02 (1H, m, H
4’ dU), 3.83 (1H, dd, J = 17.6, 5.0 Hz, H
1’), 3.77 (1H, dd, J = 17.6,
5.0 Hz, H
1’), 3.71 (6H, s, O-CH3), 3.39 (1H, dd, J = 10.8, 2.8 Hz, H
5’ dU), 3.30 (2H, m,
H
12, 5’ dU), 2.44 (1H, ddd, J = 13.6, 6.0, 3.0 Hz, H
2’ dU), 2.21 (1H, m, H
2’ dU), 1.82 (2H, t,
J = 7.3 Hz, H
11), 1.49 (2H, t, J = 7.0 Hz, H
2), 1.42 (2H, br t, J = 7.0 Hz, H
3), 1.25 (14H,
m, H
4-10).
13C NMR (100MHz, CDCl3): C 172.9 (s, C
1O), 162.1 (s, C
4 dUO), 159.0 (3s, C
1’’O,
C
4 DMT), 149.4 (s, C
2 dUO), 144.9 (s, C
1’ DMT), 143.5 (d, C
6 dU), 135.9 (2s, C
1 DMT), 132.4
(2d, C
DMT), 132.3 (d, C
DMT), 132.2 (d, C
DMT), 130.4 (d, C
DMT), 128.9 (d, C
DMT), 128.8
(d, C
DMT), 128.3 (d, C
DMT), 128.1 (d, C
DMT), 117.7 (s, C
2’’) 113.7 (4d, C
3 DMT), 99.8 (s,
C
5 dU), 89.9 (s, C
3’), 87.4 (d, C
4’ dU), 87.1 (s, C
0 DMT), 86.2 (d, C
1’ dU), 74.5 (s, C
2’), 72.4
(d, C
3’ dU), 63.6 (t, C
5’ dU), 55.6 (2q, OCH3), 54.2 (t), 42.0 (t), 40.3 (t, C
2), 29.4-36.8
(7t), 29.2 (t, C
1’), 26.9 (t, C
10), 25.7 (t, C
3).
LRMS [ES
+]: m/z 900 ([M+Na]
+, 30%).
HRMS [ES
+]: m/z for C43H72N2O3Na [M+Na]
+: calcd 899.3813, found 899.3825.108
5'-O-(4,4-Dimethoxytrityl)-5-[12-(2’’,2’’,2’’-trifluoroacetamido)-N-(prop-2’-
ynyl)dodecanamido]-2’-deoxyuridine 3’-O-(2-cyanoethyl)-N,N-diisopropyl
phosphoramidite, 15
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Under  an  argon  atmosphere,  2-O-cyanoethyl-N,N-diisopropyl  chlorophosphoramidite
(122 μL, 548 μmol) was added dropwise to a degassed solution of 14 (437 mg, 498
μmol) in THF (1.5 mL) with DIPEA (217 μL, 1.25 mmol). After stirring at rt for 1.5
hours,  the  solution  was  transferred via cannula  under an argon atmosphere to  a
separating  funnel  containing  degassed  ethyl  acetate.  The  mixture  was  washed  with
degassed saturated aqueous KCl, dried (Na2SO4) and the solvent was removed in vacuo.
Purification by silica gel column chromatography under argon pressure (EtOAc: hexane
7:3, 0.5 % pyridine) gave 15 as a diastereomeric mixture as a colourless (ca. 1:1) air-
and acid-sensitive foam (251 mg, 47%).
Rf (EtOAc:hexane 7:3, 0.5% Et3N, C) 0.26 and 0.31.
1H NMR (400 MHz, d6-DMSO): δH11.6 (1H, br s, NH
3 dU), 9.36 (2H, br s, NH
1’’), 8.14
(1H, m, NH
1), 7.93 (1H, s, H
6  dU), 7.21-7.41(9H, m, H
DMT), 6.88 (4H, dd, J = 8.8,
1.3 Hz, H
3 DMT), 6.09 (1H, dd, J = 15.9, 6.7 Hz, H
1’ dU), 4.48 (1H, m, H
3’ dU), 4.04 (1H,
m, H
4’ dU), 3.95 (1H, dd, J = 17.9, 5.2 Hz, H
1’), 3.89 (1H, dd, J = 17.9, 5.2 Hz, H
1’),
3.74 (6H, s, O-CH3), 3.63 (2H, m, OCH2CH2CN), 3.53 (2H, m, iPr-CH), 3.32 (2H, m,
H
5’ dU), 3.16 (2H, q, J = 6.6 Hz, H
12), 2.75 (1H, t, J = 5.9 Hz, CH2CN), 2.65 (1H, t,
J = 5.9 Hz, CH2CN), 2.30-2.43 (2H, m, H
2’ dU), 2.05 (2H, t, J = 7.6 Hz, H
2), 1.46 (4H,
m, H
3,11), 1.22 (14H, s, H
4-10), 0.98-1.14 (12H, m, iPr-CH3).
LRMS [ES
+]: m/z 1100 ([M+Na]
+, 100%).
31P NMR (162 MHz, d6-DMSO)δp 148.3, 147.9.109
3’,5’-O-Acetyl-5-iodo-2’-deoxyuridine, 17
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5-Iodo-2’-deoxyuridine 16 (500 mg, 1.41 mmol) was dissolved in the minimum volume
of pyridine (3 mL) and acetic anhydride (40 μL, 4.24 mmol) was added. The reaction
was stirred under an argon atmosphere for 16.5 hours. The pyridine was removed and
the residue was co-evaporated with toluene in vacuo. The crude mixture was purified by
silica gel column chromatography (EtOAc:hexane 3:2) to give 17 as a colourless solid
(610 mg, 99%).
Rf (EtOAc:hexane 3:2, C) 0.28; (EtOAc:MeOH:NH3 5:1:1, C) 0.25.
mp 156-157 °C.
νmax (neat)/cm
-1 3236 (m, NH), 1736 (s, CO), 1673 (s, CO), 1362 (s, CH), 1235 (s, C-
O), 1194 (s, C-O), 1106 (s, C-O).
1H NMR (400 MHz, CDCl3): δH9.20 (1H, s, NH
3 dU), 7.96 (1H, s, H
6 dU), 6.28 (1H, dd,
J = 8.3, 5.6 Hz, H
1’ dU), 5.23 (1H, dt, J = 5.0, 2.0 Hz, H
3’ dU), 4.40 (1H, dd, J = 12.6, 3.0
Hz, H
5’ dU), 4.33 (1H, dd, J = 12.6, 3.0 Hz, H
5’ dU), 4.29 (1H, dt, J = 5.0, 3.0 Hz, H
4’ dU),
2.54 (1H, ddd, J = 14.1, 5.5, 2.0 Hz, H
2’ dU), 2.17 (1H, m, H
2’), 2.20 (3H, s, CH3), 2.11
(3H, s, CH3).
13C NMR (100 MHz, CDCl3): δC 170.7 (s, CO-CH3), 170.5 (s, CO-CH3), 160.0 (s,
C
2 dUO), 150.2 (s, C
4 dUO), 144.1 (d, C
6 dU), 85.8 (d, C
1’ dU), 83.0 (d, C
4’ dU), 74.4 (d,
C
3’  dU), 69.3 (s, C
5  dU), 64.2 (t, C
5’  dU), 38.6 (t, C
2’  dU), 21.4 (q, CO-CH3), 21.2 (q,
CO-CH3).
LRMS [ES
+]: m/z 461 ([M+Na]
+, 20%).
HRMS [ES
+]: m/z for C13H15IN2O7Na [M+Na]
+: calcd 460.9816, found 460.9823.
Anal calculated: C, 35.63; H, 3.45; N, 6.39, found: C, 35.60; H, 3.38; N, 6.31.
Analytical results consistent with reported data.
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3',5'-O-Acetyl-5-[12-amino-N-(prop-2’-ynyl)dodecanamido]-2’-deoxyuridine, 18
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Compound 3 (1.00 g, 2.87 mmol) was dissolved in ethanolic methylamine (33% w/v, 25
mL, 201 mmol) and the reaction mixture was stirred at 55 °C for 20 hours. The solvent
was removed in vacuo and the residue was dried overnight under high vacuum to give 9
as a white solid (929 mg). Compound 9 (244 mg, 966 μmol), was then added to a
solution of 17 (193 mg, 440 μmol) in anhydrous DMF (2 mL) followed by Et3N (2.46
mL, 17.6 mmol) and CuI (34 mg, 179 μmol). The solution was stirred in the dark, at rt,
under an argon atmosphere for  10  min  before  adding
tetrakis(triphenylphosphine)palladium  (102  mg,  88  μmol).  The  reaction  had  gone  to
completion  after  30.5  hours.  The  solvents  were  removed in  vacuo and  the  residue
dissolved in a mixture of CH2Cl2 and MeOH and filtered through celite and the solvents
were again removed in vacuo. The crude material was preadsorbed onto silica gel with
MeOH and purified by silica gel column chromatography (EtOAc:hexane 8:2) to give
18 as brown syrup (238 mg, 73% overall).
Rf (EtOAc:MeOH:NH3 5:1:1, C) 0.20; (CH2Cl2:MeOH 6:4,C) 0.14.
νmax(neat)/cm
-1 3254 (w, NH), 2925 (m, CH2), 2844 (w),1710 (s, CO), 1651 (s, CO),
1456 (m), 1362 (m, CH), 1228 (s, C-O), 1101 (m), 1023 (m), 977 (C-O), 776 (m), 603
(m), 564 (m).
1H NMR (400 MHz, MeOH): δH 7.93 (1H, s, H
6 dU), 6.18 (1H, dd, J = 7.7, 6.2 Hz,
H
1’ dU), 5.24 (1H, dt, J = 6.6, 2.6 Hz, H
3’ dU), 4.26-4.37 (3H, m, H
5’ dU, 4’ dU), 4.10 (2H, s,
H
1’), 2.89 (2H, t, J = 7.7 Hz, H
12), 2.47 (1H, ddd, J = 14.6, 6.2, 2.7 Hz, H
2’ dU), 2.36
(1H, m, H
2’ dU), 2.15 (2H, m, H
2), 2.11 (3H, s, CH3), 2.11 (3H, s, CH3), 1.60 (4H, m,
H
3,11), 1.28 (14H, m, H
4-10).111
13C NMR (100MHz, MeOH): C 177.0 (s, C
1O), 173.2 (2s, COCH3), 145.6 (d, C
6 dU),
134.3 (s), 134.1 (s), 131.2 (s), 105.8 (s), 101.6 (s, C
5 dU), 88.4 (d, C
1’ dU), 85.2 (d, C
4’ dU),
76.7 (d, C
3’ dU), 66.1 (t, C
5’ dU), 42.0 (t, C
2), 39.6 (2t, C
2’ dU,12), 38.0 (t, C
11), 31.6 (t,
C
4-9), 31.5 (2t, C
4-9), 31.4 (t, C
4-9), 31.3 (2t, C
4-9), 29.7 (t, C
3,10,1’), 28.5 (t, C
3,10,1’), 27.9
(t, C
3,10,1’), 21.9 (2q, CH3).
LRMS [ES
+]: m/z 563 ([M+H]
+, 30%).
HRMS [ES
+]: m/z for C28H43N4O8 [M+H]
+: calcd 563.3075, found 563.3066.112
3',5'-O-Acetyl-5-[12-cholesteryloxycarbonylamino-N-(prop-2’-
ynyl)dodecanamido]-2’-deoxyuridine, 19
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A solution of cholesteryl chloroformate (133 mg, 297 μmol) in distilled CH2Cl2 (0.6
mL) was added to a stirred solution of 18 (139 mg, 247 μmol) in anhydrous DMF (1
mL) with DIPEA (52 μL, 297 μmol). The solution was stirred at 0 ºC, under an argon
atmosphere for 2 hours and then at rt for 2 hours again. The solvents were removed in
vacuo and the residue was dissolved in CH2Cl2, washed with aqueous citric acid (10%
w/v) and saturated aqueous KCl then dried (Na2SO4), filtered and the solvents were
removed in vacuo. The crude mixture was purified by silica gel column chromatography
(gradient of EtOAc:hexane 3:2 to 4:1) to give 19 as a yellow solid (77 mg, 32%).
Rf(EtOAc:hexane 9:1, C) 0.30.
mp 132 °C.
νmax (neat)/cm
-1 3273 (w, NH), 2924 (m, CH2), 2845 (m, CH3), 2358 (w, CC alkyne),
1695 (s, CO), 1628 (s), 1542 (m), 1459 (m, CH2), 1361 (m, CH3), 1224 (s, C-O), 1039
(m), 953 (m, C-O), 776 w), 604 (w).
1H NMR (400 MHz, CDCl3): δH9.06 (1H, s, NH
3 dU), 7.80 (1H, s, H
6 dU), 6.26 (1H, dd,
J = 7.5, 6.0 Hz, H
1’ dU), 6.06 (1H, br s, NH), 5.36 (1H, m, H
6 Chol), 5.23 (1H, dt, J = 7.0,
3.0 Hz, H
3’ dU), 4.64 (1H, br s, NH), 4.48 (1H, br s, H
3 Chol), 4.36 (2H, m, H
5’ dU), 4.28
(1H, m, H
4’  dU), 4.23 (2H, d, J = 5.0 Hz, H
1’), 3.13 (2H, m, H
12), 2.54 (1H, ddd,
J = 14.1, 6.0, 2.5 Hz, H
2’ dU), 2.20-2.25 (3H, m, H
2’ dU,2), 2.16 (3H, s, CH3), 2.11 (3H, s,
CH3), 1.47 (4H, m, H
3,11), 1.25 (14H, s, H
4-10), 1.07-2.56 (43H, br m).113
13C NMR (100MHz, CDCl3): C 173.0 (2s, CO), 170.4 (2s, COCH3), 149.1 (2s, CO),
142.3 (d, C
6 dU), 140.0 (s, C
5 Chol), 122.6 (d, C
6 Chol), 100.1 (s, C
5 dU), 90.3 (s, C
3’), 85.8
(d, C
1’ dU), 82.8 (d, C
4’ dU), 74.1 (s and d, C
2’, 3’ dU), 63.8 (t, C
5’ dU), 56.8 (d), 56.3 (d),
50.2 (d), 42.5 (s), 39.9 (t), 39.7 (2t), 38.7 (t), 38.4 (t), 37.1 (t), 36.7 (t), 36.6 (t), 36.3 (t),
35.9 (d), 32.0 (t and d), 30.1 (t), 30.0 (t), 29.8 (t), 29.6 (t), 29.5 (t), 29.4 (2t), 28.4 (2t),
28.1 (d), 25.6 (t), 24.4 (t), 23.9 (t), 22.9 (d), 22.7 (2q), 21.2 (t), 21.0 (t), 20.9 (2q), 19.5
(q), 18.9 (q), 12.0 (q).
LRMS [ES
+]: m/z 997 ([M+Na]
+, 100%).
HRMS [ES
+]: m/z for C56H86N4O10Na [M+Na]
+: calcd 997.6236, found 997.6244.114
5'-O-(4,4-Dimethoxytrityl)-5-[12-cholesteryloxycarbonylamino-N-(prop-2’-
ynyl)dodecanamido]-2’-deoxyuridine, 12
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Compound 19 (800 mg, 0.82 mmol) was dissolved in 0.4 M potassium carbonate in
MeOH:H2O (4:1 v/v, 13 mL, 5.20 mmol). The reaction mixture was stirred at rt for 1
hour 45 min and then diluted with CH2Cl2. DOWEX 50WX8-400 resin (pyridinium
form) was added and the solution was stirred until pH 7. The mixture was filtered and
the solvents were evaporated and co-evaporated with pyridine in vacuo to give 20 as a
solid (891 mg). Compound 20 (653 mg, 0.73 mmol) was dissolved in CH2Cl2 (5 mL) to
which 3 mL of pyridine was added followed by 4,4’-dimethoxytrityl chloride (298 mg,
0.88 mmol) in small portions. The reaction was stirred for 5 hours and 5 mL of MeOH
was added to the solution. The solvents were evaporated and co-evaporated with toluene
in  vacuo and  the  crude  mixture  was  purified  by  silica  gel  column  chromatography
(EtOAc:hexane 4:1, 1% pyridine) to give 12 as a yellow solid (358 mg, 45% overall)
Rf (EtOAc:hexane 4:1, 0.5% Et3N, C) 0.41.
mp 104 °C.
νmax(neat)/cm
-1 3346 (w, NH), 3056 (w, CH Ar), 2925 (m, CH2), 2844 (m, CH3), 2357
(w, C-C alkyne), 1687 (s, CO), 1601 (m), 1503 (s, Aryl C=C), 1446 (s, CH2), 1283 (s),
1242 (s, C-O), 1172 (s), 1172 (s), 1086 (m), 1025 (s, C-O), 825 (m), 723 (m), 694 (m),
576 (s).
1H NMR (400 MHz, CDCl3): δH 9.40 (1H, s, NH
3 dU), 8.19 (1H, s, H
6 dU), 7.17-7.44
(9H, m, H
DMT), 6.84 (4H, d, J = 8.5 Hz, H
3 DMT), 6.32 (1H, br t, J = 6.5 Hz, H
1’ dU), 6.18115
(1H, br s, NH ), 5.53 (1H, br s, NH), 5.37 (1H, br s, H
6 Chol), 4.83 (1H, br s, NH), 4.69
(1H, br s, H
3’ dU), 4.11 (1H, br s, H
4’ dU), 3.87 (2H, d, J = 5.5 Hz, H
1’), 3.81 (3H, s,
CH3), 3.79 (3H, s, CH3), 3.43 (1H, br d, J = 9.0 Hz, H
5’ dU), 3.33 (1H, br d, J = 8.0 Hz,
H
5’ dU), 3.13 (2H, br s, H
12), 2.51 (1H, m, H
2’ dU), 2.22-2.36 (3H, m, H
2’ dU, 2), 1.52 (4H,
m, H
3,11), 1.26 (14H, m, H
4-10), 0.97-6.16 (44H, br m).
13C NMR (100MHz, CDCl3): C 172.8 (s, CO), 172.7 (s, CO), 158.8 (2s, C
4 DMT),
147.5 (2s, CO), 144. 7 (s, C
1’ DMT), 143.3 (d, C
6 dU), 140.0 (s, C
5 -Chol), 135.7 (s, C
1 DMT),
135.6 (s, C
1 DMT), 130.2 (2d, C
DMT), 130.1 (d, C
DMT), 129.3 (d, C
DMT), 129.2 (d, C
DMT),
128.2 (d, C
DMT), 128.1 (d, C
DMT), 127.9 (d, C
DMT), 127.2 (d, C
DMT), 122.6 (d, C
6-Chol),
113.3 (4d, C
3 DMT), 99.1 (s, C
5 dU), 89.9 (s, C
3’), 86.3 (d, C
4’ dU), 86.0 (s, C
0 DMT), 85.9
(d, C
1’ dU), 74.4 (d, C
3’ dU), 74.2 (s, C
2’), 72.2 (t, C
5’ dU), 56.3 (d), 55.4 (d), 55.4 (q, O
CH3), 55.3 (q, O CH3), 50.2 (d), 42.5 (s), 39.9 (t), 39.7 (t), 38.2 (t), 37.1 (t), 36.7 (t),
36.4 (2t), 36.3 (2t), 35.9 (d), 32.0 (t), 31.0 (d), 30.1 (t), 30.0 (t), 29.6 (2t), 29.5 (t), 29.4
(2t), 28.4 (t), 28.3 (t), 28.1 (d), 25.7 (t), 24.4 (t), 24.0 (t), 22.9 (d), 22.7 (2q), 21.2 (2t),
19.5 (2q), 18.9 (2q), 12.0 (q).
LRMS [ES
+]: m/z 1216 ([M+Na]
+, 40%).
Anal calculated: C, 73.46; H, 8.44; N, 4.69, found: C, 73.16; H, 8.46; N, 4.59.116
5'-O-(4,4-Dimethoxytrityl)-5-[12-cholesteryloxycarbonylamino-N-(prop-2’-
ynyl)dodecanamido])-2’-deoxyuridine-3’-O-(2-cyanoethyl)-N,N-diisopropyl
phosphoramidite, 13
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Under  an  argon  atmosphere,  2-O-cyanoethyl-N,N-diisopropyl  chlorophosphoramidite
(61 μL, 0.28 mmol) was added dropwise to a degassed solution of 12 (298 mg, 0.25
mmol) in THF (1.5 mL) with DIPEA (109 μL, 0.62 mmol). After stirring at rt for 30
min, the solution was transferred via cannula under an argon atmosphere to a separating
funnel  containing  degassed ethyl  acetate.  The  mixture  was  washed  with  degassed
saturated  aqueous  KCl,  dried  (Na2SO4)  and  the  solvent  was  removed in  vacuo.
Purification by silica gel column chromatography under argon pressure (EtOAc: hexane
4:1, 0.5 % pyridine) gave 13 as a diastereomeric mixture (ca. 1:1) colourless and air-
and acid-sensitive foam (284 mg, 82%).
Rf (EtOAc:hexane 4:1, 0.5% Et3N, C) 0.20 and 0.33.
1H NMR (400 MHz, d6-DMSO): δH11.61 (1H, br s, NH
3 dU), 8.12 (1H, dd, J = 12.8, 5.3
Hz, NH
1), 7.92 (1H, s, H
6 dU) 7.22-7.40 (9H, m, H
DMT), 6.96 (1H, br s, NH
1’’), 6.88 (4H,
dd, J = 8.3; 5.8 Hz, H
3 DMT), 6.09 (1H, dd, J = 15.6; 7.0 Hz, H
1’ dU), 5.31 (1H, br s,
H
6 Chol), 4.48 (1H, br s, H
3 Chol), 4.29 (1H, m, H
3’ dU), 4.02 (1H, m, H
4’ dU), 3.94 (1H, dd,
J = 17.7, 5.0 Hz, H
1’), 3.88 (1H, d, J = 17.7, 5.0 Hz, H
1’), 3.74 (3H, s, O-CH3), 3.73
(3H, s, O-CH3), 3.67 (2H, m, OCH2CH2CN), 3.52 (2H, m, iPr-CH),  3.19 (1H, dd,
J = 10.5, 3.0 Hz, H
5’), 3.14 (2H, dd, J = 10.5, 3.0 Hz, H
5’), 2.92 (2H, q, J = 6.5 Hz,117
H
12), 2.75 (1, t, J = 5.8 Hz, CH2CN), 2.64 (1, t, J = 5.8 Hz, CH2CN), 2.40 (1H, m, H
2’
dU), 2.23 (1H, m, H
2’ dU), 1.21 (14H, m, H
6-12), 0.64-2.05 (58H, br m).
31P NMR (162 MHz, d6-DMSO)δp 148.5, 148.9.
LRMS [ES
+]: m/z 1216 ([M+Na]
+, 40%).
6-(Cholesteryloxycarbonylamino)-hexanol, 22
O
H
H H
N
H
O
6
5
4
OH
3
2
1
H 3 Chol
6 Chol
H 1'
A solution of cholesteryl chloroformate 21 (1.10 g, 2.45 mmol) in distilled CH2Cl2
(5 mL) was added to a stirred solution of 6-aminohexanol (631 mg, 5.38 mmol) in
distilled CH2Cl2 (5 mL). The solution was stirred at 0 ºC, under an argon atmosphere
for 2 hours, then at rt for a further 16.5 hours. The reaction was diluted with CH2Cl2,
washed  with  aqueous  citric  acid  (10%  w/v)  and  saturated  aqueous  NaHCO3,  dried
(Na2SO4), filtered and the solvents were removed in vacuo to give a yellow solid. The
crude mixture was purified by silica gel column chromatography (EtOAc:hexane 3:2) to
give 22 as a colourless solid (1.12 g, 86%).
Rf (EtOAc:hexane 3:2, A) 0.41.
mp 126-127 °C.
νmax(neat)/cm
-1 3350 (w, NH), 2925 (s, CH2), 2864 (m), 1687 (s, CO), 1538 (m), 1467
(m, CH2). 1373 (m), 1251(s, CO), 1144 (m), 1005 (m, C-O), 645 (m, C=C).
1H NMR (400 MHz, CDCl3): δH 5.36 (1H, m, H
4 Chol), 4.60 (1H, br s, NH), 4.49 (1H,
m, H
3 Chol), 3.63 (2H, t, J = 6.5 Hz, H
1), 3.15 (2H, t, J = 6.8 Hz, H
6), 2.35 (1H, ddd,118
J = 13.0, 5.0, 1.5 Hz, H
2 Chol), 2.26 (1H, m, H
2 Chol), 1.52 (2H, m, H
2), 1.34 (2H, m, H
5),
0.67-2.16 (46H, br m).
13C NMR (100MHz, CDCl3): C 182.7 (s, C
1’O), 142.0 (s, C
5 Chol), 124.6 (d, C
6 Chol),
64.9 (t, C
2), 58.9 (d), 58.3 (d), 52.2 (d), 44.5 (2s), 42.9 (t, C
4), 41.9 (t), 41.7 (t), 40.8 (t),
39.2 (t), 38.7 (t), 38.4 (t), 38.0 (d), 34.7 (t), 34.1 (t and d), 32.2 (t), 30.4 (t and d), 30.2
(d), 28.6 (t), 27.5 (t), 26.5 (t), 26.0 (t), 25.0 (2q), 23.2 (t), 21.5 (q), 20.9 (q), 14.0 (q).
LRMS [ES
+]: m/z 553 ([M+Na]
+, 100%), 1082 ([2M+Na]
+, 70%).
HRMS [ES
+]: m/z for C34H60NO3 [M+H]
+ : calcd 530.4567, found 530.4571.
Anal calculated: C, 77.07; H, 11.22; N, 2.64, found: C, 77.19; H, 11.33; N, 2.66.119
6-(Cholesteryloxycarbonylamino)-hexanol 1-O-(2-cyanoethyl)-N,N-diisopropyl
phosphoramidite, 23
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Under  an  argon  atmosphere,  2-O-cyanoethyl-N,N-diisopropyl  chlorophosphoramidite
(491 μL, 2.20 mol) was added dropwise to a degassed solution of 22 (1.06 g, 2.00
mmol) in THF (5 mL) with DIPEA (872 μL, 5.00 mmol). After stirring at rt for 30 min,
the solution was transferred via cannula under an argon atmosphere to a separating
funnel  containing  degassed  ethyl  acetate.  The  mixture  was  washed  with  degassed
saturated  aqueous  KCl,  dried  (Na2SO4)  and  the  solvents  were removed in  vacuo.
Purification by silica gel column chromatography under argon pressure (EtOAc:hexane
3:7, 0.5 % pyridine) gave 23 as a colourless air- and acid-sensitive foam (626 mg, 43%).
Rf (EtOAc:hexane 3:7, A) 0.46.
1H NMR (400 MHz, d6-DMSO): H6.98 (1H, t, J = 5.5 Hz, NH), 5.33 (1H, m, H
4 Chol),
4.29 (1H, m, H
1 Chol), 3.71 (2H, m, OCH2CH2CN), 3.51-3.60 (4H, m, iPr-CH, H
1), 2.93
(2H, q, J = 6.8 Hz, H
6), 2.79 (2H, t, J = 6.0 Hz, CH2CN), 2.28 (1H, dd, J = 12.8, 3.9 Hz,
H
2  Chol), 2.19 (1H, m, H
2  Chol), 1.51 (2H, m, H
2), 1.31 (2H, m, H
5), 0.69-2.30 (57H,
br m).
31P NMR (162 MHz, d6-DMSO)δp 147.6.
LRMS [ES
+]: m/z 753 ([M+Na]
+, 100%).
HRMS [ES
+]: m/z for C43H76N3O4PNa [M+Na]
+: calcd 752.5466, found 752.5468.120
Hexa(ethylene glycol) mono-p-toluenesulfonate, 25
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A solution of p-toluenesulfonyl chloride (2.53 g, 13.28 mmol) in CH2Cl2 (5 mL) was
added dropwise over 2 hours to an ice-cooled solution of hexa(ethylene glycol) 24 (15
g, 53.13 mmol), Et3N (7.41 mL, 53.13 mmol) and DMAP (779 mg, 6.37 mmol) in
CH2Cl2 (10 mL) and the reaction mixture was stirred for a further 5 h at rt. The reaction
mixture  was  dissolved  in  CH2Cl2,  washed  with  distilled  water,  saturated  aqueous
NaHCO3, and aqueous citric acid (10% w/v), dried (Na2SO4), filtered and solvent was
removed in vacuo. The crude mixture was purified by silica gel column chromatography
(gradient of EtOAc:toluene 7:3 to neat EtOAc, then EtOAc:MeOH 95:5) to give 25 as a
yellow oil (3.47 g, 60 %).
Rf (EtOAc) 0.18, (EtOAc:MeOH:Et3N 5:1:1) 0.49, (CH2Cl2:MeOH:AcOH 10:2:1) 0.30.
νmax(neat)/cm
-1 3450 (w, OH), 2869 (m, CH2), 1598 (w, Aryl C=C), 1452 (w, CH2),
1351 (m, SO2), 1175 (s, SO2), 1095 (s, C-O).
1H NMR (400 MHz, CDCl3): H 7.79 (2H, dd, J = 8.3, 1.8 Hz, H
2 Ts), 7.33 (2H, br d,
J = 8.5 Hz, H
3 Ts), 4.13-4.17 (4H, m, H
1, 2’’), 3.57-3.71 (20H, m, H
2,1’-8’,1’’), 2.44 (3H, s,
CH3).
13C NMR (100MHz, CDCl3): C 144.9 (s, C
4  Ts), 133.2 (s, C
1  TS), 129.9 (2d, C
3  Ts),
128.1 (2d, C
2 Ts), 72.7 (t, C
2), 70.9 (t, C
1’-8’), 70.7 (4t, C
1’-8’), 70.6 (2t, C
1’-8’), 70.4 (t,
C
1’-8’), 69.4 (t, C
1’’), 68.8 (t, C
2’’), 61.8 (t, C
1), 21.7 (q, CH3).
LRMS [ES
+]: m/z 454.5 ([M+NH4]
+, 50%), 459.4 ([M+Na]
+, 100%).
HRMS [ES
+]: m/z for C19H32O9NaS [M+Na]
+: calcd 459.1659, found 459.1659.
Analytical results consistent with reported data.
144121
2-O-[(2''-Phthalimido-ethoxy)tetra(ethylene oxy)]ethanol, 26
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Compound 25 (1.94 g, 4.44 mmol) and potassium phthalimide (1.24g, 6.66 mmol) were
heated in anhydrous DMF (8 mL) under reflux in an argon atmosphere for 8 hours. The
solvent was removed in vacuo and the residue was dissolved in CH2Cl2, washed with
water  and  with  saturated  aqueous KCl,  dried  (Na2SO4),  filtered  and  solvents  were
removed in vacuo. The crude mixture was purified by silica gel column chromatography
(CH2Cl2 with a gradient of MeOH, 1-3%) to give 26 as yellow oil (1.41 g, 78 %).
Rf (CH2Cl2:MeOH 19:1, D) 0.23, (CH2Cl2:MeOH 8:2, D) 0.65, (EtOAc:MeOH:Et3N
5:1:1, E) 0.63.
νmax(neat)/cm
-1 3468 (w, OH), 2869 (m, CH2), 1773 (m, C=O), 1707 (s, C=O), 1467
(w, CH2), 1095 (s, C-O), 720 (s, CH2).
1H NMR (400 MHz, CDCl3): H 7.82 (2H, dd, J = 5.5, 3.0 Hz, H
2 Phth), 7.69 (2H, dd,
J = 5.0, 3.0 Hz, H
3 Phth), 3.88 (2H, t, J = 5.8 Hz, H
2’’), 3.69-3.73 (4H, m, H
1, 1’’), 3.54-
3.66 (18H, m, H
2,1’-8’).
13C NMR (100MHz, CDCl3): C 168.3 (2s, CO), 134.0 (2d, C
3 Phth), 132.3 (2s, C
1 Phth),
123.3 (2d, C
2 Phth), 72.6 (t, C
2), 70.7 (2t, C
1’-8’), 70.6 (4t, C
1’-8’), 70.4 (t, C
1’-8’), 70.2 (t,
C
1’-8’), 68.0 (t, C
1’’), 61.8 (t, C
1), 37.4 (t, C
2’’).
LRMS [ES
+]: m/z 429.5 ([M+NH4]
+, 10%), 434.4 ([M+Na]
+, 100%).
HRMS [ES
+]: m/z for C19H32O9SNa [M+Na]
+: calcd 434.1785, found 434.1789.
Analytical results consistent with reported data.
157122
2-O-[(2''-Phthalimidoethoxy)tetra(ethylene oxy)]acetic acid, 27
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Compound 26 (1.00 g, 2.43 mmol) was dissolved in a 1:1 v/v mixture of water and
acetonitrile (7 mL). TEMPO (76 mg, 0.49 mmol) was added followed by BAIB (2.35 g,
7.29 mmol). The reaction mixture was stirred at rt for 3.5 hours, then the solvents were
removed. Purification by silica gel column chromatography (CH2Cl2, 3% MeOH) gave
27 as yellow oil (748 mg, 72 %).
Rf (CH2Cl2, MeOH 9:1, F) 0.30, (EtOAc:MeOH:Et3N 5:1:1, F) 0.21,
(CH2Cl2:MeOH:AcOH 10:2:1, F) 0.73.
νmax(neat)/cm
-1 2872 (m, CH2), 1706 (s, C=O), 1467 (w, CH2), 1393 (m), 1353 (w),
1101 (s, C-O), 1024 (m), 719 (s, CH2).
1H NMR (400 MHz, CDCl3): H 7.82 (2H, dd, J = 5.0, 3.0 Hz, H
2 Phth), 7.70 (2H, dd,
J = 5.3, 3.3 Hz, H
3 Phth), 4.12 (2H, s, H
2), 3.88 (2H, t, J = 5.8 Hz, H
2’’), 3.72 (2H, t,
J = 5.8 Hz, H
1’’), 3.55-3.68 (16H, m, H
1’-8’).
13C NMR (100 MHz, CDCl3): C 172.3 (s, C
1), 168.4 (2s, CO), 134.1 (2d, C
3  Phth),
132.3 (2s, C
1 Phth), 123.4 (2d, C
2 Phth), 71.2 (t, C
1’-8’), 70.7 (t, C
1’-8’), 70.6 (2t, C
1’-8’), 70.4
(2t, C
1’-8’), 70.3 (t, C
1’-8’),70.1 (t, C
1’-8’), 69.2 (t, C
2), 68.1 (t, C
1’’), 37.4 (t, C
2’’).
LRMS [ES
+]: m/z 443.4 ([M+NH4]
+, 40%), 448.4 ([M+Na]
+, 100%), 464.3 ([M+K]
+,
10%).
HRMS [ES
+]: m/z for C19H32O9NNa [M+Na]
+: calcd 448.1578, found 448.1576.123
5'-O-(4,4-Dimethoxytrityl)-5-[2,2,2-trifluoro-N-(prop-2’-ynyl)-acetamido]-2’-
deoxyuridine, 35
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5'-O-(4,4’-Dimethoxytrityl)-5-iodo-2’-deoxyuridine 11
141 (5.00  g,  7.62  mmol)  was
dissolved  in anhydrous DMF  (50  mL)  to  which  2’,2’,2’-trifluoro-N-(prop-2-
ynyl)acetamide 34 (1.20 mL, 10.8 mmol), Et3N (7.43 mL, 53.3 mmol) and CuI (338
mg, 1.77 mmol) were added. The solution was stirred in the dark, at rt, under an argon
atmosphere for  10  min before  tetrakis(triphenylphosphine)palladium  (880  mg,  0.76
mmol) was added. The reaction had gone to completion after 1.5 hours. The solvents
were  removed in  vacuo,  the  residue  dissolved  in  EtOAc,  washed  with aqueous
Na2EDTA (5% w/v), dried (Na2SO4), filtered and the solvents were removed in vacuo.
The  crude  mixture  was  purified  by  silica  gel  column  chromatography  (gradient  of
CH2Cl2:acetone 9:1 to 7:3, 1% pyridine) to give 35 as a yellow foam (4.96 g, 96%).
Rf (CH2Cl2:acetone 4:1, C) 0.33; (EtOAc:MeOH:NH3 5:1:1, A) 0.29.
1H NMR (400 MHz, CDCl3): H 9.78 (1H, br s, NH), 8.23 (1H, s, H
6 dU), 7.16-7.42
(9H, m, H
DMT), 6.84 (4H, d, J = 8.5 Hz, H
3 DMT), 6.35 (1H, dd, J = 7.7, 6.0 Hz, H
1’ dU),
4.59 (1H, dt, J = 5.8, 2.8 Hz, H
3’ dU), 4.14 (1H, m, H
4’ dU), 3.95 (1H, dd, J = 17.9, 4.8
Hz, H
1’), 3.88 (1H, dd, J = 17.9, 4.7 Hz, H
1’), 3.77 (6H, s, O-CH3), 3.38 (1H, dd,
J = 11.3, 3.0 Hz, H
5’ dU), 3.35 (1H, dd, J = 11.0, 3.0 Hz, H
5’ dU), 2.57 (1H, ddd, J = 13.8,
5.8, 2.8, H
2’ dU), 2.32 (1H, m, H
2’ dU).
13C NMR (100 MHz, CDCl3): δC 162.5 (s, CO), 158.8 (2s, C
4-DMT), 149.5 (2s, CO),
144.6  (s, C
1’-DMT),  143.7  (d, C
6  dU),  135.6  (2s, C
1-DMT),  130.2  (d, C
DMT),  130.1  (d,
C
DMT), 129.2 (2d, C
DMT), 128.4 (2d, C
DMT), 128.2 (2d, C
DMT), 128.0 (d, C
4’-DMT), 124.0124
(s, C
2), 113.5 (4d, C
3-DMT), 99.2 (s, C
5 dU), 87.6 (s, C
0-DMT), 87.2 (d, C
4’ dU), 86.2 (d,
C
1’ dU), 77.6 (s, C
3’), 75.5 (s, C
2’), 72.5 (d, C
3’ dU), 63.7 (t, C
5’ dU), 55.4 (2q, CO-CH3),
41.7 (t, C
2’ dU), 30.5 (t, C
1’).
LRMS [ES
+]: m/z 702 ([M + Na]
+, 100); 697 ([M + NH4]
+, 15).
HRMS [ES
+]: m/z for C35H32F3N3O8[M + Na]
+: calcd 702.2034, found 702.2043.
Analytical results consistent with reported data.
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5'-O-(4,4-Dimethoxytrityl)-5-{2-O-[(2''-phthalimido-ethoxy)tetra(ethylene oxy)]-N-
prop-2’’’-ynyl-acetamido}-2’-deoxyuridine, 29
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Compound 35 (3.11g, 4.58 mmol) was dissolved in ethanolic methylamine (33% w/v)
(28.48 mL, 229 mmol) and the reaction mixture was stirred at rt for 2 hours. The solvent
was removed in vacuo and the product was dried overnight under high vacuum to give
28 as a yellow foam (2.97 g, 5.09 mmol) which was used without further purification.
2-[(2-Phthalimido-ethoxy)tetra(ethylene oxy)]acetic acid 27 was dissolved in CH2Cl2
(10 mL) to which PyBroP (1.21 g, 2.59 mmol) and DIPEA (1.23 mL, 7.05 mmol) were
added. The solution was stirred at rt under an argon atmosphere for 20 mins before
adding the nucleoside 28 (1.51 g, 2.59 mmol). The reaction had gone to completion
after 1.5 hours. The solvents were removed in vacuo and the residue was dissolved in
CH2Cl2, washed with saturated aqueous NaHCO3, dried (Na2SO4) and the solvent was
removed in  vacuo. Purification  by  silica  gel  column  chromatography  under  argon125
pressure (CH2Cl2 with a gradient of MeOH from 0.5% to 2%, 0.5 % Et3N) gave 29 as a
pale yellow foam (1.13 g, 49%).
Rf (CH2Cl2:acetone 4:1, A) 0.11; (CH2Cl2:MeOH 95:5, C) 0.19.
νmax(solid)/cm
-1 3100 (w, CH
Phth), 2868 (w, CH2), 1772 (w), 1708 (s, CO), 1607 (m),
1508 (m, C=C), 1456 (m, CH2), 1393 (m), 1348 (w), 1280 (m), 1247 (s, CO), 1175 (m,
CO), 1089 (s, CO), 1028 (s, C–O), 838 (s), 721 (s, CH
Phth), 583 (m).
1H NMR (400 MHz, CDCl3): H 7.98 (1H, s, H
6 dU), 7.82 (2H, dd, J = 5.5, 3.0 Hz,
H
2 Phth), 7.68 (2H, dd, J = 5.5, 3.0 Hz, H
3 Phth), 7.18-7.42 (10 H, m, H
DMT, NH), 6.83
(4H, d, J = 8.5 Hz, H
3 DMT), 6.26 (1H, dd, J = 7.3, 6.0 Hz, H
1’ dU), 4.54 (1H, dt, J = 6.0,
3.0 Hz, H
3’ dU), 4.08 (1H, m, H
4’ dU), 4.03 (1H, dd, J = 18.0, 5.5 Hz, H
1’’’), 3.93 (1H, dd,
J = 18.0, 5.5 Hz, H
1’’’), 3.94 (2H, s, H
2), 3.87 (2H, t, J = 5.8 Hz, H
2’’), 3.76 (6H, s,
O-CH3), 3.71 (2H, t, J = 5.8 Hz, H
1’’), 3.55-3.62 (16H, m, H
1’-8’), 3.38 (1H, dd, J =
10.6, 4.0 Hz, H
5’ dU), 3.31 (1H, dd, J = 10.5, 3.0 Hz, H
5’ dU), 2.49 (1H, ddd, J = 13.6,
6.0, 3.0 Hz, H
2’ dU), 2.26 (1H, m, H
2’ dU).
13C NMR (100 MHz, CDCl3): δC 169.7 (s, CO), 168.5 (2s, CO), 161.6 (s, CO), 158.8
(2s, C
4-DMT), 149.2 (s, CO), 144.7 (s, C
1’-DMT), 143.2 (d, C
6 dU), 135.7 (s, C
1-DMT), 135.6
(s, C
1-DMT), 134.1 (2d, C
3 Phth), 132.2 (2s, C
1 Phth), 130.2 (2d), 130.1 (4d), 128.1 (d),
128.0 (d), 127.1 (d, C
4’-DMT), 123.4 (2d, C
2 Phth), 113.5 (4d, C
3-DMT), 99.6 (s, C
5 dU), 87.1
(s, C
0-DMT), 86.5 (d, C
4’ dU), 85.9 (d, C
1’ dU), 77.3 (s, C
3’’’), 74.1 (s, C
2’’’), 72.2 (d, C
3’ dU),
71.1 (2t, C
1’-8’), 70.6 (4t, C
1’-8’), 70.5 (t, C
1’-8’), 70.3 (t, C
3’-8’), 70.2 (t, C
2), 68.0 (t, C
1’’),
63.8 (t, C
5’ dU), 55.4 (2q, CO-CH3), 41.5 (t, C
2’ dU), 37.4 (t, C
2’’), 29.4 (t, C
1’’’).
LRMS [ES
+]: m/z 1014 ([M + Na]
+, 100%); 1009 ([M + NH4]
+, 81).
HRMS [ES
+]: m/z for C53H58N4O15Na [M + Na]
+: calcd 1013.3791, found 1013.3787.126
2-O-[(2''-Phthalimido-ethoxy)tetra(ethylene oxy)]-N-prop-2’’’-ynyl-acetamide, 33
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2-[(2-Phthalimido-ethoxy)tetra(ethylene oxy)]acetic acid 27 (150 mg) was dissolved in
CH2Cl2 (1.5 mL) to which PyBroP (181 mg, 0.39 mmol) and DIPEA (184 μL, 1.06
mmol) were added. The solution was stirred at rt under an argon atmosphere for 20
mins before adding prop-2-yn-1-amine (36 μL, 0.53 mmol). The reaction had gone to
completion after 1 hour 15 min. The reaction mixture was diluted in CH2Cl2, washed
with saturated aqueous NaHCO3, distilled water and aqueous citric acid (10% w/v),
dried (Na2SO4), filtered and the solvent was removed in vacuo. Purification by silica gel
column chromatography under argon pressure (EtOAc to EtOAc:acetone 1:4) gave 33
as a pale yellow oil (85 mg, 53%).
Rf (CH2Cl2:MeOH, 9:1,G) 0.55; (EtOAc:MeOH:NH3 5:1:1, G) 0.54; (EtOAc:acetone,
9:1, A) 0.25.
νmax (neat)/cm
-1 3255 (m, CH), 2886 (w, CH), 2864 (w, CH), 1773 (w, CO), 1707 (s,
CO), 1664, m), 1519 (w), 1468 (w, CH2), 1425 (w), 1342 (m), 1320 (w), 1286 (w),
1141 (w), 1107 (s, C–O), 1096 (s, C–O), 1058 (m), 1031 (m), 956 (w), 935 (w), 841
(m), 714 (s, CH2).
1H NMR (400 MHz, CDCl3): H 7.82 (2H, dd, J = 5.5, 3.0 Hz, H
2 Phth), 7.70 (2H, dd,
J = 5.5, 3.0 Hz, H
3 Phth), 7.38 (1H, br s, NH), 4.06 (2H, dd, J = 5.5, 2.5 Hz, H
1’’’), 4.00
(2H, s, H
2), 3.88 (2H, t, J = 5.8 Hz, H
2’’), 3.72 (2H, t, J = 5.8 Hz, H
1’’), 3.56-3.67 (16H,
m, H
1’-8’), 2.21 (1H, t, J = 2.5 Hz, H
3’’’).
13C NMR (100 MHz, CDCl3): C 170.0 (s, CO), 168.4 (2s, CO), 134.0 (2d, C
3 Phth),
132.3 (2s, C
1 Phth), 123.3 (2d, C
2 Phth), 79.3 (s, C
2’’’), 71.3 (d, C
1’’’), 70.7 (8t, C
1’-8’), 70.2
(t, C
2), 68.0 (t, C
1’’), 37.4 (t, C
2’’), 28.5 (t, C
3’’’).
LRMS [ES
+]: m/z 480.5([M + NH4]
+, 10%), 485.4 ([M + Na]
+, 100%).
HRMS [ES
+]: m/z for C23H30N2NaO8[M + Na]
+: calcd 485.1894, found 485.1894.127
2-O-[(2''-Amino-ethoxy)tetra(ethylene oxy)]-N-prop-2’’’-ynyl-acetamide, 36
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Compound 33 (490 mg, 1.06 mmol) was dissolved in EtOH (5 mL) to which hydrazine
monohydrate (98% w/v, 0.41 mL, 8.48 mmol) was added. The reaction mixture was
stirred at rt for 1 hour 20 min. The solvent was removed in vacuo, the residue was
dissolved in EtOAc, the precipitate was removed by filtration and solvent was removed
in  vacuo.  The  crude  mixture  was  purified  by  silica  gel  column  chromatography
(CH2Cl2:MeOH, 95:5, 0.5 % Et3N) to give 36 as brown syrup (249 mg, 71%).
Rf (CH2Cl2:MeOH 9:1, G) 0.29; (CH2Cl2:MeOH 19:1, G) 0.21; (acetone:MeOH 3:2, G)
0.18.
νmax (neat)/cm
-1 3293 (w), 2871 (m, CH), 1665 (CO), 1531 (w, NH), 1455 (w), 1348
(w), 1284 (w), 1248 (w), 1096 (s, C–O), 944 (w), 843 (m).
1H NMR (400 MHz, CDCl3): H 7.44 (1H, br s, NH), 4.06 (2H, dd, J = 5.5, 2.5 Hz,
H
1’’’), 3.99 (2H, s, H
2), 3.60-3.66 (16H, m, H
1’-8’), 3.48 (2H, t, J = 5.3 Hz, H
1’’), 2.83
(2H, t, J = 5.3 Hz, H
2’’), 2.21 (1H, t, J = 2.5 Hz, H
3’’’), 1.64 (2H, br s, NH2).
13C NMR (100 MHz, CDCl3): C 170.0 (s, CO), 79.8 (s, C
2’’’), 73.5 (t, C
1’’), 71.2 (d,
C
3’’’), 70.7 (8t, C
1’-8’), 70.2 (t, C
2), 41.9 (t, C
2’’), 28.4 (t, C
1’’’).
LRMS [ES
+]: m/z 333.2 ([M + H]
+, 100%).
HRMS [ES
+]: m/z for C15H29N2O6 [M + H]
+: calcd 333.2020, found 333.2017.128
2-O-[(2''-Cholesteryloxycarbonylamino-ethoxy)tetra(ethylene oxy)]-N-prop-2’’’-
ynyl-acetamide, 37
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A solution of cholesteryl chloroformate (404 mg, 0.90 mmol) in distilled CH2Cl2 (2.5
mL) was added to a stirred solution of 36 (176 mg, 0.53 mmol) in distilled CH2Cl2 (2
mL). The solution was stirred at 0
ºC, under an argon atmosphere for 2 hours, then at rt
for a further 19 hours. The reaction mixture was diluted with CH2Cl2, washed with
aqueous citric acid (10% w/v) and saturated aqueous KCl, dried (Na2SO4), filtered and
the  solvent was removed in  vacuo.  The  crude  mixture  was  purified  by  column
chromatography (CH2Cl2:MeOH 97:3) to give 37 as a pale pink oil (347 mg, 88%).
Rf (CH2Cl2:MeOH 19:1, G) 0.21; (CH2Cl2:MeOH 9:1, G) 0.57; (EtOAc:MeOH:NH3
5:1:1, A) 0.59.
νmax(neat)/cm
-1 3306 (w), 2933 (m, CH), 2866 (m, CH), 1674 (m, CO), 1530 (m, NH),
1442 (m), 1398 (m), 1376 (m), 1344 (m),1233 (m), 1105 (s, C–O), 949 (w), 843 (w).
1H NMR (400 MHz, CDCl3): H 7.38 (1H, br s, NH), 5.35 (1H, m, H
6 Chol), 4.50 (1H,
m, H
3 Chol), 4.08 (2H, dd, J = 5.5, 2.5 Hz, H
1’’’), 4.00 (2H, s, H
2), 3.60-3.68 (16H, m,
H
1’-8’), 3.53 (2H, t, J = 5.0 Hz, H
2’’), 3.34 (2H, br d, H
1’’), 2.22 (1H, t, J = 2.5 Hz, H
3’’’),
0.67-2.38 (br m, 44H).
13C NMR (100 MHz, CDCl3): δC 170.0 (s, CO), 154.6 (s, CO), 140.0 (s, C
5 Chol), 122.6
(d, C
6 Chol), 79.9 (s, C
2’’’), 75.2 (t, C
3 Chol), 71.3 (t, C
1’’), 71.2 (d, C
3’’’), 70.7 (8t, C
1’-8’),
69.1 (d, C
2), 56.8 (t), 56.3(t), 50.2 (t), 42.5 (s and t, C
2’’), 39.9 (s), 38.7 (t), 38.6 (t), 36.7
(t), 36.3 (t), 35.9 (2d), 32.0 (d and t), 28.3 (t, C
3’’’), 28.2 (d), 28.1 (d), 24.4 (t), 24.0 (t),
22.9 (d), 22.7 (q), 21.4 (t), 21.2 (q), 19.5 (q), 18.8 (q), 12.0(q).
LRMS [ES
+]: m/z 762.6 ([M + NH4]
+, 10%), 767.6 ([M + Na]
+, 100%).
HRMS [ES
+]: m/z for C43H72N2NaO8 [M + Na]
+: calcd 767.5181, found 767.5176.129
5'-O-(4,4-Dimethoxytrityl)-5-{2-O-[(2''-cholesteryloxycarbonylamino-
ethoxy)tetra(ethylene oxy)]-N-prop-2’’’-ynyl-acetamido}-2'-deoxyuridine, 31
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5'-O-(4,4’-Dimethoxytrityl)-5-iodo-2’-deoxyuridine 11 (106  mg,  0.16  mmol)  was
dissolved in anhydrous DMF (1.5 mL) to which Et3N (7.43 mL, 53.3 mmol), CuI (7 mg,
0.04 mmol) and a solution of 37 (181 mg, 0.24 mmol) in anhydrous DMF (2 mL) were
added. The solution was stirred in the dark, at rt, under an argon atmosphere for 10 min
before tetrakis(triphenylphosphine) palladium (18 mg, 0.02 mmol) was added. After 1.5
hours  TLC analysis  indicated that  the  reaction  had  not  gone  to  completion,  hence
further CuI (7 mg, 0.04 mmol) was added to the reaction mixture. The reaction was
complete  after  3.5  hours.  The  solvents  were  removed in  vacuo,  the  residue  was
dissolved in EtOAc, washed with aqueous Na2EDTA (5% w/v), the organic layer was
dried (Na2SO4), filtered and the solvents were removed in vacuo. The crude mixture
was purified by silica gel column chromatography (EtOAc:MeOH 95:5, 0.5 % Et3N) to
give 31 as a pale yellow foam (129 mg, 63%).
.
Rf (CH2Cl2:MeOH 19:1, C) 0.21; (CH2Cl2:MeOH 97:3, C) 0.14; (EtOAc:MeOH:NH3
5:1:1, C) 0.29.
νmax(solid)/cm
-1 3350 (w), 2932 (m, CH), 2866 (m, CH), 1694 (s, CO), 1607 (w), 1508
(m, NH), 1455 (m), 1402 (w), 1344 (m), 1280 (m), 1248 (s, CO), 1175 (m), 1095 (s,
CO), 1032 (m), 949 (w), 827 (m).
1H NMR (400 MHz, CDCl3): H 8.04 (1H, s, H
6 dU), 7.31-7.47 (9H, m, H
DMT), 7.20
(1H, br s, NH), 6.89 (4H, dd, J = 8.5, 1.5 Hz, H
3 DMT), 6.32 (1H, dd, J = 6.5, 6.5 Hz,130
H
1’ dU), 5.39 (1H, m, H
6 Chol), 4.52-4.58 (2H, m, H
3 Chol, 3’ dU), 4.12 (1H, br m, H
4’ dU),
4.05 (2H, br m, H
1’’’), 3.99 (2H, s, H
2), 3.83 (6H, s, O-CH3), 3.64-3.68 (18H, m, H
1’-
8’,2’’), 3.56 (2H, br s, H
1’’), 3.44 (1H, dd, J = 10.5, 3.5 Hz, H
5’ dU), 3.38 (1H, dd, J =
10.5, 3.5 Hz, H
5’ dU), 2.53 (1H, ddd, J = 13.5, 5.5, 3.0 Hz, H
2’ dU), 2.30 (1H, m, H
2’ dU),
0.72-2.39 (br m, 43H).
13C NMR (100 MHz, CDCl3): C 169.70 (2s, CO), 161.5 (s, CO), 158.8 (2s, C
4 DMT),
149.2 (s, CO), 144.7 (s, C
1’ DMT), 143.1 (d, C
6 dU), 140.0 (s, C
5 Chol), 135.6 (2s, C
DMT),
130.1  (2d, C
DMT),  128.2  (4d, C
DMT),  128.0  (2d, C
DMT),  127.1  (s, C
DMT),  122.6  (d,
C
6  Chol), 113.5 (2d, C
DMT), 99.7 (s, C
5  dU), 89.5 (s, C
0  DMT), 87.2 (s, C
3’’’), 86.5 (d,
C
4’ dU), 85.8 (d, C
1’ dU), 75.3 (d), 74.1 (s), 72.3 (d), 70.3-71.1 (9t, C
1’-8’, 2), 69.1 (t), 63.8
(t, C
5’ dU), 56.8 (d), 56.3 (d), 55.4 (2q, CO-CH3), 51.1 (2d), 48.9 (t), 42.5 (s), 41.5 (t,
C
2’ dU), 39.9 (t), 39.7 (t), 38.6 (t), 37.1 (t), 36.7 (t), 36.3 (t), 35.9 (d), 32.0 (d and t), 29.4
(d), 28.3 (t, C
1’’’), 28.3 (t), 28.1 (d), 24.4 (t), 24.0 (t), 23.0 (d), 22.7 (q), 21.4 (t), 21.2
(q), 19.5 (q), 18.9 (q), 12.0 (q).
LRMS [ES
+]: m/z 1295.4 ([M + Na]
+, 100%).131
5’-O-(4,4-Dimethoxytrityl)-5-{2-O-(2’’-cholesteryloxycarbonylamino-
ethoxy)tetra(ethyleneoxy)]-N-prop-2’’’-ynyl-acetamido}-2’-deoxyuridine 3’-O-(2-
cyanoethyl)-N,N-diisopropyl phosphoramidite, 32
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Under an argon atmosphere, 2-O-cyanoethyl-N,N,N’,N’-tetraisopropylphosphoramidite
(137 μL, 0.43 mmol) was added dropwise to a degassed solution of 31 (500 mg, 0.39
mmol) in CH2Cl2 (3 mL) with dry DIHT (33 mg, 0.20 mmol). After stirring at rt for 2
hours 20 min, the reaction mixture was diluted with degassed CH2Cl2 and washed with
degassed saturated aqueous NaHCO3. The aqueous layer was washed with degassed
CH2Cl2 and the combined organic layers were combined, dried (Na2SO4), filtered and
the solvents removed in vacuo. Purification by silica gel column chromatography under
argon pressure (EtOAc:hexane 4:1, 0.5 % Et3N) gave 32 as diastereomeric mixture (ca.
1:1) pale yellow air- and acid-sensitive foam (378 mg, 66%).
Rf (CH2Cl2:Acetone 3:2, C) 0.46; (CH2Cl2:MeOH 19:1,C) 0.61; (EtOAc:MeOH:NH3
5:1:1, C) 0.35.
1H NMR (400 MHz, d6-DMSO): H 11.62 (1H, br s, NH), 8.01 (1H, dd, J = 12.1,
6.2 Hz, NH), 7.93 (1H, s, H
6 dU), 7.23-7.41 (9H, m, H
DMT), 6.88 (4H, m, H
3 DMT), 6.08
(1H, dd, J = 13.0, 6.0 Hz, H
1’ dU), 5.33 (1H, m, H
6 Chol), 4.51 (1H, m, H
3 Chol), 4.35 (1H,
m, H
3’ dU), 3.95-4.06 (5H, m, H
3’’’,4’ dU, 1’’’), 3.89 (2H, s, H
2), 3.73 (6H, s, O-CH3), 3.55-
3.73 (4H, m, OCH2CH2CN and iPr-CH), 3.48-3.55 (18H, m, H
1’-8’, 2’’), 3.56 (2H, br s,
H
1’’), 3.15 (2H, m, H
5’ dU), 2.64 (1H, t, J = 6.0 Hz, CH2CN), 2.75 (1H, t, J = 6.0 Hz,
CH2CN), 2.53 (1H, m, H
2’ dU), 2.36 (1H, m, H
2’ dU), 0.64-2.18 (br m, 57H).
31P NMR (162 MHz, d6-DMSO) p 148.4, 148.8.132
Hex-5-yn-1-O-(2-O-cyanoethyl-N,N-diisopropyl) phosphoramidite, 39
O
P
N O
CN
1
2
3
4 5
6
Under  an  argon  atmosphere,  2-O-cyanoethyl-N,N-diisopropyl  chlorophosphoramidite
(2.50 mL, 11.21 mmol) was added dropwise to a degassed solution of 5-hexyn-1-ol 38
(1.00 g, 10.2 mmol) in CH2Cl2 (10 mL) with DIPEA (4.44 mL, 25.5 mmol). After
stirring at rt for 40 mins, the reaction mixture was diluted with degassed CH2Cl2 and
washed with degassed saturated aqueous KCl, dried (Na2SO4), filtered and the solvent
was removed in vacuo. Purification by column chromatography under argon pressure
(Et2O:hexane  1:1,  1  %  pyridine)  gave 39 as  a  colourless, air- and  acid-sensitive
sensitive oil (609 mg, 20%).
Rf (EtOAc:hexane 9:1, 0.5% Et3N, A) 0.27; (EtOAc:hexane 9:1, 1 % pyridine, A) 0.23;
(Et2O:hexane 1:1, 1 % pyridine, A) 0.48.
1H NMR (400 MHz, d6-DMSO): H 3.83 (2H, m, OCH2CH2CN) 3.76-3.53 (4H, m,
iPr-CH, H
1), 2.63 (2H, t, J = 6.5 Hz, CH2CN), 2.23 (2H, td, J = 7.0, 2.5 Hz, H
4), 1.94
(1H, t, J = 2.5 Hz, H
6), 1.71 (2H, tt, J = 14.7, 6.5 Hz, H
2), 1.61 (2H, tt, J = 14.7, 6.5 Hz,
H
3), 1.18 (3H, d, J = 3.5 Hz, iPr-CH3), 1.17 (3H, d, J = 3.5 Hz, iPr-CH3).
31P NMR (162 MHz, d6-DMSO) p 148.1.
LRMS [ES
-]: m/z 299 ([M+H]
+, 100%).
HRMS [ES
+]: for C15H27N2NaO2P [M + Na]
+: calcd 321.1702, found 321.1698.
Analytical results consistent with reported data.
135133
Ethyl 6-azido-hexanoate, 41
O
O
N3
1 2
3
4
5
6
1'
2'
To a stirred suspension of sodium azide (1.47 g, 22.6 mmol) and potassium carbonate
(2.34 g, 16.9 mmol) in anhydrous DMF (25 mL), ethyl-6-bromohexanoate 40 (2 mL,
11.3 mmol) was added under an argon atmosphere. The reaction mixture was stirred at
50 °C for 5 hours 45 min. The reaction mixture was then filtered through a celite plug
and washed with toluene. Purification by silica gel column chromatography (hexane to
hexane:EtOAc 95:5) gave 41 as a colourless oil (1.80 mg, 86%).
Rf (EtOAc:hexane, 1:4, A) 0.48.
νmax (neat)/cm
-1 2939 (w, CH), 2867 (w, CH), 2091 (s, N3), 1731 (m, CO), 1457 (w,
CH), 1373 (m), 1249 (m), 1179 (m), 1153 (m), 1096 (s, CO), 1029 (m).
1H NMR (400 MHz, CDCl3): H 4.12 (2H, q, J = 7.2 Hz, H
1’), 3.26 (2H, t, J = 7.2 Hz,
H
6), 2.30 (2H, t, J = 7.3 Hz, H
2), 1.65 (2H, p, J = 7.7 Hz, H
3), 1.61 (2H, p, J = 7.5 Hz,
H
5), 1.40 (2H, p, J = 7.5 Hz, H
4), 1.25 (3H, t, J = 7.3 Hz, H
2’).
13C NMR (100 MHz, CDCl3): δC 173.6 (s, C
1), 60.4 (t, C
1’), 51.4 (t, C
6), 34.2 (t, C
2),
28.7 (t, C
5), 26.4 (t, C
4), 24.6 (t, C
3), 14.4 (q, C
2’).
LRMS [ES
+]: m/z 208 ([M + Na]
+, 100%).
HRMS [ES
+]: for C8H15N3NaO2[M + Na]
+: calcd 208.1056, found 208.1058.134
6-Azidohexanoic acid, 42
HO
O
N3
1
3
2 4
5
6
Compound 41 (1.68 mg, 9.08 mmol) was dissolved in a mixture of H2O and dioxane
(2:1 v/v) (13.5 mL) to which 2 M aqueous sodium hydroxide (9.08 mL, 18.2 mmol) was
added. The reaction mixture was stirred at rt for 1 hour. The crude mixture was purified
by filtration through DOWEX resin (pyridinium form) (H2O:MeOH, 1:1 v/v) to give 42
as a colourless oil (1.23 mg, 91%).
Rf (EtOAc:hexane, 1:4, A) 0.11.
νmax (neat)/cm
-1 2939 (m, CH), 2866 (m, CH), 2090 (s, N3), 1702 (m, CO), 1412 (w,
CH), 1252 (m), 1154 (w), 931 (m).
1H NMR (400 MHz, CDCl3): H 10.38 (1H, br s, CO2H), 3.28 (2H, t, J = 6.8 Hz, H
6),
2.37 (2H, t, J = 7.5 Hz, H
2), 1.65 (2H, p, J = 7.5 Hz, H
3), 1.61 (2H, p, J = 7.3 Hz, H
5),
1.40 (2H, p, J = 7.4 Hz, H
4).
13C NMR (100 MHz, CDCl3): δC 179.9 (s, C
1), 51.3 (t, C
6), 34.0 (t, C
2), 28.7 (t, C
5),
26.3 (t, C
4), 24.3 (t, C
3).
LRMS [ES
-]: m/z 156 ([M – H]
–, 60%).
HRMS [ES
+]: for C6H11N3NaO2[M + Na]
+: calcd 180.0743, found 180.0745.
Analytical results consistent with reported data.
158135
N-Succinimidyl 6-azido-hexanoate, 43
O
O
N3 N
O
O
1 2
3
4
5
6
Compound 42 (1.20g,  7.62  mmol)  was  dissolved  in  CH2Cl2 (20  mL)  to  which N-
hydroxysuccinimide (1.11 mg, 9.65 mmol) and EDC (2.04g, 10.7 mmol) were added.
The  reaction  was  complete  after  6.5  hours.  The  reaction  mixture  was  diluted  with
CH2Cl2, washed with water, dried (Na2SO4), filtered and the solvent was removed in
vacuo. The crude mixture was purified by silica gel column chromatography (CH2Cl2to
CH2Cl2:MeOH 99:1) to give 43 as a yellow oil (1.00 g, 52%).
Rf (EtOAc: CH2Cl2, 3:7, A) 0.67, (CH2Cl2, A) 0.38, (CH2Cl2:MeOH 99:1, A) 0.56.
νmax (neat)/cm
-1 2944 (w, CH), 2869 (w, CH), 2094 (s, N3), 1812 (w), 1782 (m), 1731
(m, CO), 1363 (m), 1200 (s), 1063 (s), 645 (m).
1H NMR (400 MHz, CDCl3): H 3.28 (2H, t, J = 6.8 Hz, H
6), 2.82 (4H, s, H
Succ), 2.62
(2H, t, J = 7.3 Hz, H
2), 1.78 (2H, p, J = 7.5 Hz, H
3), 1.63 (2H, p, J = 7.2 Hz, H
5), 1.49
(2H, p, J = 7.2 Hz, H
4).
13C NMR (100 MHz, CDCl3): δC 169.2 (2s, CO
Succ), 168.5 (s, C
1), 51.2 (t, C
6), 30.9 (t,
C
2), 28.5 (t, C
5), 26.0 (t, C
4), 25.7 (2t, C
Succ), 24.3 (t, C
3).
LRMS [ES
+]: m/z 277 ([M + Na]
+, 50%).
HRMS [ES
+]: for C10H14N4NaO4[M + Na]
+: calcd 277.0907, found 277.0904.
Analytical results consistent with reported data.
158136
4.3 Biophysical studies
4.3.1 Preparation of synthetic oligonucleotides
The  synthesised  monomers  were  treated  as  follows: After  purification  by  column
chromatography  the  monomer  was  dissolved  in DNA  grade  anhydrous  acetonitrile
except  for  the  cholesterol  monomers  which  were  dissolved  in anhydrous
CH2Cl2:acetonitrile (3:1 v/v) and filtered through a Millipore Millex-FH syringe filter
(0.45 m, 25 mm). The solvent was then removed and the monomer was redissolved in
freshly distilled CH2Cl2. Aliquots corresponding to 100 mg were transferred to ABI
monomer reagent bottles and dried in a desiccator overnight under high vacuum before
being stored under a positive pressure of argon at –20 C until use.
Standard A, G, C and T DNA phosphoramidites, solid supports and additional reagents
including the C-7 aminoalkyl CPG were purchased from Link Technologies or Applied
Biosystems Ltd. All oligonucleotides were synthesised on an Applied Biosystems 394
automated  DNA/RNA  synthesiser  using  a  standard  0.2 mole  or  1.0 mole
phosphoramidite  cycle  of  acid-catalysed  detritylation,  coupling,  capping  and  iodine
oxidation. Stepwise coupling efficiencies and overall  yields were determined by the
automated  trityl  cation  conductivity  monitoring  facility  and  were  >98.0%.  All -
cyanoethyl phosphoramidite monomers were dissolved in anhydrous acetonitrile to a
concentration of 0.1 M immediately prior to use.
Cleavage of the oligonucleotide from the solid support was achieved by exposure to
concentrated ammonia solution (30 min at room temp) in a sealed vial and deprotection
achieved by heating for various time periods and monitoring by mass spectrometry.
Purification of oligonucleotides was carried out by reversed phase HPLC on a Gilson
system using an ABI Aquapore column (C8), 8 mm  250 mm, pore size 300 Å. The
system was controlled by Gilson 7.12 software and the following protocol was used: run
time 30 mins, flow rate 4 mL per min, binary system, gradient: time in mins (% buffer
B);0  (0);  3(0);  5(20);  21  (100);  25(100);  27  (0);  30(0).  Elution  buffer  A:  0.1  M
ammonium acetate, pH 7.0, buffer B: 0.1 M ammonium acetate with 35% acetonitrile
pH 7.0. Elution of oligonucleotides was monitored by ultraviolet absorption at 295 nm.137
After HPLC purification, oligonucleotides were desalted using a disposable NAP-10
Sephadex column purchased from GE Healthcare, aliquoted into an eppendorf tube and
stored at –20 ºC. Purified oligonucleotides were then analysed by MALDI-TOF MS.
4.3.2 Oligonucleotides synthesised
Sequences (5’-3’)
ODNs (Bz
Chol = monomer 8, T
Chol = monomer 13, H
Chol = monomer 23, H =
HEG, K = alkyne, Z = azide, NH2 = amino C7, T* = fluorescein dT,
L = linear, L* =  linear and fluorescent, C =  cyclic, C* = cyclic and
fluorescent)
ODN-1 Bz
Chol -TTTTTTTTTTTT
ODN-2 Bz
Chol -TTT
ODN-3 CGCAT
CholAT
CholCGC
ODN-4 GCGAT
CholAT
CholGCG
ODN-5 ACCAAGGTGCTAT
CholCGTCG
ODN-6 CGACGAT
CholAGCACCTTGGT
ODN-7 H
Chol -TGACTGTGACAC
L-ODN-8 K-TTTTTTTTTTGCACCAGAATTCATCACGGAGTTTTTTTTTT-NH2
L-ODN-9 K-HHHCTCCGTGATGAATTCTGGTGCHHH-NH2
L-ODN-10 K-TTTTTTTTTTGCACCAGAATTCATCACGGAGTTTTTTTTTT-Z
L-ODN-11 K-HHHCTCCGTGATGAATTCTGGTGCHHH-Z
C-ODN-10 Circular ssDNA form of ODN-10
C-ODN-11 Circular ssDNA form of ODN-11
L-ODN-12 K-TTTTTTTTTTTTTTTCCAGAATTCATCTTTTTTTTTTTTTTT-NH2
L*-ODN-13 K-GCGT*HHHGATGAATTCTGGHHHTGCG-NH2
L-ODN-14 K-TTTTTTTTTTTTTTTCCAGAATTCATCTTTTTTTTTTTTTTT-Z
L*-ODN-15 K-GCGT*HHHGATGAATTCTGGHHHTGCG-Z
C-ODN-14   Circular ssDNA form of ODN-14
C*-ODN-15 Circular ssDNA form of ODN-15
ODN-16 CGCCGC
L*-ODN-17 K-TTT*TTTTTTTTTTTTCCAGAATTCATCTTTTTTTTTTTTTTT-NH2138
L-ODN-18 K-GCGTHHHGATGAATTCTGGHHHTGCG-NH2
L*-ODN-19 K-TTT*TTTTTTTTTTTTCCAGAATTCATCTTTTTTTTTTTTTTT-Z
L-ODN-20 K-GCGTHHHGATGAATTCTGGHHHTGCG-Z
C*-ODN-19 Circular ssDNA form of ODN-19
C-ODN-20 Circular ssDNA form of ODN-20
Catenane      Catenane form of C-ODN-19 and L-ODN-20
4.3.3 Oligonucleotide characterisation
ODNs Expected mass Observed mass
ODN-1 4421.5 4420.0
MALDI
ODN-2 1683.8 1680.7
MALDI
ODN-3 4287.0 4286.9
MALDI
ODN-4 4287.0 4366.6
MALDI
ODN-5 6149.6 6149.6
MALDI
ODN-6 6149.6 6150.7
MALDI
ODN-7 4235.5 4237.8
MALDI
L-ODN-8 12876 12883.9
MALDI
L-ODN-9 8860 8867
ES
L-ODN-10 13015 13223.6
MALDI
L-ODN-11 8999 9006
ES
C-ODN-10 13015 13017.9
MALDI
C-ODN-11 9001 9002.8
MALDI
L-ODN-14 13222 13226.6
MALDI
L*-ODN-15 9289 9293.8
MALDI
C-ODN-14 13222 nd
C*-ODN-15 9289 nd
L*-ODN-19 13757 13761.7
MALDI
L-ODN-20 8777 8779.7
MALDI
C*-ODN-19 13735 nd
C-ODN-20 8777 8778.7
MALDI
ODN-27 22511 nd
nd = non determined139
4.3.4 UV melting studies
UV  melting  experiments  were  performed  on  a  Varian Cary  400  Scan  UV-Visible
spectrophotometer,  in  Hellma SUPRASIL  synthetic  quartz,  10  mm  pathlength
cuvettes, monitoring at 260 nm, at a 1 M concentration in a volume of 1.5 mL, or at
0.25 or 2 M concentration in a volume of 1.2 mL. Buffers were prepared according to
literature  procedure
159 and  kept at  5 ºC  until  needed.  The  buffers  were  allowed  to
equilibrate to rt and the pH was checked before use.
Samples were prepared as follows: The complementary strands were mixed in a 1:1
ratio in 2 mL eppendorf tubes then lyophilised before resuspending in 1.5 or 1.2 mL of
the appropriate buffer solution pH 7.0 (10 mM sodium phosphate, 1 mM Na2EDTA and
200 mM, 500 mM or 1 M NaCl) to give a final concentration of 0.25, 1 or 2 M of each
strand. The samples were then filtered into the cuvettes through Kinesis regenerated
cellulose 13 mm, 0.45 M syringe filters.
For experiments in chapter 1, the following procedure was followed:
Following an initial rapid heat (20 to 80 ºC at 10 ºC/min) and cool cycle (80 to 20 ºC
at 1 ºC/min) to ensure uniform annealing of the strands, the UV-melting curves were
recorded for 3 consecutives heat and cool cycles (20 to 80 to 20 ºC at 1 ºC/min).
For experiments in chapter 2, the following procedure was followed;
Following an initial rapid heat (20 to 80 ºC at 10 ºC/min), the UV-melting curves were
recorded for 3 cool and heat cycles: 80 to 20 ºC at 0.5 ºC/min with a hold time of 20
min to favour the duplex formation and to 80 ºC at 0.5 ºC/min with a hold time of 2
min.
Tm values were calculated for each experiment using Cary WinUV Thermal Application
software.140
4.3.5 Fluorescence melting studies
Fluorescence  melting  experiments  were  performed  using  a  Roche  LightCycler
® 1.5
instrument, in LightCycler glass capillaries (20 L volume). The Lightcycler has one
excitation source (488 nm) and the changes in fluorescence emission were measured at
520 nm.
The  capillaries contained 0.5 M  of  each  strand using  the  fluorescent  intercalator
SYBR Green I (intercalator:total volume 1:10 v/v), in 10 mM sodium phosphate buffer
(pH 7.0) with 1 mM Na2EDTA and the appropriate concentration of NaCl (200 mM,
400 mM or 600 mM NaCl). The complexes were denaturated by heating to 95 ºC at a
rate of 20 ºC/sec and were maintained at this temperature for 5 mins before cooling to
30 ºC at 0.1 ºC/sec. Samples were then held at 30 ºC for 5 mins before melting again
by  heating  to  95 ºC  at  0.1 ºC/sec.  Data  was  collected during both annealing  and
melting steps and compared. Each reaction was performed in duplicate. Tm values were
determined  from  the  first  derivatives  of  the  melting  profile  using  the  Roche
LightCycler
® software version 3.5.
4.3.6 Click chemistry experimental
Water soluble tris-(hydroxypropyltriazolylmethyl)amine ligand was synthesised by the
reported literature method.
88
4.3.6.1 Synthesis of azidohexanamide-labeled
oligonucleotides
The  following  procedure  was  used  to  incorporate  the  azide at  the  3’-end  of  C7-
aminoalkyl ODN. A 1.00 μmol synthesis of the ODN was incubated for 4 hours in 0.5
M Na2CO3/NaHCO3 buffer (pH 8.75, 70 μL) with N-succinimidyl 6-azido-hexanoate 43
(3 μL) and DMSO (100 μL). The crude ODN was desalted by NAP-10 gel-filtration
according to the manufacturer’s instructions (GE Healthcare) and purified by reversed-
phase HPLC. The purified ODNs were characterised by ES-MS: L-ODN-11 ([M–H]
–
calcd, 8999; found, 9006) and MALDI-TOF MS: L-ODN-10 ([M+H]
+ calcd, 13015;141
found, 13223.6); L-ODN-14: ([M+H]
+ calcd,  13022;  found,  13226.6); L*-ODN-15
([M+H]
+ calcd,  9289  ;  found,  9294); L*-ODN-19 ([M+Na]
+ calcd,  13757  ;  found,
13761.7) and L-ODN-20 ([M+H]
+calcd, 877; found, 8779.7).
4.3.6.2 Click cyclisation of ssDNA
Excess Cu[II] (10, 20 and 50 eq) was used in order to obtain high yields of cyclic ODNs
whilst keeping  the  ratio  of  Cu[II]/sodium  ascorbate/ligand  at  1/10/7.  The  following
method produced the best yields:
To a solution of tris-(hydroxypropyltriazolylmethyl)amine ligand
88 (1.22 mg, 2.80 μmol
in  590  μL  0.2  M  NaCl)  under an argon atmosphere was  added
0.4 M NaCl (955 μL), sodium ascorbate (8 μL, 4 μmol) followed by CuSO4.H2O (4 μL,
0.40 μmol). The azido-labelled alkyne ODN (943 μL, 20 nmol) was added and the
solution was incubated at rt for 2 hours. The reaction mixture was desalted by NAP-25
gel-filtration according to the manufacturer’s instructions (GE Healthcare) and purified
by reversed-phase HPLC. The purified ODNs were characterised by MALDI-TOF MS
C-ODN-10 ([M+H]
+ calcd, 13015; found, 13017.9); C-ODN-11 ([M+H]
+ calcd, 9001;
found, 9002.8); C-ODN-20 ([M+H]
+ calcd, 8777; found, 8778.7). No MS analysis was
possible for very high molecular weight ODNs: C-ODN-14, C*-ODN-15 and C*-ODN-
19.
4.3.6.3 Preparation of dsDNA catenane
Excess Cu[II] (10, 20 and 50 eq) was used in order to give high yields of cyclic ODNs
whilst keeping  the  ratio  of  Cu[II]/sodium  ascorbate/ligand  at  1/10/7.  The  following
method gave the best yields:
A solution of cyclised ssDNA (7 nmol) and its complementary azido-labelled alkyne
ODN (7 nmol) in 5 mL of 0.2 M NaCl was prepared and heated to 80 ºC then cooled
down slowly to rt for 2 hours. ODN-16 (14 nmol) and 0.4 M NaCl (21.0 μL) were
added and the reaction was incubated at rt for 30 min (solution 1). To a solution of tris-
(hydroxypropyltriazolylmethyl)amine  ligand (1.06  mg,  2.45  μmol  in  0.2  M  NaCl,142
1937.0  μL)  under an argon atmosphere was  added  0.4  M  NaCl  (10.5  μL),  sodium
ascorbate (7.0 μL, 3.50 μmol) followed by CuSO4.H2O (3.5 μL, 350 nmol) (solution 2).
Solution 1 was  added  to  the  above  prepared  catalyst solution  (solution 2) and  the
reaction was incubated at rt for 2 hours. The reaction mixture was desalted by NAP-10
gel-filtration  according  to  the  manufacturer’s  instructions  (GE  Healthcare)  and
lyophilized, then analysed and purified by denaturating 20% PAGE.
4.3.6.4 Denaturating  PAGE  gel  electrophoresis
analysis and purification
The ODNs were analysed or purified on 20% polyacrylamide/7M urea gels (up to 20
A260 of crude DNA per gel) at a constant power of 20 W, for 3-4 hours, using 0.09M
tris-borate-EDTA buffer (pH 8.0). Gels were visualised on a fluorescent TLC plate and
illuminated with a UV lamp (254 nm) or trans-illuminated with a UV light when a
fluorescein dT modification was present. For purification of the catenane, the bands
were excised, and the gel pieces were crushed and incubated with 1 mL of sterile water
at 37C for 16 hours. The tubes were then agitated and centrifuged and the supernatants
were desalted using NAP-10 gel-filtration according to the manufacturer’s instructions
(GE Healthcare).
4.3.6.5 Ferguson plot analysis
L-ODN-14, L*-ODN-15, C-ODN-14, C*-ODN-15 and the catenane were subjected to
analysis using a 5 point Ferguson-plot. The 5 different acrylamide concentrations used
for this study were 8, 11, 14, 17 and 20%. The protocol involved a run of 2, 2.25, 2.33,
2.5 and 3.33 hours respectively, at rt, with a constant power of 20 W. Using the linear
plots  in  Figure 1,  the  experimentally  obtained  retardation  coefficients (i.e  negative
slopes) for L-ODN-14, L*-ODN-15, C-ODN-14, C*-ODN-15 and the catenane were
found to be 0.036, 0.020, 0.020, 0.026 and 0.058 respectively.143
4.3.6.6 Native PAGE gel electrophoresis analysis
The ODNs were analysed on 14% polyacrylamide/7M urea gels (up to 20 A260 of crude
DNA per gel) at a constant voltage of 130 V, for 11 hours, using 0.09M tris-borate
buffer (pH 8.0). The gel was visualised on a fluorescent TLC plate and illuminated with
a  UV  lamp  (254  nm)  or  trans-illuminated  with  a  UV  light  when  a  fluorescein  dT
modification was present.
4.3.6.7 EcoR1 digestion
ODNs (3 μg) containing an EcoR1 restriction site were digested with or without 18 U
EcoR1 (1.5 μL ) (Promega) at 37 C for 3.15 hours. The reaction mixture also contained
6 μL EcoR1 buffer ( 10, Buffer H), 6 μL BSA (1 μg/mL) and 46.5 μL H2O. Products
were subsequently separated by 20% denaturating PAGE electrophoresis.144
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HPLC trace of ODN-1
T12
ODN-1
= Bz
Chol -T12